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In 2006 it was first reported by Takahashi et al that somatic cells can be reprogrammed to a 
pluripotent state by four reprogramming factors – Oct3/4, Sox2, Klf4 and c-Myc. These 
pluripotent stem cells were termed induced pluripotent stem cells (IPSCs). They offer 
promising possibilities for regenerative medicine and tissue engineering due to their unlimited 
proliferation and differentiation potential while facing less ethical concerns than embryonic 
stem cells (ESCs). Many different cell types and reprogramming strategies have been described 
since then. Transposon-based reprogramming systems like the Sleeping Beauty system 
combine the higher efficiency of integrating vectors with the enhanced safety profile of non-
viral vectors, and are therefore an interesting option for the generation of IPSCs both for 
research and clinical applications. 
Articular cartilage is a highly specialized connective tissue that covers the surfaces of 
diarthrodial joints. Due to its limited intrinsic regeneration potential, lesions of articular 
cartilage progress into osteoarthritis that can only be efficiently treated with total joint 
replacement by endoprostheses at the moment. Repair strategies for chondral lesions lead to 
formation of biomechanically inferior fibrocartilage or require invasive harvesting and 
destruction of healthy articular cartilage. Patient-derived autologous or HLA (human leucocyte 
antigen)-matched allogenic IPSCs might overcome these limitations and become an attractive 
alternative for cartilage repair. However, there is still no optimal protocol for chondrogenic 
differentiation of IPSC available.  
In this thesis we generated IPSCs from primary murine fibroblasts and established an efficient 
and reliable protocol for their chondrogenic differentiation.  
Embryonic and adult murine fibroblasts were successfully reprogrammed to IPSCs using the 
Sleeping Beauty reprogramming system for delivery of the reprogramming factors. Several 
clonal IPS cell lines were established and assessed for pluripotency traits and expression of 
pluripotency-related genes as well as for their tree-lineage differentiation potential. Transposon 
copy number analysis by Splinkerette PCR revealed two single integration clones.  
Efficient and reliable chondrogenic differentiation was achieved in one of these single-
integration clones by culturing embryoid bodies (EBs) in chondrogenic medium in a free-




TGFβ1 the developing chondrogenic spheroids expressed chondrogenic markers like Sox9, 
Integrin α10 and showed deposition of aggrecan and type II collagen in their extracellular 
matrix (ECM). Expression of pluripotency markers was downregulated yet still detectable.  
In conclusion, we have not only generated and assessed more than 20 IPS cell lines from 
primary murine fibroblasts reprogrammed by the Sleeping Beauty transposon system, but we 
have also developed an efficient and scalable protocol for their chondrogenic differentiation. 
More research is required to assess the impact of more elaborate growth factor substitution 
during chondrogenic differentiation on the resulting spheroids as well as their potential to repair 
osteochondral defects in vitro and in vivo. Furthermore, removal of the reprogramming factor 
cassette or its replacement by chondrogenic factors by recombinase mediated cassette exchange 
(RMCE) facilitated by heterospecific loxP sites incorporated in the Sleeping Beauty transposon 
would allow formation of chondrogenically primed IPSCs. It remains to be elucidated whether 








Im Jahre 2006 wurde erstmalig von Takahashi et al. beschrieben, dass somatische Zellen durch 
die vier Reprogrammierungsfaktoren – Oct3/4, Sox2, Klf4 und c-Myc – in einen pluripotenten 
Zustand reprogrammiert werden können. Diese pluripotenten Stammzellen wurden induzierte 
pluripotente Stammzellen genannt. Aufgrund ihres unbegrenzten Proliferations- und 
Differenzierungspotentials bieten sie vielversprechende Möglichkeiten für die Zukunft der 
regenerativen Medizin und der Gewebetechnologie, wobei ihnen weniger ethische Bedenken 
als embryonalen Stammzellen entgegengebracht werden. Die Reprogrammierung 
verschiedener Zellarten sowie die Verwendung verschiedener Reprogrammierungsstrategien 
wurden in den letzten Jahren beschrieben. Transposon-basierte Reprogrammierungs-Systeme, 
wie zum Beispiel das Sleeping-Beauty Transposon System, vereinen die hohe Effektivität 
integrativer Vektoren mit dem besseren Sicherheitsprofil nicht-viraler Vektoren und stellen 
daher eine interessante Option für die Herstellung induzierter pluripotenter Stammzellen 
sowohl für Forschungs- als auch für klinische Anwendungen dar.  
Gelenkknorpel ist ein hoch spezialisiertes Bindegewebe, das die Oberflächen diarthrodialer 
Gelenke bedeckt. Aufgrund seines limitierten intrinsischen Regenerationspotentials führen 
Verletzungen des Gelenkknorpels zu Arthrose, die gegenwärtig nur durch Gelenkersatz mit 
Totalendoprothesen effektiv behandelt werden kann. Reparaturstrategien für Verletzungen des 
Gelenkknorpels führen zur Bildung von biomechanisch minderwertigem Faserknorpel oder 
erfordern invasive Gewinnung und Zerstörung von intaktem Gelenkknorpel. Autologe, vom 
Patienten abstammende oder HLA-gematchte, allogene induzierte pluripotente Stammzellen 
könnten diese Einschränkungen überwinden und sich zu einer attraktiven Alternative für die 
Knorpelregenerierung entwickeln. Allergings gibt es bislang kein optimales chondrogenes 
Differenzierungsprotokoll für induzierte pluripotente Stammzellen. 
In dieser Doktorarbeit haben wir induzierte pluripotente Stammzellen ausgehend von primären 
murinen Fibroblasten hergestellt und ein effizientes und verlässliches Protokoll für deren 
chondrogene Differenzierung entwickelt. 
Murine embryonale und adulte Fibroblasten wurden erfolgreich zu induzierten pluripotenten 
Stammzellen reprogrammiert, wobei das Sleeping Beauty Reprogrammierungssystem für die 




pluripotente Stammzelllinien wurden etabliert und bezüglich pluripotenter Merkmale und der 
Expression pluripotenter Marker sowie ihres Differenzierungspotentials in Derivate aller drei 
embryonalen Keimblätter untersucht. Analyse der Anzahl genomischer Insertionsstellen des 
Transposons mittels Splinkerette PCR zeigte zwei Klone mit einer einzelnen Integration.  
Zur effizienten und verlässlichen chondrogenen Differenzierung eines dieser Klone mit einer 
einzelnen Integrationsstelle wurden zunächst embryoide Körperchen im hängenden Tropfen 
gebildet, die anschließend im chondrogenen Medium frei-schwimmend kultiviert wurden.  
Durch Stimulierung dieser chondrogenen Spheroide mit den chondrogenen Wachstumsfaktoren 
BMP2 und TGFβ1 wurde die Exprimierung chondrogener Marker, wie z.B. Sox9 und Integrin 
α10 induziert und die Ablagerung von Aggrecan und Typ II Collagen in der extrazellulären 
Matrix erreicht. Die Exprimierung pluripotenter Marker war reduziert aber dennoch 
nachweisbar.  
Zusammenfassend haben wir nicht nur erfolgreich mehr als 20 induzierte pluripotente 
Stammzelllinien mit dem Sleeping Beauty Reprogrammierungssystem etabliert und getestet, 
sondern auch ein effizientes und anpassbares Protokoll für deren chondrogene Differenzierung 
entwickelt. Weitere Forschungsarbeiten sind notwendig, um die Auswirkung ausgeklügelterer 
Wachstumsfaktorsubstitutionsschemata auf die chondrogene Differenzierung der Spheroide 
sowie deren Potential osteochondrale Defekte in vivo und in vitro zu reparieren zu untersuchen. 
Zudem würde der der Austausch der Reprogrammierungsfaktorexpressionskassette gegen 
chondrogene Differenzierungsfaktoren mittels Rekombinase-vermitteltem Kassettenaustausch 
über heterospezifische loxP Stellen, die im Sleeping Beauty Reprogrammierungssystem 
enthalten sind, die Herstellung chondrogen-geprimter induzierter pluripotenter Stammzellen 
ermöglichen. Es muss weiter untersucht werden, ob dies zu verbesserter chondrogener 








3. Introduction  
3.1. Induced pluripotent stem cells 
3.1.1. Potency of stem cells 
Stem cells are undifferentiated cells that are capable of self-renewal and differentiation into 
more specialized cell types [1, 2]. Self-renewal refers to the ability to undergo multiple divisions 
while maintaining an undifferentiated state [3]. According to their differentiation potential stem 
cells can be classified as totipotent, pluripotent, multipotent or unipotent (Figure 1) [2].  
Totipotent stem cells can give rise to all embryonic and extraembryonic tissues, thus they can 
form a complete embryo and the placenta [2]. Traditionally only a fertilized oocyte up to the 8-
cell stage of the morula is considered totipotent [1].  
Pluripotent stem cells are able to differentiate into all cell types of the three embryonic germ 
layers – ectoderm, endoderm and mesoderm [2]. They can form a complete embryo but cannot 
give rise to extraembryonic tissues like the placenta [4]. There are many different types of 
pluripotent stem cells that will be discussed in detail in 3.1.2. Types of pluripotent stem cells.  
Multipotent stem cells can differentiate into several cell types from a single germ layer [2]. 
Mesenchymal stem cells e.g. can give rise to various mesodermal tissues like adipose tissue, 
bone or cartilage [2]. Unipotent stem cells produce only one specific cell type [4]. Muscle stem 
cells for example can develop only into mature muscle cells [2].  
By the traditional developmental dogma, totipotent stem cells differentiate via a pluripotent and 
multipotent intermediate state to unipotent stem cells that finally give rise to fully differentiated, 
mature cells [4]. During this process, their self-renewal capacity and differentiation potential 
gradually decreases [4]. However, the discovery of reprogramming methods like somatic cell 
nuclear transfer (SCNT) and induced pluripotent stem cells (IPSCs) by which fully 





Figure 1: Potency of stem cells (self-designed).  
Totipotent stem cells are present up to the morula stage of embryonic development and can differentiate into all embryonic and 
extraembryonic cell types. The blastocyst is composed of the surrounding trophoblast that gives rise to the placenta and the 
inner cell mass (ICM) that contains pluripotent embryonic stem cells (ESCs). These develop in vivo to the embryo and have 
the potential to give rise to cell types of all three germ layers – ectoderm, mesoderm and endoderm. Multipotent stem cells can 
differentiate into several cell types of their respective lineage, whereas unipotent stem cells can give rise to only one single cell 
type.  
 
3.1.2. Types of pluripotent stem cells 
3.1.2.1. Sources of pluripotent stem cells 
Many types of pluripotent stem cells have been described including embryonic carcinoma cells 
(ECCs) derived from teratocarcinomas [5], embryonic germ cells (EGCs) derived from primary 
germ cells (PGCs) of the embryo or germ stem cells (GSCs) derived from neonatal and adult 
spermatogonial cells [4]. However, the most important types of pluripotent stem cells are 
embryonic stem cells (ESCs), somatic cell nuclear transfer-derived stem cells (NT-SCs) and 





Embryonic stem cells (ESCs) can be isolated from the inner cell mass of a preimplantation 
blastocyst. The blastocyst consists of the inner cell mass (ICM) that will form the embryo, a 
fluid filled cavity, the blastocoele, and the outer cell mass, the trophoblast, that gives rise to the 
placenta [1, 2]. ESCs have first been isolated in mouse by Evans and Kaufman in 1981 [6]. In 
1998 Thomson et al. reported the isolation of ESCs from human blastocysts [7]. ESCs show 
unlimited proliferation capacity in vitro and can differentiate into cells from all germ layers in 
vivo and in vitro [4]. However, their use in regenerative medicine is limited due to ethical 
concerns and the risk of immune rejection after allogenic transplantation [1, 8].   
In rodents, pluripotent stem cells can also be isolated from the epiblast layer of post-
implantation blastocysts [9]. These cells are termed epiblast stem cells (EpiSCs) [9]. In humans, 
an equivalent stem cell population has not been isolated due to ethical restrictions regarding the 
destruction of post-implantation embryos [4].   
Over the last decades two reprogramming techniques which reverse the differentiation process 
of somatic cells and return the cells into a pluripotent state have been described.  
During somatic cell nuclear transfer (SCNT), the nucleus of a somatic cell is transferred into 
the cytoplasm of an enucleated oocyte [10]. Unknown factors in the oocyte cytoplasm then 
reprogram the somatic nucleus to a totipotent state by erasing epigenetic marks. This process is 
comparable to the reprogramming of the sperm genome after fertilization [11]. Following 
activation, the oocyte starts to divide and develops into an artificial embryo carrying the same 
genetic information as the donor nucleus [10]. This embryo can be transferred into the uterus 
of a recipient animal via in vitro fertilization resulting in development of a clone like the sheep 
“Dolly” in 1997 [12]. Furthermore, pluripotent stem cells can be isolated from the inner cell 
mass of the developing blastocyst [13, 14]. These nuclear transfer derived stem cells are 
comparable to ESCs in terms of morphology, gene expression pattern and differentiation 
potential [13, 14]. Despite their potential to produce isogeneic pluripotent stem cells, the utility 
of SCNT in regenerative medicine and tissue engineering is limited due to ethical concerns 
regarding need for human oocytes and destruction of human embryos [1, 11]. Furthermore, 
complete reprogramming is achieved only in a very small portion of cells, whereas many 




Induced pluripotent stem cells (IPSCs) were first described by Takahashi and Yamanaka in 
2006 [15]. They screened 24 candidate genes known to play important roles for the maintenance 
of pluripotency or to contribute to carcinogenesis for their ability to induce reexpression of 
Fbx15, a gene that is expressed in mouse ESCs but dispensable for the maintenance of 
pluripotency [15]. Thereby they showed that four factors, namely octamer-binding 
transcription factor 3/4 (Oct3/4), SRY (Sex determining region of Y)-box2 (Sox2), kruppel-like 
factor 4 (Klf4) and avian myelocytomatosis viral oncogene homolog (c-Myc), were sufficient 
to reprogram mouse embryonic and adult fibroblasts to an embryonic stem cell-like state [15]. 
These factors were therefore termed reprogramming factors [15, 16]. 
The reprogrammed cells were similar to ESCs in terms of morphology, proliferation, gene 
expression and epigenetic status [15]. Furthermore, they formed teratomas containing tissues 
from all three germ layers after subcutaneous injection into nude mice [15]. Therefore, these 
cells represent an additional type of pluripotent stem cells and are designated induced 
pluripotent stem cells [15].  
Although these IPSCs contributed to embryonic development after injection into blastomeres, 
no live-born chimeras could be obtained from the Fbx15-IPSCs [15]. By selection for 
reexpression of Nanog or endogenous Oct3/4, however, adult chimeras could be obtained from 
IPSCs [17, 18]. Furthermore, these IPSCs could be transmitted through the germ line and were 
able to produce “all IPSC embryos” after injection into tetraploid (4N) blastocysts [17, 18].  
In 2007 the first human IPSCs were generated from human dermal fibroblasts by retroviral 
transduction of the same set of factors (Oct3/4, Sox2, Klf4 and c-Myc) [19]. Yu et al. showed 
that a different combination of reprogramming factors, namely Oct3/4, Sox2, Nanog and Lin28, 
was also sufficient to reprogram human somatic cells [20].  
As IPSCs represent a potential source of personalized, patient specific pluripotent stem cells 
omitting the ethical concerns associated with ESCs and NT-SCs they offer promising 
possibilities for the future of stem cell research and regenerative medicine. Therefore S. 
Yamanaka was awarded the Nobel Prize in medicine for the discovery of induced pluripotent 







Figure 2: Types of pluripotent stem cells (self-designed). 
(A) Embryonic stem cells (ESCs) are derived from the inner cell mass of a blastocyst that is generated by the fertilization of 
an oocyte by a sperm cell. (B) During somatic cell nuclear transfer (SCNT), the nucleus of a somatic cell is transferred into an 
enucleated oocyte. After activation the oocyte now carrying the somatic cell’s genetic material starts to develop into a blastocyst 
from which pluripotent stem cells can be isolated. (C) Induced pluripotent stem cells (IPSCs) are derived from somatic cells 
by expression of reprogramming factors. After successful reprogramming IPSC colonies can be picked and clonal IPS cell lines 
can be established.  
 
3.1.2.2. Naïve and primed state of pluripotent stem cells 
Comparison of the various types of pluripotent stem cells showed that pluripotency is rather 
dynamic, and that there are multiple pluripotent states [4, 22]. Two main different states of 
pluripotency can be distinguished: naïve and primed [22]. 
Mouse ESCs obtained from preimplantation blastocysts represent the naïve or ground state of 
pluripotency [22]. These cells form compact, dome shaped colonies and proliferate rapidly in 
vitro [23]. As a characteristic epigenetic feature, female naïve embryonic stem cells show two 
active X-chromosomes (XaXa) [22, 24]. Furthermore, they readily form chimeras after 
injection into blastocysts [4]. Mouse IPSCs have been shown to reach the naïve state of 




Human ESCs and IPSCs, however, show a primed state of pluripotency comparable to mouse 
EpiSCs [22, 24]. These cells form flatter colonies and proliferate slower in vitro [23]. They 
represent a developmentally more advanced state of pluripotency [24]. Female cells contain an 
epigenetically silenced X-chromosome (XaXi) [22, 24]. Mouse epiblast stem cells fail to 
contribute to chimeras, however due to ethical reasons this assay is not applicable to human 
stem cells [22].  
However, both, naïve and primed pluripotent stem cells, show three-lineage differentiation 
potential in vitro and form teratomas when implanted into immunodeficient mice [4, 22]. How 
different states of pluripotency affect their utility for tissue engineering and regenerative 
medicine applications needs to be further elucidated.  
 
3.1.3. Methods for the generation of induced pluripotent stem cells  
Since their discovery, successful generation of IPSCs has been reported in a broad range of 
species including not only human [19, 20] and mice [15, 17] but also for example rat [26, 27], 
rabbit [28], pig [29, 30], horse [31], cattle [32] and monkey [33, 34]. Various somatic cell types 
including e.g. fibroblasts [15, 19], adipose-derived cells [35], blood cells [36], keratinocytes 
[37], neural progenitor cells [38], hepatocytes [39] or pancreatic beta islet cells [40] have been 
used as starting cell population for reprogramming [41].  
Furthermore, different gene delivery methods have been applied for the induction of 
pluripotency. Whereas integrating viral vectors like retroviruses or lentiviruses provide stable 
transgene expression over a prolonged time allowing high reprogramming efficiencies, they 
bear the risk of insertional mutagenesis [15, 19, 42]. Non-integrating viral vectors, however, 
are considered safer but suffer from lower reprogramming efficiencies due to limited duration 
of transgene-expression [43]. Adenoviral vectors have been successfully used for 
reprogramming [44]. As they do not integrate their cargo into the host genome, multiple 
transfections are required and reprogramming efficiency remains low [41]. The non-integrating 
RNA Sendai virus offers efficient and safe reprogramming as it does not bear the risk of 
insertional mutagenesis [3, 45]. However, Sendai viruses are difficult to handle and not suitable 





The reprogramming factors can also be delivered non-virally as plasmids, minicircles or 
episomal plasmids [46-48]. Although these DNA-based vectors are easy to produce, they suffer 
from low reprogramming efficiencies [3, 41, 42]. Delivery of the reprogramming factors as 
mRNA or proteins has also been reported [49, 50]. These methods do not bear the risk of 
insertional mutagenesis. However, mRNA is unstable and multiple transfections are required 
[3], whereas proteins are difficult to synthesize in an appropriate quality and offer only low 
reprogramming efficiencies [3, 41].  
 
3.1.3.1. Transposons  
Transposons are integrating, non-viral vectors which combine the advantages of integrating 
viral vectors (i.e. efficient reprogramming due to long-term transgene expression due to stable 
genomic integration) with the advantages of non-viral delivery systems (i.e. safer integration 
profile, cost effective production, no requirement for a specialized biohazard containment 
facility) [42, 51]. Therefore, transposons represent a promising gene vector for the generation 
of induced pluripotent stem cells for various applications. 
Transposons are mobile genetic elements with the ability to change their position within the 
genome by a cut-and-paste mechanism called transposition [43]. Wild-type transposons consist 
of a transposase gene flanked by terminal inverted repeats (TIRs) that carry the transposase 
binding sites (Figure 3A) [42]. These two components can be separated from each other to use 
transposons as DNA delivery vehicles [42]. The gene of interest is placed between the 
transposon TIRs, whereas the transposase is supplemented from an alternative source (Figure 
3B) [43]. Although, there are no known active wild-type transposons in mammals, many 
transposon systems have been genetically engineered during the last decades [52]. Of these, the 
Sleeping Beauty (SB) and the PiggyBac (PB) transposon systems have been used successfully 
for the generation of IPSCs [53-55]. Reprogramming efficiencies with the SB system are 






Figure 3: Transposons. Modified from Ivics et al. [43]. 
(A) Wild-type transposons are composed of the transposase gene flanked by the terminal inverted repeats (TIRs) that act as 
transposase binding sites. (B) Transposon gene delivery system. A gene of interest is placed between the transposons TIRs and 
the transposase is provided from an alternative source, most conveniently as a second plasmid.  
 
3.1.3.2. Sleeping Beauty transposon system 
The SB transposon system was reawakened from inactive transposons of the Tc1/mariner 
family found in fish in 1997 [56]. It was the first known transposon system to be active in 
vertebrate cells [43]. The TIRs of SB are about 230 bp long and contain two direct repeats 
(DRs) of about 32 bp length each [57]. These direct repeats act as transposase binding sites 
during transposition [57]. By screening amino acid replacements for more active variants of the 
transposase, the hyperactive transposase SB100X was developed [58]. Thereby the SB 
transposon system was the first non-viral gene delivery system with gene delivery efficiency 
rates comparable to viral vectors [59]. Optimization of the TIRs and insertion of a multi-cloning 
site between the TIRs led to the pT2 SB transposon vector [42].  
After its delivery into a host cell, four transposase molecules bind the DRs within the TIRs 
flanking the gene of interest [57]. This leads to the formation of the so-called synaptic complex 
in which the ends of the element are bought close together [60]. Then the transposase catalyzes 
the excision of the transposon and its integration into a TA dinucleotide which is duplicated 
upon insertion [61]. Thereby SB transposition leaves a characteristic footprint within the 
genome (Figure 4) [61].  
The transposase can be provided on the same plasmid as the transposon, on a second plasmid 
or as mRNA [57]. A second plasmid, however, is the most convenient source as it is easy to 
produce and handle, and allows adjusting of the transposase : transposon ratio. Too high levels 





[52, 62]. For the SB100X transposase the optimal transposase : transposon ratio was shown to 
be 1 : 10 [63].  
On the primary DNA sequence level SB integrations occur only at TA dinucleotides located 
within a bendable DNA structure composed of AT-rich palindromes [56, 64]. On a genome 
wide level, the integration profile of SB is fairly random with no overt bias for integration into 
genes or transcriptional regulatory regions [59, 65]. Its favorable integration profile renders 
Sleeping Beauty a safer gene delivery vehicle than other transposons like e.g. PiggyBac or viral 
vectors that show a considerable potential for genotoxicity [42, 65].  
Taken together, the Sleeping Beauty transposon system is an easy to use and comparably safe 
gene delivery system that provides high reprogramming efficiencies in mouse and human [53, 
54]. Therefore, we decided to use a Sleeping Beauty based reprogramming system for the 
generation of IPSCs in this thesis.  
 
 
Figure 4: Sleeping Beauty transposition. Modified from Liu et al [57]. 
After delivery of the transposase (SB100X) and the transposon plasmid to the nucleus the transposase gene is transcribed, 
and transposase enzyme is produced. This enzyme binds the direct repeats (DRs) within the transposon’s terminal inverted 
repeats (TIRs) flanking the gene of interest and catalyzes excision of the transposon followed by formation of the synaptic 





3.1.4. Mechanisms of reprogramming 
Despite the successful generation of IPSCs from a broad range of species and a wide variety of 
cell types, the molecular and epigenetic mechanisms behind induction of pluripotency by 
reprogramming factors are still not completely understood.  
Most studies of the reprogramming process have been carried out in mouse embryonic 
fibroblasts (MEFs) [66-69]. It remains yet to be elucidated whether the mechanisms described 
in this population also account for other starting cell types or human cells [66, 70]. 
Reprogramming of MEFs takes at least one to two weeks and occurs at low frequencies 
rendering studies of the reprogramming process difficult [24, 70]. Dissecting the molecular and 
epigenetic mechanisms behind reprogramming relies on population wide analysis [67, 68] or 
on tracing back successful reprogramming events [66, 69] carried out in inducible secondary 
reprogramming systems [66-68, 71].  
Overall, the reprogramming process is considered a stochastic event [71]. Yet, recent studies 
have identified key intermediate steps that are reached by fewer and fewer cells during the 
reprogramming process [24]. Based on transcriptional profiling Samavarchi-Tehrani et al. 
described three phases of reprogramming: initiation, maturation and stabilization [68, 70]. Polo 
et al. reported that transcriptional changes during the reprogramming process occur in two 
major waves separated by a phase of more gradual changes by analysis of intermediately 
reprogrammed populations (Figure 5) [67, 70].  
 
3.1.4.1. Early events of the reprogramming process 
At the beginning of the reprogramming process each cell undergoes certain transcriptional and 
morphological changes [67, 68, 70]. During this initiation phase of reprogramming the original 
cell identity is erased [72]. Furthermore, cells increase their proliferation to an ESC-like rate 
and become resistant to apoptosis and senescence during the initiation phase [69, 70].  
One of the first obvious signs of ongoing reprogramming in murine fibroblasts is a change in 
morphology [69, 73]. The cells start to aggregate in tightly packed clusters of small rounded 





(MET) is a critical step during early reprogramming [68, 73]. On the molecular level MET is 
marked by the upregulation of epithelial markers like E-Cadherin and by the downregulation 
of mesenchymal markers like Snail [68, 73]. These transcriptional changes account for the first 
wave of transcriptional changes revealed by gene expression profiling [67, 68].  
Reprogramming of epithelial cells like keratinocytes or hepatocytes is more effective than 
reprogramming of cells of a mesenchymal origin likely due to skipping the MET step [24, 74, 
75]. It remains to be elucidated whether the remaining steps of reprogramming are the same for 
cells of different origins or whether they take different pathways to pluripotency.  
At the epigenetic level, mostly changes of histone modifications occur during early 
reprogramming, whereas DNA methylation changes take place later in the process [67, 70]. 
Gain of activating H3K4 methylation marks at the promoters and enhancers of pluripotency 
associated genes occurs during the initiation phase prior to their transcriptional activation [24, 
76]. Remaining repressive H3K27 marks and DNA methylation that are lost only towards the 
end of the reprogramming process likely prevent expression of these genes [67, 77]. Loss of the 
activating H3K4 methylation at somatic genes, however, is followed by their downregulation 
[24, 76]. Correspondingly, transcriptional changes are limited to pre-existing accessible 
chromatin that can be targeted directly by the reprogramming factors leading to the observed 
activation of proliferation-associated genes and silencing of somatic genes [24, 76] 
Despite deciphering certain key events occurring during the initiation phase, no clear sequence 
of events has been described so far [70]. The significant variation of gene expression profiles 
between single cells during the initiation phase indicates that changes in gene expression occur 
in a stochastic manner [66]. Yet – as long as all steps associated with the initiation phase are 
acquired – cells may proceed in the reprogramming process no matter in which order the key 
events have been reached [66, 70]. 
 
3.1.4.2. Intermediate events of the reprogramming process 
Transition from the initiation phase to the maturation phase is marked by appearance of the first 




phosphatase (AP) [68, 70]. This transition is one of the major bottlenecks in the reprogramming 
process [68, 70].  
During this phase, pluripotency associated genes are activated and the pluripotency network is 
gradually established [70]. These changes in the transcriptional profile account for the second 
wave of transcriptional changes described by Polo et al. [67].  
Single cell gene expression analyses have revealed that pluripotency-associated markers are 
activated in a sequential manner during reprogramming [66, 67, 70]. First, the markers Fbx15, 
Sall4 and endogenous Oct3/4 can be detected, followed by upregulation of Nanog and Rex1 
[66-68, 70]. Finally, expression of endogenous Sox2 and Dppa4 appears towards the end of the 
maturation phase [66, 67, 70]. Although these markers are good indicators of successful 
reprogramming, their acquisition does not guarantee complete reprogramming of cells [66, 67, 
70].  
On the epigenetic level, changes in DNA methylation take place during the late maturation 
phase [67, 70]. Methylation of cytosine (C) residues of CG dinucleotides in promoter regions 
leads to stable silencing of the corresponding genes [11]. Methylation of somatic genes and 
demethylation of pluripotency associated genes “locks” the acquired pluripotency [67, 72]. 
Thereby, the cells reach a stably reprogrammed state that marks the transition to the 
stabilization phase [70]. Whereas methylation is carried out by DNA-methyltransferases, it 
remains unclear, if methylation marks at pluripotency associated genes are passively lost during 
repeated cell divisions, or whether they are actively removed by still unknown mechanisms [24, 
67]. 
Overall, the maturation phase represents a slow, hierarchical process [66, 70]. Only few SSEA1 
positive cells completely activate the pluripotency network and successfully complete the 
reprogramming process [24, 78]. The exact mechanisms of how exogenous Oct3/4, Sox2, Klf4 






3.1.4.3. Late events of the reprogramming process 
Once the pluripotency network is stably established, the freshly reprogrammed cells can 
maintain their pluripotency independently from the exogenous reprogramming factors [24, 70]. 
Therefore, transgene silencing marks the transition from the maturation phase towards the 
stabilization phase [68, 70]. During this phase, clonal IPS cell lines are usually established and 
analyzed [70].  
Despite being already successfully reprogrammed to a pluripotent state, epigenetic changes 
continue [70]. Although expression of somatic genes is downregulated early during 
reprogramming, methylation of their promoters occurs only at the end of the reprogramming 
process [24, 76]. Low passage induced pluripotent stem cells show residual DNA methylation 
signatures characteristic of the cell type of origin [24, 79, 80]. This “epigenetic memory” affects 
their differentiation potential as it favors differentiation along the original lineage [24, 79, 80]. 
By continuous passaging these remaining epigenetic marks can be removed [24, 80]. This 
resetting of the epigenetic memory occurs during the stabilization phase [70, 78].  
 
 
Figure 5: Phases of the reprogramming process. Adapted from David et al. [70] and Plath et al. [24]. 





3.1.4.4. Function of the reprogramming factors 
Oct3/4, also known as Pou5f1, is a member of the POU homeodomain transcription factors 
[81]. It is an essential part of the pluripotency network in ESCs involved in the maintenance of 
pluripotency [24, 82]. Oct3/4 is a crucial reprogramming factor and fundamentally required in 
most reprogramming experiments [83]. It cooperates with many other factors to induce the 
expression of pluripotency associated transcriptional regulators including its own and to repress 
expression of lineage specific genes during reprogramming [81, 84]. Activation of endogenous 
Oct3/4 during reprogramming marks the transition of partially reprogrammed cells to fully 
reprogrammed induced pluripotent stem cells [24, 85]. 
Sox2 is a member of the sex determining region of Y (SRY)-related, high-mobility group box 
transcription factors [81]. It is one of the core transcription factors of the pluripotency network 
in ESCs, however, it is also expressed at high levels in a variety of other cell types like e.g. 
neural progenitor cells [24, 38]. In ESCs, it forms heterodimers with Oct3/4 and enhances 
expression of genes that are required for the maintenance of pluripotency including its own [84, 
86]. Sox2 is an essential reprogramming factor, however, in cells with high endogenous levels 
of Sox2 reprogramming can be achieved with Oct3/4 alone [38, 84]. In MEFs endogenous Sox2 
is reactivated late during the reprogramming process and marks the transition to the stabilization 
phase of reprogramming [68, 70]. 
Klf4 (Krüppel-like factor 4) is a zinc finger transcription factor that belongs to the family of 
Sp1-like transcription factors [81, 87]. It is part of the pluripotency network in ESCs but is also 
highly expressed in adult epithelial tissues with high turnover like gut or skin [81, 87]. It plays 
important roles in many physiological processes such as cell cycle control, DNA repair, 
apoptosis and differentiation [87]. It can act as a tumor-suppressor or exhibit oncogenic activity 
in a context-specific manner [87]. During the reprogramming process Klf4 induces epithelial 
genes during mesenchymal to epithelial transition and later acts as a cofactor of Oct3/4 and 
Sox2 in establishing the pluripotency network [73, 86].  
c-Myc is known as an oncogene associated with many types of cancer including e.g. Burkitt 
lymphoma [81, 88]. Although it is not absolutely required during reprogramming, it greatly 
enhances efficiency and kinetics of the reprogramming process [81, 83]. Expression of c-Myc 





state during the initiation phase of reprogramming [24, 83]. By interacting with chromatin 
remodelers, it creates a permissive cellular state that facilitates the activation of the pluripotency 
network by the other transcription factors despite not being directly involved in the upregulation 
of the network itself [81, 83]. Re-expression of genomically integrated c-Myc can lead to tumor 
formation upon differentiation of IPSCs hampering clinical applicability of these cells [81, 89]. 
The potentially oncogenic factors Klf4 and c-Myc are not absolutely required for 
reprogramming as they can be replaced e.g. by Nanog and Lin28 [20].  
Nanog is a core member of the pluripotency network that co-occupies more than 300 target 
genes together with Oct3/4 and Sox2 in ESCs [24, 25]. Its upregulation is essential for the 
generation of IPSCs and marks the transition from an intermediate to the fully reprogrammed 
state during the maturation phase of reprogramming [24, 70].  
Lin28 is an ESC-specific RNA binding protein that is induced by c-Myc [81, 84]. By degrading 
let-7 miRNAs that are expressed ubiquitously in somatic cells but repressed in pluripotent stem 
cells, it accelerates the reprogramming process [81, 84]. 
 
3.1.4.5. Roles of the reprogramming factors in reprogramming 
In ESCs, an autoregulatory network of transcription factors is responsible for maintenance of 
pluripotency [90, 91]. This pluripotency network needs to be established in somatic cells during 
the reprogramming process. 
Repressive chromatin at pluripotency associated genes is one of the major barriers that has to 
be overcome during reprogramming [24]. Pioneer factors are transcription factors that can 
engage target genes in closed, inactive chromatin and thereby enable other transcription factors 
and chromatin remodelers to access and activate these sites finally leading to acquisition of an 
active chromatin state and expression of the target genes [92]. Oct3/4, Sox2 and Klf4 have been 
shown to act as pioneer factors during establishment of the pluripotency network, whereas          
c-Myc only enhances their binding without having pioneer activity itself [93].  
Genome wide analysis of the binding patterns of Oct3/4, Sox2, Klf4 and c-Myc during the 




during the reprogramming process [85, 93]. Whereas the binding patterns of the factors are 
comparable between fully reprogrammed IPSCs and ESCs, the binding patterns at the initiation 
of reprogramming and in partially reprogrammed IPSCs are markedly different [85, 93].  
After 48h of expression in fibroblasts, Oct3/4, Sox2, Klf4 and c-Myc (OSKM)-binding sites 
show only partial overlap with their binding pattern in ESCs [93]. The factors bind together at 
genes with pre-existing active chromatin marks inducing the early transcriptional changes 
associated e.g. with mesenchymal to epithelial transition [24, 76, 93]. They also activate 
apoptosis-related genes likely presenting a protective mechanism to eliminate cells in which 
aberrant transcription factor expression has occurred [93]. Other than that, OSKM binding 
occurs mostly at enhancers of genes that will become activated later during the reprogramming 
process [93]. Still unknown events are required for the factors to engage with promoters and 
activate transcription during the reprogramming process [72, 93].   
In partially reprogrammed pre-IPSCs, Oct3/4, Sox2 and Klf4 show a different binding pattern 
than c-Myc indicating their different roles in establishing the pluripotency network [85]. 
Partially reprogrammed cells constitute a stable intermediate cell population in which cells have 
already acquired the proliferative and biosynthetic properties of IPSCs but the endogenous 
pluripotency network has not been activated yet [24]. At this pre-IPSC stage, c-Myc has already 
bound most of its final targets [85]. These are mostly genes associated with proliferation and 
metabolism indicating that c-Myc is not directly involved in the upregulation of the 
pluripotency network [85].   
In fully reprogrammed IPSCs, Oct3/4 and Sox2 together with Klf4 and other factors like Nanog 
co-occupy promoters of highly expressed pluripotency associated genes including their own 
[24]. Thereby these factors are core elements of the pluripotency network [90, 91]. However, 
Oct3/4, Sox2 and Klf4 only bind about 1/3 of their targets at the pre-IPSC state [85]. In 
accordance partially reprogrammed cells have not upregulated endogenous pluripotency 
markers yet [24]. The different binding patterns might result from repressive epigenetic 
modifications at the pluripotency associated genes or lack of cofactors like e.g. Nanog in pre-
IPSCs [24, 85]. Stochastic events are required to overcome these barriers that represent one of 






3.1.5. Applications of induced pluripotent stem cells 
IPSCs, as a somatic-cell derived cell source with unlimited proliferation and differentiation 
potential, offer promising possibilities for regenerative medicine. Currently, there are three 
major applications for IPSCs: basic research, disease modeling and drug discovery, and finally 
replacement of diseased or injured tissues and organs by autologous transplants (Figure 6) [23].  
The reprogramming process itself is an intensively studied topic in basic research. Deciphering 
the mechanisms of reprogramming offers valuable insights into the pluripotency network that 
plays important roles in embryogenesis and early development [23, 72, 86].  
Furthermore, as carcinogenesis and reprogramming are closely related processes IPSCs are now 
broadly applied in cancer studies [23, 94]. Cancer cells share many features with IPSCs like for 
example their unlimited proliferation potential, their ability to self-renew, their metabolic state 
and, to a certain extent, their gene expression pattern and epigenetic status [94]. The 
reprogramming factors Klf4 and c-Myc are known oncogenes, whereas Oct3/4 and Sox2 exhibit 
high expression in certain types of cancer [94]. Reprogramming of cancer-derived cells to so-
called induced cancer stem cells (ICSCs) offers insights into cancer development and 
progression, therapy resistance and relapse and may contribute to the development of novel 
anti-cancer therapies [94].  
IPSCs offer new ways to study genetic diseases and provide a platform for drug discovery and 
toxicity screening [95]. Conventional disease models rely on immortalized cell lines or on 
transgenic animal models [95, 96]. However, animal models often show significant differences 
from human pathophysiology and certain tissue samples like e.g. cardiac or neuronal tissue are 
difficult or impossible to access from patients [95, 96]. IPSCs can be generated from patients 
suffering from a known genetic disease and differentiated into disease-relevant cell types [95]. 
This “patient-in-a-dish” can be used to study the pathophysiology of the disease as these patient-
derived IPSCs exhibit a diseased phenotype [23, 97].  Patient-specific IPSCs have been 
established from a broad range of neurologic disorders including e.g. amyotrophic lateral 
sclerosis [98] or Parkinson’s disease [99], heart diseases like hypertrophic or dilatative 
cardiomyopathy [100, 101] and other genetic diseases like familial hypercholesterinemia [102] 
or juvenile diabetes [103]. The main limitation for the application of IPSCs to study disease 




relevant cell types [104]. Furthermore, these patient-derived IPSCs could be used for high-
throughput drug testing and toxicity screening [95, 96]. For example, human IPSC-derived 
cardiomyocytes could become an important alternative to cardiotoxicity screening in animal 
models or on cell lines [95]. 
Patient-derived IPSCs could open the road to individual precision medicine in which the right 
drug is provided for the right patient in the right dosage [95]. Every patient has a different 
genetic background and will therefore react differently to medication. IPSCs based drug 
screening for an individual patient could contribute to find the ideal therapeutic option for every 
single patient [95]. On the other hand, IPSCs derived from cohorts of patients could be used for 
high-throughput drug and toxicity screening in a “clinical trial in a dish” set-up [95]. Thereby 
a large number of compounds can be easily screened, and potential responders and non-
responders could be identified prior to testing the drug in an actual patient [95, 105]. Many 
IPSC-based drug screenings are currently performed on various genetic disorders and first 
clinical trials using IPSC-discovered compounds are ongoing [96, 106].  
Organ transplantation is limited by lack of donor organs and immunorejection of allogenic 
tissues [95]. IPSCs could provide a source of autologous cells that can be differentiated into 
any cell type needed [95, 97]. IPSCs derived cells and tissues could be transplanted back into 
the patient without the risk of rejection and thus without need for immunosuppressive drugs 
[95]. Unlike ESCs, patient-derived IPSCs face less ethical concerns and immune barriers [95]. 
The potential of IPSCs to replace diseased tissues has been shown in many animal models 
including models of liver failure [107, 108], spinal cord injury [109] or hematological disorders 
[110, 111]. First clinical trials using patient-derived IPSCs are on their way [112]. However, 
there is still a lack of efficient and reliable differentiation protocols for many desired cell types 
[97]. Furthermore, IPSCs still face many safety concerns. Transplantation of residual 
pluripotent stem cells imposes the risk of teratoma formation [97]. Incomplete reprogramming 
and genetic mutations occurring during reprogramming might render even patient-derived IPS 
cell lines immunogenetic [97].  Lastly, efficiency of reprogramming is still low and generating 
patient derived IPSCs under good manufacturing practice (GMP) conditions is a time 
consuming and costly process [16]. Therefore, the generation of a human IPSC-bank from 






Figure 6: Applications of induced pluripotent stem cells (self-designed). 
Patient-derived IPSCs can be used for basic research purposes including deciphering of the reprogramming mechanism itself 
or cancer studies. Furthermore, patient-derived IPSCs can be differentiated to disease-relevant cell types and used as a model 
to study the pathomechanisms of the disease or discover new possible drug targets in high-throughput screenings. Finally, 
IPSCs can serve as an autologous cell source for cell therapy or tissue transplants.  
 
3.2. Articular cartilage 
Cartilage is a highly specialized connective tissue. There are three kinds of cartilage within the 
human body: hyaline cartilage, fibrocartilage and elastic cartilage [115]. Hyaline cartilage is 
present e.g. in diarthrodial joints and in the trachea [115]. Fibrocartilage contains more collagen 
fibers in the extracellular matrix (ECM) and can be found e.g. in the intervertebral discs or knee 
menisci [115, 116].  Elastic cartilage contains elastin in the ECM and forms parts of ear and 
nose [116].  
Articular cartilage is a specialized hyaline cartilage that covers the surfaces of diarthroidal joints 
[115]. The mean thickness of articular cartilage in human is 3 - 4 mm but it can reach up to 6 - 
8 mm e.g. at the patellar articular surface [117]. Together with the synovial fluid, articular 
cartilage provides almost frictionless articulation in the joint [118]. The viscoelastic properties 
of the ECM endow articular cartilage with high resistance to mechanical stress and help to 
distribute joint loads [115, 119]. As articular cartilage is devoid of blood and lymphatic vessels, 
nutrition is provided only via diffusion from the synovial fluid [117, 119]. This together with 
the limited proliferation capacity of chondrocytes accounts for the low intrinsic regenerative 




3.2.1. Components of articular cartilage 
Generally, articular cartilage is composed of a solid and a liquid phase [115]. 60 - 80% of the 
wet weight of articular cartilage consist of water and electrolytes (fluid phase), whereas cells 
and ECM make up about 20 - 40% of the wet weight (solid phase) [115]. 
The cells, so called chondrocytes, are embedded in an extensive ECM [117]. The ECM of 
articular cartilage is made up of a meshwork of collagen fibrils, proteoglycans and other non-
collagenous proteins and is responsible for articular cartilage’s unique mechanical properties 
[117]. 
 
3.2.1.1. Chondrocytes  
Chondrocytes are the only cell type found in healthy articular cartilage [115]. They make up 
only about 1-3% of the tissue volume [120]. These specialized cells synthesize and maintain 
the ECM [115]. Chondrocytes have cilia that extend into the ECM and allow the cells to sense 
and respond to mechanical stimuli from joint loading [116].  
Chondrocytes originate from mesenchymal stem cells (MSCs) in a process called 
chondrogenesis [116, 121]. This is discussed in detail in 3.2.3.1. Chondrogenesis and 
endochondral ossification. At birth, articular cartilage is highly cellular and composed of small 
cells in scanty matrix [116]. Postnatally, articular cartilage expands vertically and laterally by 
chondrocyte proliferation, chondrocyte hypertrophy and matrix accumulation [116]. As mature 
chondrocytes are completely encapsulated by dense ECM, they are not able to migrate or 
proliferate significantly [115, 116]. This in addition to the lack of vascular, lymphatic and 






3.2.1.2. Extracellular matrix 
3.2.1.2.1. Collagens 
The ECM of articular cartilage is composed of collagen fibrils that form an extensive network 
and account for about 50 - 75% of the dry weight of articular cartilage [115, 118].  
Collagens are the main structural proteins of tissues providing resistance to tensile stress [122]. 
Collagens consist of three α chains that contain glycine as every third amino-acid and have a 
high proline and hydroxyproline-content, and therefore form triple helixes, the characteristic 
structural feature of all collagen molecules [123]. Collagens can be divided into fibril-forming 
collagens (Types I, II, III, V, XI), network forming collagens (Types IV, VIII, X), fibril-
associated collagens (Types IX, XII, XIV) and transmembrane proteins (Types XIII, XVII) 
[122]. 
Fibril-forming collagens are synthesized as procollagen molecules containing an amino-
terminal propeptide followed by a N-telopeptide, a central triple helix, a C-telopeptide and a 
carboxy-terminal propeptide [123]. Proteolytic cleavage of both propeptides by procollagen N- 
and C-proteinases results into mature collagen molecules which then spontaneously assemble 
into fibrils [122]. The telopeptides contain lysine residues that form intra- and intermolecular 
cross links, which stabilize collagen fibrils and networks [118, 123].  
The ECM of articular cartilage contains collagen types II, VI, IX, X and XI [115]. With over 
90% type II collagen is the dominant type of collagen in articular cartilage [118]. Type II 
collagen fibrils consist of three identical α1(II)-chains (Col2a1) and form an extensive network 
in the extracellular matrix of articular cartilage [118]. Evidence of Col2a1 expression during 
chondrogenic differentiation of mesenchymal stem cells (MSCs) [124, 125] or pluripotent stem 
cells (PSCs) [126, 127] is widely accepted as a marker for successful chondrogenesis. There 
are two isoforms of type II procollagen, named procollagen IIA and procollagen IIB that are 
generated by alternative splicing of exon 2 [128]. The type IIA isoform contains exon 2 and is 
produced mainly by chondroprogenitor cells during chondrogenesis. It can furthermore be 
found in non-cartilaginous tissues like retina, heart or tendons, too [128, 129]. The type IIB 
isoform, however, is devoid of exon 2 and found predominantly in differentiated cartilage [128, 




IIA procollagen expression is characteristic for chondroprogenitor cells, type IIB procollagen 
expression identifies differentiated chondrocytes [128]. 
Type IX and type XI collagens crosslink with type II collagen fibrils, regulate fibril assembly, 
modify fibril diameters and stabilize the collagen network [115, 118]. Type VI collagen forms 
beaded filaments that intertwine to a highly branched filamentous network at pericellular sites 
and mediate cell-collagen-interactions via mechanotransduction [115, 118, 123]. 
Type X collagen is expressed in the calcified cartilage layer and in hypertrophic cartilage during 
endochondral ossification [118, 123]. Expression of type X collagen during in vitro 
chondrogenesis is therefore a marker of hypertrophic cartilage [130].  
Articular cartilage as a type of hyaline cartilage is per definition devoid of type I collagen [118]. 
This collagen type is present in fibrocartilage tissue like meniscal cartilage [118]. Its occurrence 




Aggrecan (Acan) is the main proteoglycan of cartilage ECM accounting for about 5% of the 
wet weight of articular cartilage [131]. Proteoglycans consist of glycosaminoglycan (GAG)-
chains attached to a protein core [117]. The GAGs are long polysaccharide chains made up of 
repeating disaccharides that contain many negatively charged sulfate- and carboxyl-groups 
[117]. Aggrecan consists of a core protein and some keratan sulfate (KS) and many chondroitin 
sulfate (CS) chains that spread out from the core protein like tubular brushes [115, 132]. 
Aggrecan forms large aggregates in the ECM of articular cartilage (Figure 7) [131]. Up to 100 
aggrecan molecules are attached to a long hyaluronan filament [132]. Hyaluronan is a non-
sulfated GAG that is characterized by its large length and its synthesis by hyaluronan-synthases 
(HAS) at the plasma membrane of cells [132]. The so called link protein (LP) can bind 






As described in 3.2.1.2.4. Function of articular cartilage extracellular matrix aggrecan is 
responsible for the unique viscoelastic properties of articular cartilage. Furthermore, it is an 
important marker for successful chondrogenic differentiation of MSCs [130, 133] and PSCs 
[134, 135].  
 
 
Figure 7: Structure of aggrecan. Adapted from Brody et al. [117].  
(A) Aggrecan is composed of a core protein to which chondroitin sulfate (CS) and keratan sulfate (KS) chains are attached. 
Link protein (LP) connects aggrecan monomers and hyaluronan filaments. (B) Several aggrecan molecules bind to long 
hyaluronan chains the ECM of articular cartilage forming large aggregates. 
 
3.2.1.2.3. Non-collagenous proteins 
Besides collagens and aggrecan there are many other proteins in the ECM of articular cartilage.  
Small leucin rich repeat proteins (SLRPs) like e.g. biglycan, decorin, fibromodulin and lumican 
are a group of proteins characterized by repeats of a leucin rich motif flanked by disulfide loop 
structures [131, 132]. These proteins bind collagen fibers and thereby modify fiber formation, 
and promote cross linking of collagen fibers to an extensive collagen network [131]. 
Furthermore, they can act as binding sites for growth factors and cytokines in the extracellular 
matrix or provide cell-matrix interactions [131]. 
The cartilage oligomeric matrix protein (COMP) can bind five collagen molecules and by 
bringing these molecules in close proximity it enhances collagen fibril formation [131]. 




3.2.1.2.4. Function of articular cartilage extracellular matrix  
Interaction of the matrix components provides articular cartilage with viscoelastic properties 
that are important for its ability to dissipate compressive loads, redistribute loading forces and 
lower joint friction (Figure 8) [115].  
The negatively charged sulfate- and carboxyl-groups of keratan sulfate and chondroitin sulfate 
bound to aggrecan provide an extreme anionic charge density in the ECM of articular cartilage 
[117, 131]. Since the network of collagen fibers entraps aggrecan and prevents it from escaping 
the tissue, the fixed negative charges attract mobile cations [115, 132]. The high density of ions 
within the tissue creates an osmotic gradient attracting water and causes cartilage to swell [115]. 
The tendency to swell is restricted by the tensile properties of the collagen fibers [118, 131].  
During compression, interstitial fluid flows out of the porous collagen-proteoglycan matrix 
until the frictional drag that increases with tissue condensation counterbalances the compressive 
force [115, 136]. The fluid exudation from the tissue also provides lubrication of the joint [115]. 
With decompression, the swelling pressure of the proteoglycans causes the tissue to expand 
again and drags water back into the tissue [118, 136]. Alteration between compression and 
decompression of articular cartilage during motion enhances the flow of interstitial fluid what 







Figure 8: Extracellular matrix of articular cartilage. Adapted from Brody et al [117] and Poole et al. [118].  
Type II collagen fibrils form an extensive network in the ECM of articular cartilage. Type IX and type XI collagens bind type 
II collagen fibrils. Aggrecan forms large aggregates with hyaluronan filaments that intertwine with the collagen meshwork. 
The negatively charged GAG-chains attached to aggrecan attract mobile cations and water causing the tissue to swell. The 
tendency to swell is restricted by the collagen meshwork leading to articular cartilages unique viscoelastic properties. 
 
3.2.1.3. Integrins 
Integrins are heterodimeric transmembrane proteins composed of α and β subunits [137]. 
Today, at least 24 different integrin heterodimers formed by the combination of 8 types of β 
subunits and 18 types of α subunits have been described [137].  
Integrins are cell surface receptors and have large extracellular domains that bind components 
of the ECM, and short cytoplasmatic domains that bind cytoskeletal structures. By connecting 
ECM and cytoskeleton, integrins serve as transducers of chemical and mechanical signals [137]. 
Additionally, integrins can indirectly activate various intracellular signaling pathways and take 
part in the regulation of cell proliferation, migration, differentiation and survival [137, 138].  
Integrins α1β1, α2β1, α10β1 and α11β1 constitute a subset of the integrin family with affinity 




Articular cartilage chondrocytes express many types of integrins including α1β1, α3β1, α5β1, 
α10β1, αVβ1, αVβ3, and αVβ5 [137]. Integrin α10β1 is the most abundant collagen-binding 
integrin in cartilage and shows high affinity for type II collagen [137, 139]. It was first identified 
in 1998 by Camper et al [140]. Mice deficient of integrin α10β1 develop a mild 
chondrodysplasia due to a disorganized growth plate [141]. It serves as an important mediator 
of cell-matrix interactions during endochondral ossification [139, 141]. As integrin α10β1 is a 
unique marker of chondrocytes, upregulation of α10-integrin (Itga10) mRNA during in vitro 
chondrogenesis is considered as a sign of successful chondrogenic differentiation [139, 142].  
 
3.2.2. Structure of articular cartilage 
Due to differences in cell morphology and matrix composition, articular cartilage can be divided 
into four different layers [115, 117]. These are termed superficial, middle, deep and calcified 
zone [115].  
The superficial or tangential zone is the outermost zone, making up about 10 - 20% of the total 
articular cartilage thickness [115]. It is designed to resist shear forces that occur during joint 
movements [117]. The chondrocytes here are flattened and aligned parallel to the surface and 
the direction of shear stress [115, 118]. Cell density is the highest in this zone [117]. The ECM 
is composed of thin collagen fibers that are densely packed and orientated tangential to the 
articular surface forming the lamina splendens [115]. Proteoglycan content is the lowest in this 
layer [118].  
The lower layers with vertical fiber orientation and higher proteoglycan content are designed 
to resist compressive forces and distribute joint loads [117]. The middle or tangential zone 
accounts for 40 - 60% of articular cartilage thickness [115, 117]. Cell density in this layer is 
lower and chondrocytes exhibit a round morphology [117, 118]. Collagen fibers are orientated 
more randomly as they change their direction from a tangential orientation in the superficial 
zone to an orientation vertical to the surface in the deep zone [115]. Furthermore, the fiber 
diameter gradually increases [115]. The matrix in this layer has the highest proteoglycan content 
[118]. The remaining 20 - 30% of articular cartilage thickness are termed deep or radial zone 





columns [115, 117]. Thick collagen fibers are orientated parallel to the chondrocyte columns 
[117]. These fibers are inserted across the tidemark in the underlying calcified layer and help 
to anchor the cartilage layer to the subchondral bone [115].  
The tidemark is a basophilic line in histological samples that separates deep and calcified zone 
[115]. It also marks the boarder of nutritional supply in adult articular cartilage [117]. Above 
the tide mark nutritional supply is provided via diffusion from the synovial fluid, whereas the 
calcified cartilage layer below the tidemark is supplied from the subchondral bone [117].  
The calcified zone is the transitional zone between articular cartilage and subchondral bone 
with intermediate mechanical properties [115, 118]. Chondrocytes in the calcified zone exhibit 
a hypertrophic phenotype, express type X collagen and are able to calcify the surrounding ECM 
[118].  
 
3.2.3. Articular cartilage development 
3.2.3.1. Chondrogenesis and endochondral ossification 
The formation of cartilage from mesenchymal stem cells during embryonic development is 
termed chondrogenesis [121]. Osseous tissues are formed via two distinct processes: 
intramembraneous and endochondral ossification [143]. During intramembraneous ossification  
mesenchymal stem cells directly differentiate into osteoblasts, whereas during endochondral 
ossification first a cartilage template, the so-called cartilage anlage, of the respective bone is 
formed and then gradually replaced by osseous tissue (Figure 9) [143, 144]. 
During the process of gastrulation in early embryonic development the primitive streak as a 
mesoendodermal intermediate leads to the development of the three embryonic germ layers, 
ectoderm, mesoderm and endoderm [145]. The mesodermal layer gives rise to a variety of 
tissues, including heart and vascular tissues, muscles as well as cartilage and bone [145, 146]. 
Cartilaginous and osseous tissues of the limbs arise from the paraxial mesoderm that further 




The first step in chondrogenesis or endochondral ossification, is a condensation of 
mesenchymal stem cells in these limb buds [143]. These cells then differentiate into 
chondroprogenitors that start to produce a matrix rich in type II collagen and aggrecan forming 
the cartilage anlage of the skeletal element and finally develop into chondrocytes [121, 143]. 
The cells at the periphery of the condensations from the perichondrium that demarks the 
developing bone from the surrounding mesenchyme [143].  
The chondrocytes in the cartilage anlage form two different subpopulations: round, low 
proliferating chondrocytes at the distal ends of the condensation (round proliferating (RP) 
chondrocytes) and high proliferating chondrocytes that are aligned in columns at the center of 
the condensation (columnar proliferating (CP) chondrocytes) [144]. The high proliferating 
chondrocytes then exit the cell cycle and differentiate into prehypertrophic and hypertrophic 
chondrocytes [144]. These cells start to produce type X collagen and mineralize their ECM 
[143, 144]. Furthermore, the hypertrophic chondrocytes produce VEGF (vascular endothelial 
growth factor), that attracts blood vessels from the perichondrium [121]. In parallel, cells of the 
perichondrium differentiate into osteoblasts that produce a bone collar around the diaphysis of 
the skeletal element and the perichondrium becomes the periosteum [143, 144]. Together with 
blood vessels, osteoblast and osteoclasts from the bone collar migrate into the mineralized 
cartilage, which is thereby replaced by bone forming the primary spongiosa of the primary 
ossification center [143, 144].  
During postnatal development secondary ossification centers are established in the epiphyseal 
regions of bones [144]. Whereas cartilage at the epiphyseal surfaces develops into articular 
cartilage, cartilage between the ossification centers forms the growth plate that is essential for 
longitudinal bone growth [121, 144].  
The growth plate is marked by distinct zones of proliferating cartilage, hypertrophic cartilage 
and bone formation from epiphysis to diaphysis of the skeletal element [143]. Proliferation of 
the less mature chondrocytes at the epiphysis, followed by their hypertrophy and replacement 
by trabecular bone results in a distal replacement of the growth plate by ossesous tissue and in 







Figure 9: Endochondral ossification. Adapted from Long et al. [143]. 
(A) Mesenchymal stem cells condense and (B) differentiate into chondroprogenitors that depose type II collagen and aggrecan 
in their extracellular matrix forming the cartilage anlage of the bone. The cells at the border form the perichondrium. (C) Upon 
differentiation the chondrocytes form distinct subpopulations. Round proliferating (RP) chondrocytes are located at the distal 
ends whereas high proliferating chondrocytes form columns towards the center of the developing bone (columnar proliferating 
(CP) chondrocytes). These cells exit the cell cycle and become prehypertrophic and hypertrophic chondrocytes that mineralize 
their surrounding matrix and finally develop into terminally differentiated chondrocytes. (D) Blood vessels together with 
osteoblasts and osteoclasts invade the hypertrophic cartilage and form a primary ossification center surrounded by a bone collar. 
The cartilage at the ends of the primary ossification center forms the growth plate that is essential for longitudinal bone growth. 
 
3.2.3.2. Chondrogenic growth and transcription factors 
Many growth factors and transcription factors are involved in regulation of chondrogenesis, 
chondrocyte hypertrophy and endochondral ossification during embryonic development. In 
tissue engineering for cartilage regeneration, they can either be used to induce in vitro 





3.2.3.2.1. Chondrogenic growth factors 
Growth factors are extracellular proteins or peptides that bind to cell surface receptors 
activating downstream signal cascades that stimulate proliferation or differentiation of the cell.  
Development of cartilage is orchestrated by a complex signaling network including fibroblast 
growth factors (FGFs), insulin-like growth factors (IGFs), members of the wingless family 
(Wnt), indian hedgehog (Ihh) as well as bone morphogenetic proteins (BMPs) and transforming 
growth factors (TGFβ) [143, 147]. Especially BMPs and TGFβs have great potential at inducing 
in vitro chondrogenic differentiation of mesenchymal stem cells (MSCs) and pluripotent stem 
cells (PSCs) [115]. 
 
3.2.3.2.1.1. Transforming growth factor β 
The transforming growth factor β superfamily consists of bone morphogenetic proteins 
(BMPs), transforming growth factors β (TGFβ) and other proteins like growth and 
differentiation factors (GDFs), activins, inhibins and Mullerian inhibitory factor (MIF) [148, 
149]. TGFβ signaling regulates cell proliferation, differentiation and death, and plays important 
roles in skeletal development and regeneration [149, 150]. 
TGFβ receptors (TGFBR) are transmembrane serine/threonine kinases [148, 150]. There are 
two types of TGFβ receptors, TGFBR-type I and TGFBR-type II, each with several subtypes 
[147, 148]. Upon ligand binding, a heterotetramer, consisting of two TGFBR-type I and two 
TGFBR-type II subunits, is formed. The TGFBR-type II subunit now phosphorylates and 
activates the TGFBR-type I subunit [147, 150]. The TGFBR-type I subunit in turn 
phosphorylates and activates the receptor-regulated Smads (R-SMADs) 2 and 3, which form a 
heterotrimer with the common-mediator Smad (CoSMAD) 4 [147, 149]. This complex 
translocases into the nucleus where it – by interaction with other transcription factors, co-
activators and co-repressors – regulates TGFβ induced changes in gene expression (Figure 10) 
[147, 148]. 
TGFβ signaling is also mediated by Smad-independent pathways [148]. TGFβ signaling 
activates mitogen activated protein kinases (MAPKs) including extracellular signal regulated 





between Smads and MAPKs generate a complex network of intracellular signals leading to cell 
type and developmental stage specific cellular responses to TGFβ signaling [148, 149].  Many 
other signaling pathways, including the phosphatidylinositol-3-kinase (PI3K)/Akt-pathway, 
Rho-like-GTPases and proteinphosphatase2A (PP2A) have also been shown to interact with 
TGFβ signaling [148, 149]. 
TGFβ1 is one of the key transcription factors in cartilage and bone formation, and is required 
for the formation of articular cartilage [147]. Furthermore, during joint development TGFβ1 
signaling plays a significant role in the control of chondrocyte hypertrophy and prevents 
premature degeneration of articular cartilage [147]. TGFβ1 is therefore commonly used to 
induce chondrogenic differentiation of mesenchymal stem cells (MSCs) [152-154], and 







Figure 10: TGFß signaling pathway.  
Adapted from Derynck et al. [148]. 
(A) TGFß binds its receptor that is composed of a 
heterotetramer of two TGFBR-type I and two 
TGFBR-type II molecules. (B) TGFBR-II 
phosphorylates and activates TGFBR-I. (C) The 
active receptor complex phosphorylates and 
activates R-SMADs 2 and 3. (D) Active R-SMADs 
2 and 3 form a complex with the CoSMAD4. (E) 
This SMAD complex translocates into the nucleus 
and modulates gene expression of target genes 








3.2.3.2.1.2. Bone morphogenetic protein 
Bone morphogenetic proteins (BMP) belong to the transforming growth factor β (TGFβ) 
superfamily of growth factors [143]. At least 20 BMP family members have been identified and 
characterized [155]. BMPs play a crucial role in chondrogenesis, chondrocyte hypertrophy and 
endochondral ossification but are also involved in non-osteogenic developmental processes 
including neural development [155, 156].  
BMPs bind to cell surface receptors that act as serine/threonine kinases [151, 155]. These 
receptors are composed of BMP receptor type I (BMPR-I) and type II (BMPR-II) subunits 
[155]. BMPs bind primarily to BMPR-I, but heteromeric complexes of BMPR-I and BMPR-II 
subunits show higher affinity to the ligands [148]. Ligand binding induces autophosphorylation 
of the receptor starting an intracellular signaling cascade [143, 151]. The activated BMP 
receptor phosphorylates and activates the receptor-regulated Smads (R-SMADs) 1, 5 and 8 
[143, 149]. These R-SMADs form a complex with the common-mediator Smad (CoSMAD) 4 
that enters the nucleus and regulates gene expression (Figure 11) [143, 151]. 
BMP2 is one of the main chondrogenic growth factors [156]. It promotes MSCs condensation, 
chondrogenic differentiation and chondrocyte proliferation by inducing the expression of Sox9 
(sex determining region of Y box 9) [156, 157]. Therefore, BMP2 is widely used to induce and 
enhance chondrogenic differentiation of mesenchymal stem cells (MSCs) [156, 158] and 
pluripotent stem cells (PSCs) [159-161] in in vitro culture systems.  
However, BMP2 also stimulates chondrocyte hypertrophy, osteogenic differentiation and 













Figure 11: BMP signaling pathway.  
Adapted from Derynck et al. [148]. 
(A) BMP binds its receptor that is composed of a type 
I (BMPR-I) and type II (BMPR-II) subunit. (B) The 
subunits autophosphorylate and activate themselves. 
(C) The active receptor complex phosphorylates and 
activates R-SMADs 1, 5 and 8. (D) Active R-SMADs 
1, 5 and 8 form a complex with CoSMAD4. (E) This 
SMAD complex translocates into the nucleus and 
modulates gene expression of target genes together 
with other transcription factors. 
 
3.2.3.2.2. Chondrogenic transcription factors 
Transcription factors are intracellular proteins that bind genomic DNA and regulate 
transcription rate and expression of genes. Many transcription factors are involved in 
chondrogenesis and osteogenesis with Sox9 (Sex determining region of Y box 9) and Runx2 
(Runt-releated transcription factor) being the principal regulators, respectively [151]. 
 
3.2.3.2.2.1. Sox9 
Sox9 belongs to the SRY family that is encoded by the sex determining region of the Y 
chromosome [162]. Sox9 is an essential transcription factor in chondrogenesis as it is critical 
during mesenchymal condensation and differentiation of mesenchymal stem cells into 
chondrocytes [163, 164]. Later in chondrogenesis, Sox9 inhibits chondrocyte maturation and 




Together with Sox5 and Sox6, Sox9 forms the so-called Sox-trio [162]. Sox9 induces the 
expression of Sox5 and Sox6 [164]. While Sox9 is required to activate gene expression of 
cartilage specific genes like Col2a1 or Acan, Sox5 and Sox6 increase the binding efficiency of 
Sox9 to cartilage-specific enhancers [162]. So in absence of Sox5 or Sox6, the expression of 
Col2a1 and Acan is significantly reduced leading to severe impairment of chondrogenesis 
[162]. In Sox9 knock-out mice, however, no chondrogenesis occurs at all [156, 163].  
Furthermore, Sox9 prevents chondrocyte hypertrophy and osteogenic differentiation by 
repressing Runx2 expression and activity, and by inhibiting WNT/β-catenin signaling [157, 
162] 
During in vitro chondrogenesis, Sox9 is one of the earliest markers indicating successful 
chondrogenic differentiation [156]. Upregulation of Sox9 gene expression is therefore 




Runx2 belongs to the Runx family (Runt-related transcription factor) of transcription factors, 
and is one of the key transcription factors during osteoblast differentiation and bone formation 
[164, 165]. Furthermore, Runx2 is expressed in prehypertrophic and hypertrophic 
chondrocytes, and induces chondrocyte hypertrophy at the later stages of endochondral 
ossification [164, 165].  
In vitro, Runx2 has been shown to mediate BMP2-induced osteogenic differentiation of MSCs 
[156, 157]. Runx2 upregulation during in vitro chondrogenesis, however, is considered as a 








3.2.4. Clinical relevance of articular cartilage 
Articular cartilage is an avascular tissue in which nutrition is provided only by diffusion from 
the synovial fluid or the subchondral bone [117]. Furthermore, chondrocytes are embedded in 
a dense ECM that hampers their proliferation and migration [115, 116]. Cartilage lesions and 
degradation cause pain and immobility making efficient strategies for cartilage repair necessary. 
 
3.2.4.1. Focal cartilage lesions and osteoarthritis 
Focal cartilage lesions are often of traumatic origin [166]. Recent publications have stated that 
chondral lesions can be found during 57 - 66% of knee-arthroscopies [166, 167]. Furthermore, 
patients with focal chondral lesions report reduced quality of life to the same extent as patients 
with severe osteoarthritis scheduled for total joint replacement [168]. Partial thickness lesions 
do not reach the subchondral bone, so that the defect area is inaccessible for blood or progenitor 
cells from the bone marrow [115, 116]. Despite an increase in proliferation and metabolic 
activity of nearby chondrocytes, these defects usually fail to be filled up and represent 
predilection sites for tissue degeneration [115, 116]. Full thickness lesions, however, reach 
through the complete articular cartilage layer and penetrate the subchondral bone. They are 
referred to as osteochondral lesions [115, 116]. These defects are filled up with a fibrin clot 
which is invaded by progenitor cells from the bone marrow [115, 116]. These cells differentiate 
into chondrocytes and over time fill the defect with fibrocartilage that is, however, more prone 
to degeneration than healthy articular cartilage [115, 116].  So, untreated focal cartilage lesions 
over time progress into osteoarthritis [169]. 
Osteoarthritis is the most common form of arthritis and leading cause of mobility disability in 
the world resulting in a large socioeconomic burden [170, 171]. Osteoarthritis is a complex, 
multifactorial disease that finally leads to irreversible degradation and loss of articular cartilage 
causing pain, joint stiffness, crepitus, effusion and restricted range of motion [119, 172]. These 
symptoms together with the typical radiological changes (narrowing of the joint space width, 
osteophyte formation, development of subchondral sclerosis and cysts) allow the clinical 
diagnosis of osteoarthritis (Figure 12) [171]. Age, obesity, female gender and genetic 




or limb malalignment have been described as the main risk factors for developing osteoarthritis 
in human [170, 171].  
Recent research has led to a better understanding of the pathogenesis of osteoarthritis. 
Activation of chondrocytes, subchondral osteoblasts and synoviocytes by proinflammatory and 
mechanical stimuli provokes an inflammatory response. The cells release cytokines like 
interleukin 6 (IL-6) and tumor necrosis factor α (TNFα) that maintain the inflammatory 
response. Furthermore, the ECM is destroyed by matrix degrading enzymes. Metalloproteases 
(mostly MMP-1, MMP-3, MMP-13) degrade the collagen II-backbone of the ECM, whereas 
ADAMTS-4 and ADAMTS-5 (a disintegrin and metalloproteinase with thrombospondin-like 
motifs) mediate aggrecan degradation [170, 171].  
 
 
Figure 12: X-Ray Image of an osteoarthritic knee joint. Modified from Braun et al. [173].  
Some of the typical radiological signs of osteoarthritis, namely osteophyte formation, joint space narrowing and subchondral 
sclerosis are clearly visible.  
 
3.2.4.2. Current treatment options 
Despite the increasing knowledge of the pathomechanisms of osteoarthritis and advances in 
MRI technology allowing detection of early osteoarthritic changes, no targeted treatment for 
early osteoarthritis is available yet [170, 171]. Current treatment options can be divided in 
conservative and surgical methods. Conservative management includes reduction of risk 





inflammatory drugs [119, 171]. Surgical correction of predisposing conditions like hip 
dysplasia or limb malalignment by osteotomies can delay or prevent the onset of osteoarthritis 
effectively [174]. The definite treatment for end stage osteoarthritis remains joint replacement 
by endoprostheses [174]. 
There is broad consent, that – especially in younger patients – focal cartilage lesions should be 
treated to delay onset of osteoarthritis and need for joint replacement [175, 176]. Treatment 
options for focal chondral lesions can be divided into palliative (lavage, debridement), 
restorative (microfracture) and reparative (osteochondral allograft transfer (OAT) and 
autologous chondrocyte injection (ACI)) methods [119, 177]. 
 
3.2.4.2.1. Total joint replacement and endoprostheses 
Total joint replacement with endoprostheses is the maximal invasive definitive treatment for 
end stage osteoarthritis, severe joint injuries or after tumor resections [115, 174]. The damaged 
joint is resected and replaced by an artificial implant typically composed of a combination of 
metal, polyethylene or ceramic (Figure 13) [115, 178]. Due to the increasing incidence of 
osteoarthritis the number of joint replacement surgeries steadily increases [179].  
 
 





3.2.4.2.2. Microfracture and autologous matrix-induced chondrogenesis 
The microfracture technique was first introduced by Steadman et al in the 1990s [180]. 
Following arthroscopic debridement of the cartilage lesion small holes are made in the 
subchondral bone. Blood and fat emerging from the bone marrow form a clot rich in bone 
marrow mesenchymal stem cells (BM-MSCs) that over time differentiate into chondrocytes 
(Figure 14) [181, 182]. Histological examination revealed that microfracture often leads to 
biomechanically inferior fibrocartilage [183]. Although most patients initially report clinical 
improvement, deterioration often occurs after two to four years [181, 183, 184].  
Being a minimally invasive, single stage procedure with minimal morbidity [181, 185], 
microfracture is still the gold standard for treatment of small cartilage defects (< 2cm2) [186].   
Recently, application of a collagen I/III-membrane (Chondro-Gide ®, Geistlich Pharma AG, 
Wolhusen, Switzerland) to stabilize the clot formed by microfracture was described as 
autologous matrix-induced chondrogenesis (AMIC) [187]. Although clinical and functional 
improvement remained stable over more than five years [188, 189], histological examination 
revealed mostly fibrocartilaginous repair tissue [189].  
 
 
Figure 14: Microfracture. Modified from Mithoefer et al. [190].  
(A) Initial debridement of the cartilage lesion to create a stable cartilage margin. (B) Generation of small holes in the exposed 
subchondral bone with an awl. (C) Blood and fat emerging from the subchondral bone marrow form an clot rich in mesenchymal 






3.2.4.2.3. Osteochondral autograft transfer and osteochondral allograft transplantation  
Osteochondral autograft transfer (OAT) is a single stage procedure that immediately fills 
cartilage defects with mature, hyaline cartilage [191, 192]. The use of a single large autograft, 
like e.g. the lateral patellar facet, results in a considerable donor site defect. This likely causes 
donor site morbidity and surface incongruity at the recipient site, that permanently alters the 
biomechanics of the joint and might increase risk of developing osteoarthritis in the long term 
[115, 191, 193]. These limitations can be overcome by mosaic-like transplantation of multiple 
small grafts, therefore this technique is also referred to as mosaicplasty [193]. These 
osteochondral cylinders are harvested from a low weight bearing area of the joint – e.g. the 
medial and lateral femoral condyle periphery – reducing donor site morbidity [194, 195]. 
Perpendicular insertion of multiple small grafts permits progressive contouring of the surface 
leading to a more congruent resurfaced area (Figure 15) [196]. 
OAT leads to significant clinical improvement that is stable also in long term follow up [167, 
196]. Histological analysis revealed good survival of the transplanted hyaline cartilage and 
good integration of the cylinders, whereas the donor sites were filled with fibrocartilage [194]. 
But, OAT is limited to defects smaller than 4 cm2 due to limited availability of donor sites 
[193].  
As a salvage procedure for larger defects, MEGA-OAT – i.e. transfer of the posterior femoral 
condyle – might be considered [175, 197]. Osteochondral allograft transplantation (OCAT) of 
cartilage and subchondral bone cylinders harvested from post-mortal donors is another salvage 
option for large chondral and osteochondral defects [198]. Although the clinical results are good 
to excellent, limited availability of allografts and storage facilities along with the risk of 
immune rejection and infectious disease transmission hamper wide spread clinical use of this 






Figure 15: Osteochondral autograft transfer (OAT). From Winthrop et al. [199].  
Small osteochondral cylinders are harvested from a non-weight bearing area of the joint and transplanted in a mosaic-like 
fashion into the defect area. Therefore, this technique is also referred to as mosaicplasty.  
 
3.2.4.2.4. Autologous chondrocyte injection 
Autologous Chondrocyte Injection (ACI) as the first cell-based cartilage repair technique was 
described by Brittberg et al in 1994 [200]. Shortly, in a first surgery cartilage is harvested from 
a non-weightbearing area of the joint and subjected to enzymatic digestion to release the 
chondrocytes. Since cartilage consists mostly of ECM, the number of isolated chondrocytes 
usually is too small to fill up the defect immediately [115, 172]. Therefore in vitro expansion is 
necessary before the isolated chondrocytes are inserted into the defect during a second surgery 
(Figure 16) [200].  
However, during expansion in monolayer culture dedifferentiation of chondrocytes occurs, and 
injection of these dedifferentiated cells leads to formation of fibrocartilage [201, 202]. Initially, 
the in vitro expanded chondrocytes were injected either under a periosteal flap or under 
synthetic membranes consisting of collagen I/III (Bio-Gide® from Geistlich Biomaterials, 
Wolhusen, Switzerland) [200, 203]. These membranes evolved into nowadays used matrix 
assisted ACI (MACI) [176]. Here, chondrocytes are cultured in hydrogels like CaReS® from 
ArthroKinetics, Esslingen, Germany [204] or BioSeed-C® from BioTissue, Zürich, Switzerland 
[205] which prevent chondrocyte dedifferentiation and provide easier surgical handling [186, 
205].   
ACI is indicated for full-thickness osteochondral defects with a size of 2 cm2 up to 12 cm2 [177, 





significant improvements in clinical scores and better outcomes compared to microfracture or 
mosaicplasty [177, 186]. However, ACI still remains an invasive procedure. Harvesting of 
healthy cartilage can cause not only pain but also degeneration at the harvesting site (donor-site 
morbidity) [16]. Furthermore, traditional ACI requires at least two surgeries and a long 
recovering period [115, 177]. Therefore, single stage procedures using alternative cell sources 




Figure 16: Autologous chondrocyte injection (ACI). From Brittberg et al. [200].  
Biopsies of healthy cartilage are taken from non-weight bearing areas of the joint and chondrocytes are extracted and 
propagated in vitro before they are injected into the defect areal during a second surgery. Here the original protocol of Brittberg 





3.3. Stem cells for articular cartilage repair 
3.3.1. Mesenchymal stem cells for cartilage repair 
3.3.1.1. Mesenchymal stem cells 
Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, are adult, 
multipotent stem cells that can be found in various mesenchymal tissues and have multilineage 
differentiation potential [125, 130]. They were first described by Friedenstein et al as bone 
marrow derived cells capable of osteogenesis [207, 208]. 
According to the International Society for Cellular Therapy (ISCT) cells must fulfill the 
following three criteria to be classified as mesenchymal stem cells [209]: 
1. Cells must be plastic adherent, when maintained in standard culture conditions. 
2. Cells must show a specific antigen expression pattern in flow cytometry.  
3. Cells must have the capacity of trilineage mesenchymal differentiation, thus differentiating 
to osteoblasts, adipocytes and chondroblasts in standard in vitro conditions.  
MSCs have been successfully isolated from various tissues including bone marrow, adipose 
tissue, synovial membrane, periosteum, trabecular bone, skeletal muscle, dermis, peripheral 
blood, umbilical cord blood, umbilical cord stroma and placenta [172, 206, 207]. However, 
bone marrow derived MSCs (BM-MSCs) and adipose tissue derived stem cells (ADSCs) are 
the most commonly used sources of MSCs in cartilage tissue engineering [115, 119, 206]. 
 
3.3.1.2. Chondrogenic differentiation of MSCs 
Induction of chondrogenesis in MSCs requires high cell density mimicking the condensation 
step of cartilage formation during embryonic development [115, 133, 172]. The standard culture 
condition for chondrogenic differentiation of MSCs is a high-density pellet culture achieved by 
centrifugation of cells in a tube with a conical shaped bottom [124]. However, many other 
culture systems including high-density micromass, scaffold-free and scaffold-based systems 
have been successfully used for chondrogenic differentiation of MSCs [130, 133, 210]. 





mostly BMP2 and BMP6, from the transforming growth factor family, mostly TGFβ1 and 
TGFβ3, or of fibroblast growth factor (FGF2) in different combinations and concentrations is 
known to enhance chondrogenesis [115]. As different types of MSCs vary in their 
responsiveness to each growth factor, the optimal combination of growth factors must be 
amended for each MSC-type [133]. 
 
3.3.1.3. Clinical application of MSCs for cartilage regeneration 
Their ability to differentiate into cartilaginous tissue makes MSCs an interesting cell source for 
treatment of osteoarthritis and focal cartilage lesions. Injection of autologous bone marrow-
derived MSCs (BM-MSCs) into cartilage defects has resulted in significant clinical 
improvement comparable to injection of autologous chondrocytes [211]. In contrast to 
autologous chondrocytes, harvesting of BM-MSCs is less invasive and does not require the 
destruction of healthy articular cartilage [211]. The use of allogeneic MSCs would further 
reduce the invasiveness of the harvesting procedure and heterogeneity of the cell population 
[212]. Due to their hypoimmunogenicity and immunomodulatory features together with the 
immune privileged character of articular cartilage, the risk of rejection is low [206, 212]. 
Recently, a first-in human trial has shown a durable clinical improvement as well as an 
acceptable safety profile after injection of allogeneic umbilical cord blood derived MSCs in 
osteoarthritic knees [212].  
Despite their successful application in clinical trials, many challenges remain for MSCs in 
cartilage tissue engineering. These include for example their invasive harvesting, their 
propensity to form hypertrophic cartilage, and their age-related decline in in vivo frequency and 
in vitro proliferation potential [172, 213]. IPSCs could overcome these limitations and become 





3.3.2. Induced pluripotent stem cells for cartilage repair 
3.3.2.1. Applications of induced pluripotent stem cells in cartilage repair 
As described in 3.1.5. Applications of induced pluripotent stem cells, patient-specific IPSCs 
can be used as disease models for genetic diseases. IPSCs have been successfully generated 
from patients suffering from various conditions affecting cartilage like e.g. familial 
osteochondritis dissecans [214] or osteoarthritis [215]. These patient-derived IPSCs could 
provide valuable tools to study the pathomechanisms of these diseases in IPSC-derived 
chondrocytes or cartilaginous tissues especially as primary chondrocytes require invasive 
harvesting and are difficult to culture in vitro [202, 216].  
However, the most promising application of IPSCs is to use them as a source for autologous 
tissue grafts. Theoretically, it would be possible to generate IPSCs from a small skin biopsy or 
even a blood sample of a patient suffering from a symptomatic chondral lesion [19, 36, 37]. 
These IPSCs could be differentiated into chondrocytes or small cartilage particles in vitro, 
which could then be used to fill the chondral lesion [127]. 
Before IPSCs can be used in a clinical setting to treat cartilage lesions many challenges still 
need to be overcome. This includes, first of all, establishment of an efficient, safe and reliable 
differentiation protocol for IPSCs into cartilaginous tissue.  
 
3.3.2.2. Chondrogenic differentiation of pluripotent stem cells 
There are four main strategies for the differentiation of pluripotent stem cells (PSCs) into 
cartilaginous tissue (Figure 17): first, co-culture of PSCs with mature chondrocytes [134, 217, 
218]; second, culture of PSCs under the influence of growth factors mimicking physiological 
chondrogenic development during embryogenesis [127, 135, 219]; third,  two-step 
differentiation via MSC-like cells as an intermediate [220-222]; and finally, formation of 
embryoid bodies (EBs) allowing spontaneous differentiation of PSCs and subsequent selection 
of a chondrogenically primed subpopulation and its direction towards the chondrogenic lineage 
[126, 223, 224]. Although ESCs and IPSCs have both been differentiated successfully by all 






Figure 17: Methods for the chondrogenic differentiation of pluripotent stem cells. Adapted from Driessen et al. [225].  
(A) Chondrogenic differentiation of PSCs can be achieved by co-culture with primary chondrocytes. (B) By serial exposure to 
a set of defined growth factors, PSCs can differentiate into chondrocytes via mesoendodermal intermediates. (C) In a two-step 
differentiation protocol PSCs are first differentiated into mesenchymal stem cells which then are subjected to standard 
chondrogenic differentiation protocols. (D) Isolation chondrogenically primed cells from spontaneous differentiation in 
embryoid bodies.  
 
3.3.2.2.1. Chondrogenic differentiation of PSCs via co-culture and conditioned medium 
It is possible to induce chondrogenesis of ESCs by culturing the cells together with articular 
chondrocytes in a direct co-culture system [217]. However, to avoid contamination of the final 
product with mature chondrocytes, a separation step is necessary [217]. Despite lack of direct 
cell-cell interactions indirect co-culture using transwell inserts covered with bovine 
chondrocytes is sufficient driving ESCs and IPSCs towards the chondrogenic lineage [134, 
218]. Successful chondrogenic differentiation can furthermore be achieved by exposure of 
IPSCs towards a medium conditioned by mature chondrocytes, therefore omitting the need of 
complex co-culture systems completely [162, 165]. Here growth factors and cytokines secreted 
by mature chondrocytes are driving PSCs towards the chondrogenic lineage. This might even 




single growth factors [162, 165]. However, batch to batch variation of primary chondrocytes 
and the need for either human chondrocytes which require invasive harvesting or the use of 
xenogeneic material like bovine chondrocytes hamper the clinical applicability of these 
methods [134, 172, 217]. 
 
3.3.2.2.2. Chondrogenic differentiation of PSCs via sequential exposure to growth factors 
As described in 3.2.3. Articular cartilage development, cartilage tissue originates form 
primitive streak mesendoderm via a paraxial mesoderm intermediate state [146]. During 
embryonic development chondrogenesis is achieved through the direction of different growth 
factors including members of the bone morphogenetic protein (BMP), transforming frowth 
factor β (TGFβ) and wingless (Wnt) families [143, 147]. 
By exposing monolayer cultures of ESCs or IPSCs to sequential combinations of growth factors 
at defined concentrations for each time point, stepwise chondrogenic differentiation via 
mesoendodermal and mesodermal intermediates can be achieved by mimicking physiological 
embryonic development [135, 219]. The PSC-derived chondrocytes form tissue grafts that can 
be implanted into osteochondral defects in in-vivo mouse models [135]. 
When intact IPSC-colonies were cultured under the influence of defined combinations of 
growth factors, inducing first mesoendodermal pre-differentiation then chondrogenic 
differentiation of the cells, the colonies condensed to chondrogenic nodules that could be 
maintained in suspension culture [127]. These nodules resembled chondrogenic pellets and 
improved cartilage repair when implanted into osteochondral defects in rats and mini-pigs 
[127]. 
Taken together, exposure of PSCs to growth factors is effective at inducing chondrogenic 
differentiation. However, formation of teratomas, likely originating from remaining 
undifferentiated cells, was reported after implantation of PSC-chondrocyte derived grafts into 
in vivo osteochondral defect models [135]. Therefore, a separation step to prevent the 
contamination of the final product with an undifferentiated cell population would be favorable 






3.3.2.2.3. Chondrogenic differentiation in a two-step protocol via MSC-like cells 
As described in 3.3.1.2. Chondrogenic differentiation of MSCs, mesenchymal stem cells can be 
easily differentiated into cartilaginous tissue. But since MSCs suffer from the need of invasive 
harvesting procedures providing only limited cell numbers as well as age and donor related 
variations in their chondrogenic differentiation potential, IPSC-derived MSCs would be an 
attractive alternative to primary MSCs [225]. 
MSC-like cells can be derived from IPSCs via repeated passaging of IPSCs in MSC-medium 
on polystyrene dishes by selecting a rapidly cycling, plastic adherent cell population [222, 226]. 
Successful differentiation can be confirmed by fluorescence activated cell sorting (FACS) for 
MSC-markers as well as standard osteogenic, adipogenic and chondrogenic differentiation 
protocols [222, 226]. Chondrogenic differentiation of these IPSC-derived MSC-like cells can 
be achieved in standard culture systems like micromass or pellet culture [221, 227]. No 
teratomas were observed and improved cartilage repair was reported after implantation of those 
pellets into osteochondral defects in rat knee joints [227]. 
Recently, neural crest cells (NCCs), which during embryonic development give rise to many 
cranial tissues including bone and cartilage, have been described as a suitable intermediate to 
differentiate IPSCs towards MSCs [228]. These IPSC-derived MSCs readily differentiate into 
chondrocytes in a standard pellet culture system [220]. 
In summary, performing chondrogenic differentiation of IPSCs via an MSC-intermediate as a 
two-step approach is effective and might provide an attractive alternative to primary MSCs. 
Nevertheless, the need for an extensive cell culture period and repeated passaging might hamper 
clinical applicability [222, 226]. 
 
3.3.2.2.4. Chondrogenic differentiation via embryoid bodies 
When subjected to suspension culture without supplements that prevent differentiation, 
pluripotent stem cells form spherical cell aggregates called embryoid bodies (EBs) and start to 




By allowing EBs to adhere to gelatin coated plates and culturing the outgrowing cells in 
chondrogenic medium supplemented with chondrogenic growth factors like BMP2 and            
TGFβ1, cells that are primed for chondrogenesis, i.e. cells that spontaneously differentiated 
towards the mesodermal lineage, start to proliferate and differentiate into chondrocytes [126, 
160]. 
In order to form an implantable graft, it is possible to use intermediate cells from the outgrowth 
or directly from dissociated EBs to produce chondrogenic pellets [230, 231]. 
As a variation of the two-step approach described in 3.3.2.2.3. Chondrogenic differentiation in 
a two-step protocol via MSC-like cells, MSC-like cells can also be derived from EBs. By 
exposing intact EBs or EB-outgrow cultures to defined media, an MSC-like population can be 
selected and expanded [213, 224]. Standard micromass and pellet culture systems allow 
chondrogenic differentiation of this cell population [224]. 
Taken together, a chodrogenically primed cell population emerged spontaneously in embryoid 
bodies can be selected and expanded under prechondrogenic culture conditions. Chondrogenic 
differentiation can be achieved by disrupting the EBs or their outgrowth into a single cell 
suspension, and subjecting the collected cells to standard chondrogenic protocols like 
micromass or pellet culture. 
Chondrogenic differentiation of EBs formed in microcavities of a hydrogel can also be achieved 
by exposing the intact EBs to a series of different growth factors inducing chondrogenic 
differentiation via mesodermal intermediates similar to the protocols described in 3.3.2.2.2. 
Chondrogenic differentiation of PSCs via sequential exposure to growth factors [219, 223].   
Finally, the hydrogel matrix can be removed completely leading to a scaffold-free implantable 
chondrogenic graft [223].  
So, suggesting that disruption of EBs into a single cell suspension is not necessary for inducing 
chondrogenesis, maintenance of intact EBs under chondrogenic conditions could be a simple 
one-step method for chondrogenic differentiation of PSCs.  
  




4. Aims and milestones of the thesis 
Due to their unlimited proliferation and differentiation potential as well as their somatic origin 
overcoming ethical issues associated with ESCs and NT-SCs, IPSCs offer promising 
possibilities for the future of tissue engineering and regenerative medicine. Especially for 
cartilage regeneration, where currently available methods are either highly invasive or lead to 
insufficient repair tissue, IPSCs could provide an attractive alternative cell source for 
autologous and allogenic tissue grafts. However, there is still a lack of efficient and scalable 
chondrogenic differentiation protocols hampering clinical application of IPSCs.  
The aim of this thesis was therefore, first to find a reliable reprogramming protocol for primary 
murine fibroblasts using the Sleeping Beauty reprogramming system, and to establish an 
assessment panel for the generated IPSCs. Secondly, we aimed at finding an efficient and 
reliable protocol for the chondrogenic differentiation of these IPSCs.  
The following milestones were achieved in this thesis 
1. Successful reprogramming of primary murine embryonic fibroblasts, primary murine ear 
fibroblasts and primary murine tail fibroblasts to IPSCs using a Sleeping Beauty 
transposon-based reprogramming system, and establishment of more than 250 clonal IPS  
cell lines. 
2. Assessment of 22 IPS cell lines for successful induction of pluripotency by morphology, 
alkaline phosphatase staining, expression of pluripotency markers on mRNA and protein 
level as well as for three-lineage differentiation potential in spontaneously formed embryoid 
bodies. 
3. Establishment of a Splinkerette PCR protocol to determine the number of genomically 
integrated transposon copies, and identification of two single integration clones (ETA04 
and ETAC41) for subsequent chondrogenic differentiation. 
4. Successful establishment of an efficient and reliable chondrogenic differentiation protocol 
for the generated IPSCs by free floating culture of spontaneously formed embryoid bodies 
under chondrogenic conditions. 
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5. Materials and Methods 
5.1. Sleeping Beauty transposon based reprogramming system 
5.1.1. Structure of plasmid vectors 
The Sleeping Beauty transposon reprogramming system consists of two plasmids (Figure 18) 
[56]. The pCMV(CAT)T7-SB100X (SB100X) plasmid contains the cDNA of the hyperactive 
SB100X transposase under the control of a continuously active CMV (cytomegalovirus) 
promoter [58]. Once expressed in the target cell, the SB100X transposase enzyme catalyzes 
excision and integration of the sleeping beauty transposon. 
In this study we used four different transposon plasmids.  
The pT2OSKM and pT2OSKML plasmids contain the reprogramming factor cassette and a 
Puro∆TK-selection marker flanked by the SB transposon TIRs, the binding sites for the 
SB100X transposase [53, 232]. The cDNAs of the reprogramming factors Oct3/4, Sox2, Klf4 
and c-Myc with or without Lin28 (pT2OSKM and pT2OSKML) were cloned into a single 
polycistronic vector separated by self-cleaving 2A peptides allowing their expression for a 
single CAG promoter [233]. The puro∆TK-selection marker allows for both positive and 
negative selection. Cells become resistant to puromycin by expressing the puromycin N-
acetyltransferase (puro) and sensitive to 1-(2-desoxy-fluoro-1-beta-darabino-furanosyl)-5-
iodouracil (FIAU) by expression of a truncated version of herpes simplex virus type 1 thymidine 
kinase (DeltaTk) [232].   
The RMCE-OSKM-Cherry and RMCE-OSKML-Cherry plasmids contain – in addition to the 
corresponding pT2 plasmids – the EOS(3+)mCherry pluripotency reporting cassette which 
consists of the fluorescence reporter gene mCherry under the control of the EOS(3+) promoter-
enhancer fragment (ETn (early transposon) LTR (long terminal repeat) coupled with a trimer of 
the Oct4 enhancer motif), as well as heterospecific loxP (loxP and loxP257) sites which would 
allow modification of the genomically integrated transposon by recombinase mediated cassette 
exchange (RMCE) [53].  
All plasmids were kindly provided by Dr. Zoltán Ivics (Paul Ehrlich Institute, Federal Institute 
for Vaccines and Biomedicines, Langen, Germany) whose generosity we wish to acknowledge. 





Figure 18: Plasmids of the Sleeping Beauty reprogramming system. Modified from Grabundjiza et al. [53].  
(A) The pCMV(CAT)T7-SB100X plasmid contains the cDNA of the SB100X transposase under the control of a CMV promotor. 
(B) The pT2OSKM and pT2OSKML plasmids contain the cDNAs of the reprogramming factors Oct3/4, Sox2, Klf4, c-Myc and 
Lin28 in a polycistronic expression cassette separated by self-cleaving 2A-peptide sequences under the control of a CAG 
promotor, and a puro∆TK sequence allowing both positive and negative selection. These sequences are flanked by the Sleeping 
Beauty transposon TIRs. (C) The RMCE-OSKM-Cherry and RMCE-OKSML-Cherry plasmids additionally contain a mCherry 
gene under the control of the EOS(3+) promoter-enhancer motif. Furthermore, there are heterospecific loxP sites (loxP and 
loxP257) flanking the transgenes allowing later modification of the genomically integrated transgene by recombinase mediated 
cassette exchange (RMCE).  
pA: polyadenylation signal, TIR: terminal inverted repeats, T2A: self-cleaving 2A peptide, EOS: ETn (early transposon) LTR 
(long terminal repeat) coupled with a trimer of the Oct4 enhancer motif 
 
5.1.2. Plasmid transformation in competent bacteria and plasmid DNA isolation by 
MaxiPrep 
Prior to their delivery into cells, the provided plasmids were propagated in chemically 
competent Escherichia coli (E. Coli, BL21(DE3)) (Invitrogen), and were isolated by the 
plasmid MaxiPrep kit (Qiagen, Hilden, Germany). 
Briefly, bacteria were thawed on ice before approximately 2µg of plasmid-DNA were added, 
followed by 30 min incubation on ice. Transformation was achieved by a heat shock for 60 sec 
at 42°. After a 2 min relaxation on ice, bacteria were incubated in SOC medium (Invitrogen) at 
37°C with continuous shaking (225 rpm) for 1h. To select transformed clones 50 µl of 
transformed bacteria solution were plated on LB agar plates consisting of 1% Tryptone, 0,5% 
Yeast Extract, 1% NaCl, and 1,5% Agar (all Becton Dickinson, Franklin Lakes, New Jersey, 
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USA) in dH2O, pH 7.0 supplemented either with 100 µg/ml ampicillin (Carl Roth, Karlsruhe, 
Germany) for the pT2OSKM, pT2OSKML, RMCE-OSKM-Cherry and RMCE-OSKML-Cherry 
plasmids, or 150 µg/ml chloramphenicol (Sigma-Aldrich) for the pCMV(CAT)T7-SB100x 
plasmid, and cultured overnight at 37°C. The next day single colonies were picked and 
transferred to 100 ml liquid LB medium supplemented with 100 µg/ml ampicillin or 150 µg/ml 
chloramphenicol, and cultured overnight at 37°C with continuous shaking at 280 rpm. 
Plasmid DNA was extracted with the Qiagen Plasmid Maxi Kit (Qiagen) following the 
manufacturer’s instruction. Shortly, bacteria were pelleted by centrifugation with 6000 g for 10 
min a 4°C. Then bacteria were lysed, and DNA was precipitated by the provided buffers. 
Plasmid DNA was purified by centrifugation and filtration through Qiagen Tips and eluted in 
a 50 ml Falcon tube (Sarstedt, Nümbrecht, Germany). Finally, plasmid DNA was precipitated 
by isopropanol (Merck), washed with 70% ethanol (Merck) and resuspended in the provided 
Tris-EDTA (TE) buffer (Qiagen). DNA concentration and purity were determined 
spectrometrically at A260 and A260/280, respectively, using a Nanodrop 2000 
spectrophotometer (ThermoFisher Scientific). 
  




5.2. Cell culture 
5.2.1. Standard cell culture conditions and procedures 
All cells were cultured at 37° C and 5% CO2 in a humidified incubator (Hera cell 240, 
ThermoFisher Scientific). For the in vitro experiments T-25, T-75 and T-225 cell culture flasks 
(Nunc, ThermoFisher Scientific), 6-well, 24-well and 48-well cell culture plates (Nunc, 
ThermoFisher Scientific), 96-V-bottom non-treated microplates (Costar, Corning, New York, 
USA), and 6 cm- and 10 cm-cell culture as well as 6 cm- and 10 cm-Petri dishes (Costar, 
Corning, New York, USA) were used. All cell-based experiments were carried out under sterile 
conditions in a laminar flow hood. 
 
5.2.1.1. Culturing primary fibroblasts 
Primary murine fibroblasts (Mouse embryonic fibroblasts, MEFs; and adult fibroblasts, FBs) 
were cultured in monolayer in mouse embryonic feeder (EF) medium consisting of Dulbeco’s 
Modified Eagle’s medium (DMEM, Invitrogen) supplemented with 10% Fetal Bovine Serum 
(FBS, Invitrogen) and 1% Penicillin-Streptomycin (Invitrogen) (Table 1). Medium was 
changed twice a week unless otherwise indicated.   
 
Table 1: Mouse EF medium 
Supplement Concentration Volume Distributor 
Dulbeco’s Modified Eagle’s medium (DMEM) 
modified with high glucose, sodium pyruvate, 
GlutaMAXTM and phenol red 
90% 500 ml Invitrogen 
Fetal Bovine Serum (FBS) 10% 50 ml Invitrogen 
Penicillin-Streptomycin (5000 U/ml) 1% 5 ml Invitrogen 
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5.2.1.2. Culturing mouse ESCs and mouse IPSCs 
Pluripotent stem cells require specific culture conditions. Mouse ESCs (mESCs) and mouse 
IPSCs (mIPSCs) during and after successful reprogramming were maintained in mouse IPSC 
medium consisting of DMEM (Invitrogen), 20% FBS (Invitrogen) and 1% Penicillin-
Streptomycin (Invitrogen) supplemented with 1% non-essential amino acids (Invitrogen),          
25 µg/ml L-ascorbic acid (Sigma-Aldrich) and 0.1 mM β-mercaptoethanol (Sigma-Aldrich) 
(Table 2). Furthermore, Leukemia Inhibitory Factor (LIF, generously provided by Markus 
Moser, Max Plank Institute for Biochemistry, Martinsried, Germany) was added to prevent 
uncontrolled differentiation of the pluripotent stem cells [234]. Medium was changed every 
second day unless otherwise indicated.  
Furthermore, mESCs and mIPSCs were cultured either on feeder cells or on Geltrex 
(ThermoFisher Scientific)-coated plates or flasks. Feeder cells are mitotically inactivated MEFs 
generated by exposure to Mitomycin C (Sigma-Aldrich) as described in 5.2.2.3. Preparation of 
mitotically inactivated feeder cells. One day before thawing or passaging of stem cells, feeder 
cells were seeded into the desired cell culture vessel and incubated overnight under standard 
fibroblast culture conditions to allow the feeder cells to attach and spread properly. Then mouse 
EF medium was removed, and the feeder layer was washed with sterile Phosphate Buffered 
Saline (PBS) without Ca2+ and Mg2+ (Merck) to remove any feeder cells that did not survive 
the freezing and thawing procedure. Next the cell culture vessel was filled with an appropriate 
volume of mIPSC medium before pluripotent stem cells were seeded onto it. 
Geltrex is a mixture of extracellular matrix proteins that coats vessels with a basal membrane-
like matrix allowing feeder-free culture of pluripotent stem cells [53]. For the coating of plates 
and flasks, an appropriate volume of cold (T = 4°C) Geltrex was transferred to the cell culture 
vessel and incubated for 60 min at 37°C to allow formation of the matrix. The remaining 
supernatant was sucked off and medium containing feeder-free stem cells was transferred to the 
dish. 
To separate mESCs and mIPSCs from feeder cells, all cells were harvested using the procedure 
described below in 5.2.1.3. Passaging and counting of cells. The cell suspension was reseeded 
onto 10 cm-cell culture dishes and incubated for 30 – 45 min at 37°C. During that time, the 
feeder cells have already adhered to the culture dish whereas the mESCs of mIPSCs still float 




in the medium. The supernatant containing the floating stem cells was carefully collected and 
centrifuged at 500 g for 5 min, and the cell pellet was resuspended in the medium or solution 
needed for downstream experiments. 
For formation of embryoid bodies (EBs) and chondrogenic differentiation cells were cultured 
under special conditions and in special media as described below in 5.2.3. Differentiation of 
induced pluripotent stem cells. 
 
Table 2: Mouse IPSC medium 
Supplement Concentration Volume Distributor 
Dulbeco’s Modified Eagle’s medium (DMEM) 
modified with high glucose, sodium pyruvate, 
GlutaMAXTM and phenol red 
78% 400 ml Invitrogen 
Fetal Bovine Serum (FBS) 20% 100 ml Invitrogen 
Penicillin-Streptomycin (5000 U/ml) 1% 5 ml Invitrogen 
Non-essential amino acids (100x) 1% 5 ml Invitrogen 
L-Ascorbic acid (12.5 mg/ml) 0.1% 1 ml Sigma 
Leukemia Inhibitory Factor (LIF) (100000 U/ml) 0.1% 1 ml Max Plank Institute 
β-mercaptoethanol  0.1 mM 3.2 µl Sigma 
 
5.2.1.3. Passaging and counting of cells  
When fibroblasts reached 80 - 90% confluence, or mESC and mIPSC colonies reached medium 
size and started to flatten at the edges, cells were passaged.  
Therefore, the culture medium was aspirated, and the cell layer was washed with sterile PBS 
(Merck) to remove any remaining medium. Then the cell layer was covered with prewarmed 
Trypsin-EDTA (Sigma-Aldrich) and incubated at 37° C for 5 - 10 min. When most cells had 
become detached, the surface was flushed repeatedly with fresh medium at double the volume 
of trypsin, and the cell suspension was transferred into a 15 ml or 50 ml Falcon tube (Sarstedt). 
10 µl of the suspension were removed for cell counting and injected into a Neubauer chamber 
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(Brand, Grafrath, Germany). This chamber consists of four quadrants (A, B, C, D). Cells in the 
quadrants were counted and the total cell count (n) was estimated by the following formulas: 
Equation 1: number of cells/ml (CC) = [(A+B+C+D)/4] x 104  
Equation 2: total cell count (n) = number of cells/ml (CC) x total cell suspension volume (V) 
The remaining cell suspension was centrifuged at 500 g for 5 min to collect the cells at the 
bottom of the tube. Then the supernatant was aspirated, and the cell pellet was resuspended in 
prewarmed culture medium and reseeded in an appropriate cell culture vessel.  
For expansion, MEFs and adult FBs were seeded at a density of about 5000 cells/cm2. MESCs 
and mIPSCs were splitted at a ratio of 1 : 5 – 1 : 10 and seeded at a density of approximately    
4 x 105 cells/cm2 on feeder cells or on Geltrex-coated vessels. 
 
5.2.1.4. Cryo-conservation of cells 
As soon as an appropriate cell number was reached, cells were cryo-conservated until needed. 
Cells were harvested according to the standard procedure described in 5.2.1.3. Passaging and 
counting of cells. After the centrifugation step, the cell pellet was resuspended in ice cold 
freezing medium consisting of DMEM (Invitrogen), 20% FBS (Invitrogen) and 1% 
Dimethylsulfoxid (DMSO, AppliChem, Darmstadt, Germany) (Table 3). 
Aliquots were prepared and stored on dry ice until frozen completely. Then the cryovials 
(Nalgene, Thermo Fisher Scientific) were placed in a -80°C freezer for maximum one week, 
before the vials were transferred into liquid nitrogen for long-term storage.  
Fibroblasts were frozen at a density of 5 x 105 cells/ml (adult FBs) or 1 x 106 cells/ml (MEFs), 
respectively. MESCs and mIPSCs were frozen at a density of approximately 5 x 106 cells/ml 









Table 3: Freezing medium 
Supplement Concentration Volume Distributor 
Dulbeco’s Modified Eagle’s medium (DMEM) 
modified with high glucose, sodium pyruvate, 
GlutaMAXTM and phenol red 
79% 400 ml Invitrogen 
Fetal Bovine Serum (FBS) 20% 100 ml Invitrogen 
Dimethylsulfoxid (DMSO) 1% 5 ml AppliChem 
 
5.2.1.5. Thawing of cells 
The frozen cryovials were placed into a water bath at 37°C until the frozen cell suspension had 
melted completely. Then the cell suspension and 5 ml of mouse EF medium or mouse IPSC 
medium per vial were transferred into an appropriate Falcon tube and centrifuged at 500 g for 
5 min. The supernatant was removed, and the cell pellet was resuspended in prewarmed 
medium. Then cells were seeded in the desired cell culture vial and incubated at 37°C and 5% 
CO2 overnight. The next day, medium was changed to remove any cells that had not survived 
the freezing and thawing procedure.   
 
5.2.2. Generation of IPSCs from primary murine fibroblasts 
5.2.2.1. Isolation of primary murine fibroblasts 
Mouse ear fibroblasts (EAR FBs) were isolated from the ear of a four month old wild type 
C57B1/6 mouse, and mouse tail fibroblasts (TAIL FBs) were derived from the tail tip of the 
same animal. The sacrificed mouse was placed under a laminar flow hood. The biopsy sites 
were sprayed twice with 70% ethanol before small (0.5 – 1.0 cm2) tissue pieces were cut from 
ear and tail tip, and rinsed twice with sterile PBS containing 1% Penicillin-Streptomycin. On a 
6 cm-cell culture dish, the biopsies were placed into a drop of Collagenase-Dispase-medium 
consisting of 4 mg/ml collagenase (Worthington Biochemical Corp., New Jersey, USA) and 4 
mg/ml dispase (Sigma-Aldrich) dissolved in DMEM supplemented with 1% Penicillin-
Streptomycin (Table 4). The tissue samples were minced with sterile scalpel and forceps. Then, 
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fresh Collagenase-Dispase medium was added, and the tissue chunks were incubated for 30min 
at 37°C. Then the dish was filled with 6 ml of mouse EF medium and incubated overnight at 
37°C allowing the cells to spread out of the tissue chunks and attach to the plate (passage 0).  
The following day remaining large pieces of tissue were further dissociated by pipetting up and 
down to increase the cell harvest. As soon as the outgrowing fibroblasts reached 80-90% 
confluence, the cells were trypsinized and passaged into a 75 cm2 flask (passage 1) as described 
above in 5.2.1.3. Passaging and counting of cells.     
 
Table 4: Collagenase-Dispase medium 
Supplement Concentration Volume Distributor 
Dulbeco’s Modified Eagle’s medium (DMEM) 
modified with high glucose, sodium pyruvate, 
GlutaMAXTM and phenol red 
99% 1.5 ml Invitrogen 
Penicillin-Streptomycin (5000 U/ml) 1% 1.5 µl Invitrogen 
Collagenase 4 mg/ml 6 mg Worthington 
Dispase 4 mg/ml 6 mg Sigma 
 
5.2.2.2. Isolation of primary mouse embryonic fibroblasts 
Mouse embryonic fibroblasts were prepared from mouse embryos at 12.5 dpc to 13.5 dpc. After 
dissecting the uterus, the embryos were placed in a Petri dish under a laminar flow hood and 
rinsed with sterile PBS. Head and inner organs were removed using sterile scissors and forceps. 
Next, the remaining carcasses were minced into a 50 ml Falcon tube containing 1ml Trypsin 
EDTA per embryo. This suspension was incubated at 37°C for 10 min to digest the tissue. 
Remaining tissue chunks were mechanically disrupted by pipetting before 3 ml of mouse EF 
medium per embryo were added to stop the digestion. Next, the suspension was incubated at 
room temperature for 10 min to let larger pieces of tissue sink down to the bottom of the Falcon 
tube. The supernatant was carefully transferred into a 50 ml Falcon tube without disturbing the 
tissue chunks at the bottom, and centrifuged at 500 g for 5 min. The cell pellet was resuspended 
in mouse EF medium, and the cells were seeded into 75 cm2 flasks (passage 0). After two days, 
supposedly only the embryonic fibroblasts have survived and adhered to the bottom of the flask. 




Dead cells and other cell types were removed by sucking off the medium and rinsing the flask 
twice with sterile PBS before the MEFs were trypsinized and passaged using the standard 
techniques described above in 5.2.1.3. Passaging and counting of cells.  
 
5.2.2.3. Preparation of mitotically inactivated feeder cells 
Before MEFs can be used as feeders for stem cell culture, they need to be mitotically inactivated 
in order not to overgrow the stem cells. Therefore, MEFs at passage 3 – 8 were cultured in      
225 cm2 flasks under normal conditions until they nearly reached confluence. Then, medium 
was replaced by mouse EF medium supplemented with 10 µl/ml Mitomycin C (Sigma-Aldrich) 
and the cells were incubated for 2.5 - 3 hours at 37°C under 5% CO2. The monolayer was 
washed twice with sterile PBS to remove any remnants of Mitomycin C before aliquots of 
approximately 5 x 105 cells/ml were frozen and stored using the standard procedure described 
in 5.2.1.4. Cryo-conservation of cells.  
 
5.2.2.4. Nucleofection of fibroblasts 
Nucleofection is an electroporation-based method for delivery of plasmids into the nuclei of 
target cells. For nucleofection of MEFs we used the P3 Primary Cell 4D-Nucleofector® X Kit 
(Lonza, Basel, Switzerland), whereas for nucleofection of adult FBs we used the P2 Primary 
Cell 4D-Nucleofector® X Kit (Lonza). All experiments were carried out in a 4D-
Nucleofector™ X Unit (Lonza). 
To estimate and optimize efficiency of gene delivery via nucleofection, we first nucleofected 
fibroblasts with the pmaxGFP (green fluorescent protein) vector provided with the 
nucleofection kit. The cells were cultured, harvested and counted using standard techniques 
described above. Next, an appropriate number of cells was centrifuged at 200 g for 10 min 
before 100.000 cells per reaction were resuspended in 16.4 µl nucleofector solution of the 
respective kit supplemented with 3.6 µl supplement solution and 1 µg of the pmaxGFP vector 
provided by the manufacturer (Table 5). This suspension was transferred into one well of the 
16-well Nucleocuvette Strip (Lonza). Nucleofection was carried out testing different programs 
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as recommended by the manufacturer. After the run, the Nucleocuvette Strip was incubated at 
room temperature for 10 min before 80 µl of prewarmed mouse EF medium were added. The 
cell suspension was transferred into one well of a 24-well-plate and incubated overnight. 24 
hours after nucleofection survival rate and efficiency were analyzed. To estimate the survival 
rate, dead cells floating in the medium were counted using the Neubauer chamber as described 
in 5.2.1.3. Passaging and counting of cells and the survival rate was determined as follows: 
Equation 3: Survival rate (%) = (1 – mean dead cell count/100 000) x 100. 
To determine the efficiency, we screened the cells for expression of GFP. Representative 
photomicrographs were taken by an AxioCam MRm camera (Carl Zeiss, Oberkochen, 
Germany) mounted on an Axio Observer.Z1 microscope (Carl Zeiss). GFP+ cells per viewing 
field (pvf) and total cell number per viewing field were counted and efficiency rate was 
determined as follows: 
Equation 4: Efficiency rate (%) = (fluorescent cells pvf/ total cell number pvf) x 100. 
To initiate the reprogramming process, the pCMV(CAT)T7-SB100x transposase plasmid 
together with either the pT2OSKM, pT2OSKML, RMCE-OSKM-Cherry or RMCE-OSKML-
Cherry reprogramming factor plasmid were delivered into the cells by Nucleofection.  
Fibroblasts were harvested, counted and centrifuged as described above. For one reaction       
400 000 cells were resuspended in 82 µl nucleofector solution of the respective kit and 18 µl 
supplement solution. Then, 1 µg, 2 µg or 5 µg of the respective reprogramming factor plasmid 
and 0.1 µg, 0.2 µg or 0.5 µg of the transposase plasmid were added (Table 5) before the cell-
DNA-mix was transferred into a Single Nucleocuvette (Lonza), and cells were nucleofected 
with the program EH-198. After the run, the Nucleocuvette was incubated for 10 min at room 
temperature. Then 500 µl of prewarmed mouse IPS medium were added and the cell suspension 
was transferred to either standard cell culture dishes, feeder- or Geltrex-coated dishes as 








Table 5: Nucleofection reaction set up 
 Optimization Reprogramming  
Number of cells/ reaction 100 000 cells 400 000 cells 
Nucleofector solution (P2 for FBs, P3 for MEFs) 16.4 µl 82 µl 
Supplement solution 3.6 µl 18 µl 
pmaxGFP vector 1 µg  
Transposase plasmid (pCMV(CAT)T7-SB100X)  0.1/ 0.2/ 0.5 µg 
Reprogramming factor plasmid  1/ 2/ 5 µg 
 
5.2.2.5. Reprogramming of primary murine fibroblasts 
After delivery of the reprogramming factors via nucleofection, the fibroblasts were cultured in 
mouse IPSC medium and monitored daily for morphological changes indicating successful 
reprogramming. Medium was changed daily until picking of colonies was completed.  
In order to optimize the reprogramming process, different culture conditions were tested. 
Therefore, after nucleofection the fibroblasts were either seeded onto standard cell culture 
dishes or feeder cells or Geltrex-coated cell culture dishes. When the cells became highly 
confluent, plates were trypsinized and passaged using the standard techniques described above 
in 5.2.1.3. Passaging and counting of cells.  
 
5.2.2.6. Picking of colonies and establishment of clonal cell lines 
To establish clonal IPS cell lines, colonies of bona fide IPSCs that showed the typical round, 
spheroid and compact morphology of mESCs, were chosen for picking between day 19 and day 
27 after nucleofection with the reprogramming factor plasmids (Figure 19).  
Therefore, the plates were placed under a 3D-Stereomicroscope (Stemi 2000-CS, Carl Zeiss) 
and the chosen colonies were mechanically dislodged from the surface with a 20 µl pipet tip 
(1), carefully sucked into the pipet tip and transferred into one well of a 96-V-bottom non-
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treated microplate filled with prewarmed trypsin (2). After 5 min incubation at 37°C (3) mouse 
IPSC medium was added and the breakdown of the colonies to a single cell suspension was 
achieved by pipetting up and down repeatedly (4). The single cell suspension was then 
transferred into one well of a 24-well plate previously seeded with feeder cells (5). This was 
counted as passage 0 of the thereby newly established clonal IPS cell line.  
We named the established cell lines TAXX for MEF-derived IPSCs, ETAXX for EAR-FB- 
derived IPSCs, TTAXX for TAIL-FB-derived IPSCs reprogrammed with the 
pT2OSKM/OSKML vector; or ETACXX for EAR-FB-derived IPSCs reprogrammed with the 
RMCE-OSKM/OSMKL-Cherry vector.  
Picked IPSCs were cultured under standard condition for up to one week. Cells that formed 
many round, spheroid and compact colonies were considered successfully reprogrammed 
IPSCs and frozen until further analysis. Cells that failed to maintain IPSC morphology, and 
therefore were probably not successfully reprogrammed, were discarded. Cells that only formed 
few, large colonies were passaged once and then either frozen or discarded.  
 
 
Figure 19: Schematic depiction of the picking of bona fide IPSC colonies (self-designed). 
(1) Colonies are mechanically dislodged from the cell culture dish. (2) Colonies are sucked into the pipet tip and transferred 
into trypsin. (3) Colonies are incubated for 5 min in trypsin. (4) Further dissociation of the colonies into a single cell suspension. 
(5) Transfer of the single cell suspension onto feeder-coated 24-well plates. 
 




5.2.3. Differentiation of induced pluripotent stem cells 
5.2.3.1. Formation of embryoid bodies in hanging drops 
Feeder-free mIPSCs were harvested using standard techniques described in 5.2.1.2. Culturing 
mouse ESCs and mouse IPSCs and 5.2.1.3. Passaging and counting of cells, and resuspended 
in hanging drop medium consisting of DMEM with 20% FBS and 1% Penicillin-Streptomycin 
supplemented with 1% non-essential amino acids and 0.1 mM β-mercaptoethanol at a 
concentration of 40 000 cells/ml (Table 6).  
Then 20 µl drops of this suspension containing 800 cells each were placed on the lid of a              
10 cm-Petri dish. The bottom of the plate was covered with sterile PBS to provide a humid 
atmosphere preventing the small drops from drying out. Then the lid was carefully inverted in 
order not to destroy the drops, and placed on the bottom (Figure 20). Under this culture 
condition, mIPSCs cluster together forming EBs [235]. EBs were cultured for five days in 
hanging drop culture before being used for downstream experiments.   
 
 
Figure 20: Hanging drop culture of mIPSCs.  
20 µl drops containing 800 cells on the lid of a 10 cm-Petri dish. The bottom of the dish is covered with sterile PBS to provide 
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Table 6: Hanging drop medium 
Supplement Concentration Volume Distributor 
Dulbeco’s Modified Eagle’s medium (DMEM) 
modified with high glucose, sodium pyruvate, 
GlutaMAXTM and phenol red 
78% 400 ml Invitrogen 
Fetal Bovine Serum (FBS) 20% 100 ml Invitrogen 
Penicillin-Streptomycin (5000 U/ml) 1% 5 ml Invitrogen 
Non-essential amino acids (100x) 1% 5 ml Invitrogen 
β-mercaptoethanol 0.1 mM 3.2 µl Sigma 
 
5.2.3.2. Spontaneous differentiation of mIPSCs in embryoid bodies 
To evaluate the potential of the generated IPSCs to differentiate into the three germ layers, cells 
were allowed to differentiate spontaneously in EBs.  
Therefore, EBs generated by the hanging drop method described above in 5.2.3.1. Formation 
of embryoid bodies in hanging drops were transferred at day 5 into 96 V-shaped-bottom, non-
treated microplates and maintained as spheroids for further 16 days in free floating medium 
(Table 7) consisting of DMEM supplemented with 10% FBS and 10% horse serum as well as 
1% Penicillin-Streptomycin (Figure 21). Medium was changed twice a week. After a total of 
21 days of differentiation, mRNA for qPCR analysis was isolated from EBs. Spontaneous 
differentiation of mIPSCs in EBs and subsequent mRNA analysis was performed in triplicates. 
 
 
Figure 21: Spontaneous differentiation of mIPSCs in embryoid bodies (self-designed).  
IPSCs were cultured under feeder-free standard conditions before embryoid body formation was achieved by hanging drop 
culture. Embryoid bodies were maintained in hanging drops for 5 days before they were transferred to 96 V-shaped-bottom 
non-treated microplates, and maintained in suspension for additional 16 days. 




 Table 7: Free floating medium 
Supplement Concentration Volume Distributor 
Dulbeco’s Modified Eagle’s medium (DMEM) 
modified with high glucose, sodium pyruvate, 
GlutaMAXTM and phenol red 
79% 500 ml Invitrogen 
Fetal Bovine Serum (FBS) 10% 50 ml Invitrogen 
Horse Serum 10% 50 ml Invitrogen 
Penicillin-Streptomycin (5000 U/ml) 1% 5 ml Invitrogen 
 
5.2.3.3. Chondrogenic differentiation of mIPSCs via chondrogenic colonies 
Scafoldless chondrogenic differentiation of mIPSC clone ETA04 was carried out by exposure 
of intact IPSC colonies to mesoendodermal pre-differentiation medium followed by 
chondrogenic medium and subsequent transfer of the formed chondrogenic nodules into free 
floating culture as described by Yamashita et al. [127].  
IPSCs were cultured under feeder-free conditions on Geltrex-coated 6-well plates until colonies 
reached medium size. Then mesoendodermal predifferentiaton was induced by changing the 
culture medium to mesoendodermal medium (Table 8) consisting of DMEM/F12 (Invitrogen) 
with 1% FBS, 1% Penicillin-Streptomycin and 1% Insulin Transferrin Selenite Plus3 Mix (ITS, 
Sigma-Aldrich) supplemented with the growth factors Wnt3a (R&D Systems) and Activin A 
(R&D Systems) at a concentration of 10 ng/ml each. After three days of mesoendodermal pre-
differentiation chondrogenic differentiation was induced by changing the culture medium to 
chondrogenic colonies medium (Table 9) consisting of DMEM, 1% FBS and 1% Penicillin-
Streptomycin supplemented with non-essential amino acids, natrium pyruvate (Sigma-Aldrich), 
Insulin Transferrin Selenite Plus3 Mix (Sigma-Aldrich) and L-ascorbic acid (Sigma-Aldrich). 
IPSCs were maintained as colonies on Geltrex for four days either in chondrogenic colonies 
medium (noGF) or in chondrogenic colonies medium supplemented with the chondrogenic 
growth factors bone morphogenetic protein 2 (BMP2, R&D Systems), transforming growth 
factor beta1 (TGFβ1, R&D Systems) and growth and differentiation factor 5 (GDF5, R&D 
Systems) at a concentration of 10 ng/ml each (BTG). After four days, most colonies had 
spontaneously detached from the plates and were transferred to free floating culture in 6 cm-
non-adherent Petri dishes. Chondrogenic nodules were maintained in free floating culture in 
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chondrogenic colonies medium with or without supplemented growth factors for up to 42 days 
(Figure 22).  Medium was changed twice a week. At day 14, 31 and 42, nodules were either 
subjected to mRNA isolation for qPCR analysis or embedded for histological analysis.  
 
 
Figure 22: Chondrogenic differentiation of mIPSCs via chondrogenic colonies (self-designed) 
IPSCs were cultured under feeder-free standard conditions before mesoendodermal pre-differentiation was induced in 
mesoendodermal medium supplemented with Wnt3a and Activin A for 3 days. Initial chondrogenic differentiation was induced 
by culturing the predifferentiated IPSC colonies in chondrogenic colonies medium (noGF) or in chondrogenic colonies medium 
supplemented with BMP2, TGFβ1 and GDF5 (BTG) for 4 days. After one week of differentiation the colonies started to detach 




Table 8: Mesoendodermal medium  
Supplement Concentration Volume Distributor 
DMEM/F12 97% 48.5 ml Invitrogen 
Fetal Bovine Serum (FBS) 1% 0.5 ml Invitrogen 
Penicillin Streptomycin (5000U/ml) 1% 0.5 ml Invitrogen 










Table 9: Chondrogenic colonies medium 
Supplement Concentration Volume Distributor 
Dulbeco’s Modified Eagle’s medium (DMEM) 
modified with high glucose, sodium pyruvate, 
GlutaMAXTM and phenol red 
95% 47.0 ml Invitrogen 
Fetal Bovine Serum (FBS) 1% 0.5 ml Invitrogen 
Penicillin-Streptomycin (5000 U/ml) 1% 0.5 ml Invitrogen 
Non-essential amino acids (100x) 1% 0.5 ml Invitrogen 
Natrium pyruvate (100 mM) 1% (1 mM) 0,5 ml Sigma 
Insulin Transferrin Selenite Plus3 (ITS, 100X) 1% 0.5 ml Sigma 
L-ascorbic acid (5 mg/ml) 1% (50 µg/ml) 0.5 ml Sigma 
 
5.2.3.4. Chondrogenic differentiation of mIPSCs via embryoid bodies 
After spontaneous pre-differentiation of mIPSCs in EBs in hanging drop culture for 5 days, 
they were transferred into 96-V-bottom non treated microplates and maintained as spheroids 
for up to 42 days in chondrogenic medium (noGF) or chondrogenic medium supplemented with 
chondrogenic growth factors bone morphogenetic protein 2 (BMP2, R&D Systems, 
Minneapolis, Minnesota, USA) at a concentration of 100 ng/ml and transforming growth factor 
beta1 (TGFβ1, R&D Systems) at a concentration of 10 ng/ml (BT) (Figure 23). The serum-free 
chondrogenic medium (Table 10) consisted of DMEM and 1% Penicillin-Streptomycin 
supplemented with dexamethason (Sigma-Aldrich), natrium pyruvate (Sigma-Aldrich), L-
ascorbic acid (Sigma-Aldrich) and Insulin Transferrin Selenite Plus3 Mix (Sigma-Aldrich), 
representing a standard medium for chondrogenic differentiation [211, 218]. Medium was 
changed twice a week. At day 14, 28 and 42, spheroids were either subjected to mRNA isolation 
for qPCR analysis or embedded for histological analysis. Formation of chondrogenic spheroids 
and subsequent mRNA and histological analyses were performed in triplicates. 
 




Figure 23: Chondrogenic differentiation of mIPSCs via embryoid bodies (self-designed). 
IPSCs were cultured under feeder-free standard conditions before embryoid body formation was achieved by hanging drop 
culture. Embyonic bodies were maintained in hanging drops for 5 days before they were transferred to 96 V-shaped-bottom 
non-treated microplates containing either chondrogenic medium (noGF) or chondrogenic medium supplemented with BMP2 
and TGFβ1 (BT). The forming chondrogenic spheroids were maintained up to 42 days. 
 
Table 10: Chondrogenic spheroid medium 
Supplement Concentration Volume Distributor 
Dulbeco’s Modified Eagle’s medium (DMEM) 
modified with high glucose, sodium pyruvate, 
GlutaMAXTM and phenol red 
94,4% 47.2 ml Invitrogen 
Penicillin-Streptomycin (5000 U/ml) 1% 0.5 ml Invitrogen 
Dexamethason (1 mM) 1% (10 µM) 0.5 ml Sigma 
Natrium Pyruvate (100 mM) 1% (1 mM) 0.5 ml Sigma 
L-Ascorbic Acid (12.5 mM) 1.6% (0.195 mM) 0.78 ml Sigma 
Insulin Transferrin Selenite Plus3 (ITS, 100X) 1% 0.5 ml Sigma 
  




5.3. Cytological analysis 
5.3.1. Alkaline phosphatase staining 
ESCs and IPSCs were cultured in 6-well plates under standard culture conditions on feeder cells 
for 2 – 4 days. When the colonies reached medium size, the plates were washed with PBS before 
the cells were fixed with pre-cooled 4% paraformaldehyde (PFA, Merck) for 15 min at room 
temperature. Then the plates were washed twice with sterile PBS to remove all remaining PFA. 
The cells were equilibrated in DIG III Buffer (0.1 M Tris pH 9.5, 0.1 M NaCl, 0.05 M MgCl2 
in dH20, chemicals from Sigma-Aldrich and Merck) for 10 min before they were covered with 
the staining solution consisting of 200 µl nitro blue tetrazolium chloride/ 5-bromo-4-chloro-3-
indolyl-phosphate (NTC/BCIP, Roche Diagnostics, Risch, Switzerland) in 10 ml DIG III 
Buffer. Cells were allowed to stain for up to 20 min protected from light at room temperature. 
Then the staining solution was removed and the plates were washed twice with PBS before 
photomicrographs were taken using an AxioCam 105 color camera (Carl Zeiss) mounted on an 
Axio Observer.Z1 microscope (Carl Zeiss).  
AP Staining was repeated twice. 
 
5.3.2. Immunocytochemistry 
ESCs and IPSCs were cultured on 4-well glass slides (Nunc, ThermoFisher Scientific) coated 
with 500 µl human fibronectin (Merck) per well at a concentration of 0.1 mg/ml on feeder cells 
under standard culture conditions for 2 days. When the colonies reached medium size, the cells 
were fixed with pre-cooled 4% PFA for 5 min at room temperature. Then the plates were 
washed twice with PBS to remove all remaining PFA.  
After blocking and permeabilization in PBS supplemented with 1% bovine serum albumin 
(BSA, Roth) and 0.1% Triton X (Sigma) for 1h at room temperature, cells were incubated 
overnight in a wet chamber at 4°C with primary antibodies listed in Table 11. Next day, the 
slides were washed twice in PBS for 5 min to remove any primary antibodies that did not bind. 
Then the cells were incubated for 1h at room temperature with corresponding secondary 
antibodies listed in Table 11. After washing the slides again with PBS, they were mounted with 
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Fluoroshield mounting medium (Sigma-Aldrich) containing 4', 6-diamidino-2-phenylindole 
(DAPI) as a nuclear counterstaining (Sigma-Aldrich), and covered with 20 x 60 mm cover slips 
(Menzel Gläser, ThermoFisher Scientific). Fluorescence was observed and representative 
photomicrographs were taken with an AxioCam MRm camera (Carl Zeiss) mounted on an Axio 
Oberserver.Z1 microscope (Carl Zeiss).  
Immunocytochemistry (ICC) was repeated twice. 
 
Table 11: Antibodies for immunocytochemistry 
Target Type Company Catalogue number 
Dilution in PBS with  
1% BSA and 0.1% TritonX 
Primary antibodies 
Anti-Nanog Polyclonal Goat IgG 
R&D Systems 
AF2729 1:400 
Anti-Oct3/4 Monoclonal Rat IgG2B 
R&D Systems 
MAB 1759 1:400 
Anti-Sox2 Monoclonal Mouse IgG2A 
R&D Systems 
MAB 2018 1:400 
Anti-SSEA1 Monoclonal Mouse IgM 
R&D Systems 





Alexa Fluor 488 





Alexa Fluor 488 
Life Technologies 
A-21202 1:1000 















5.4. mRNA analysis 
5.4.1. Total RNA isolation 
5.4.1.1. Total RNA isolation from cells 
Total RNA was isolated from cells using the RNeasy Mini or Midi Kit (Qiagen, Hilden, 
Germany) according to the number of cells. Cells were harvested following the standard 
procedure described in 5.2.1.3 Passaging and counting of cells and lysed in RLT buffer 
supplemented with 1% β-mercaptoethanol (Sigma). The lysate was homogenized by passing 
through QIAshredder spin columns before 70% ethanol was added in a 1:1 ratio. Samples were 
loaded to the RNeasy Mini or Midi spin columns and washed once with washing solution before 
10 U of DNase (Qiagen) were added to digest genomic DNA. The columns were washed three 
times according to the manufacturer’s instructions and dried by centrifugation at maximum 
speed before total RNA was eluted in RNase-free water. RNA concentration and purity were 
determined spectrometrically at A260 and A260/280, respectively, using a Nanodrop 2000 
spectrophotometer (ThermoFisher Scientific). RNA samples were stored at -80°C. 
 
5.4.1.2. RNA isolation from embryoid bodies, chondrogenic nodules and spheroids 
Total RNA was isolated from EBs, chondrogenic nodules and chondrogenic spheroids using 
the RNeasy Mini Kit (Qiagen, Hilden, Germany). EBs, chondrogenic nodules or spheroids were 
collected in 1,5 ml DNA LoBind Tubes (Eppendorf, Hamburg, Germany) and shortly 
centrifuged in order to collect them at the bottom of the tubes. Then, the supernatant was 
removed and the probes were lysed in TRIzol (Life Technologies) for 5 min at room 
temperature before chloroform (Merck) was added in a 1 : 5 ratio. The samples were centrifuged 
at 12 000 g for 15 min in order to separate the mixture into three phases. The upper phase 
containing the total RNA was harvested and mixed with 70% ethanol (Merck) in a 1 : 1 ratio to 
purify the RNA. Samples were loaded to the RNeasy Mini spin columns and washed once with 
washing solution before 10 U of DNase (Qiagen) were added to digest genomic DNA. The 
columns were washed three times according to the manufacturer’s instructions and dried by 
centrifugation at maximum speed, before total RNA was eluted in RNase-free water.  
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RNA concentration and purity were determined spectrometrically at A260 and A260/280, 
respectively. RNA samples were stored at -80°C. 
 
5.4.2. cDNA synthesis 
cDNA (complementary DNA) was synthesized using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche Diagnostics). First, the RNA denaturation mix (Table 12) consisting of 
100 ng total RNA and random hexamer primers (600 pmol/µl) filled up with RNase free water 
to 13 µl was incubated at 65°C for 10 min. Then PCR buffer, 10 mM dNTPs, 20 U of RNase 
inhibitor and 10 U of reverse transcriptase were added (Table 13). This cDNA synthesis mix 
was incubated for 1 hour at 60°C. To evaluate quality of the synthesis, the newly synthesized 
cDNA was tested for expression of the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH).  
 
Table 12: RNA denaturation mix and program 
Total RNA (100 ng) x µl 
65°C for 5  min 
Keep on ice 
Random hexamer primers (600 µM) 2 µl 
RNAse free H2O 11 µl – x µl 
Total volume 13 µl 
 
Table 13: cDNA synthesis mix and program 
RNA denaturation mix 13 µl 
25°C for 10 min 
50°C for 60 min 
80°C for 5 min 
4°C forever 
Reaction buffer (5x) 4 µl 
RNase inhibitor (40 U/µl) 0.5 µl 
dNTP mix (10 mM each) 2 µl 
Reverse transcriptase (20 U/µl) 0.5 µl 
Total volume 20 µl 
 
  




5.4.3. Semi-quantitative reverse transcription PCR 
For semi-quantitative reverse transcription (RT)-PCRs (polymerase chain reactions), the Fast 
Start Taq DNA Polymerase Kit (Roche Diagnostics) was used. Shortly, 1 µl of cDNA synthesis 
mix (Table 13) was added to a master mix consisting of PCR buffer, 0.2 mM dNTPs each, 0.25 
pmol gene-specific primers and 1 U Taq DNA Polymerase (Table 14). This mix was incubated 
in a Thermocycler (Peqstar 2x, Peqlabs, Erlangen, Germany) using a gene specific program as 
indicated below. The primer pairs and their annealing temperatures used in this study are listed 
in Table 15. 
Amplified PCR products were separated via agarose gel electrophoresis on 2% agarose gels 
containing ethidium bromide (Sigma). As a reference for the size of the products, a 100 bp 
molecular weight standard (Invitrogen) was used. PCR bands were visualised by a gel imaging 
system (Vilber Lourmat, Eberhardzell, Germany) and densitometrically quantified by the Bio 
Capt Software (Vilber Lourmat). 
 
Table 14: RT-PCR reaction set up and program 
10x PCR reaction buffer with MgCl2 2 µl 94°C 5 min 
X cycles 
94°C 30 s 
Y°C 30 s 
72°C 60 s 
72°C 5 min 
4°C forever 
 
Primer forward (10 pmol/µl) 0.5 µl 
Primer reverse (10 pmol/µl) 0.5 µl 
dNTP Mix (10 mM each) 0.4 µl 
Taq polymerase 0.2 µl 
cDNA 1 µl 
dH2O (PCR grade) 15.4 µl 
Total volume 20 µl 
Annealing temperature (Y) and number of cycles (X) are specific for each gene and listed in Table 15 
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Table 15: Oligonucleotides used for RT-PCR 
Target 
gene 
Primer sequence (5’ to 3’) 









GAPDH f: CAACTACATGGTTTACATGTTC r: GCCAGTGGACTCCACGAC 50°C 30 181 [236] 
Embryonic stem cell markers 
Dax1 f: TGCTGCGGTCCAGGCCATCAAGAG r: GGGCACTGTTCAGTTCAGCGGATC 56°C 35 233 [55] 
Ecat1 f: TGTGGGGCCCTGAAAGGCGAGCTGAGAT r: ATGGGCCGCCATACGACGACGCTCAACT 60°C 40 164 [15] 
Eras* f: GCCCCTCATCAGACTGCTAC r: GCAGCTCAAGGAAGAGGTGT 49°C 40 66 [55] 
Nanog f: GAAATCCCTTCCCTCGCCATC r: CTCAGTAGCAGACCCTTGTAAGC 58°C 30 161 [237] 
Rex1 f: ACGAGTGGCAGTTTCTTCTTGGGA r: TATGACTCACTTCCAGGGGGCACT 56°C 35 287 [15] 
Zfp296 f: CCTATGCTTGTGCCCAGAGTA  r: CTAAAGTGCCTGCCCATTTC 53°C 30 214 [55] 
Reprogramming factors 
c-Myc f: TCAAGCAGACGAGCACAAGC r: TACAGTCCCAAAGCCCCAGC 53°C 30 242 [55] 
Klf4 f: GGCGAGAAACCTTACCACTGT r: TACTGAACTCTCTCTCCTGGCA 53°C 30 226 [55] 
Oct3/4 f: TCAGGTTGGACTGGGCCTAGT  r: GGAGGTTCCCTCTGAGTTGCTT 58°C 30 100 [237] 
Sox2* f: GAGGGCTGGACTGCGAACT  r: TTTGCACCCCTCCCAATTC 58°C 30 72 [237] 







60°C 30 IIA: 472 IIB: 268 [129] 
*:   Agarose-gel electrophoresis for PCR products was carried out on 3% agarose gel.  
**:  For simultaneous analysis of the expression of the two isoforms of procollagen II (Col II A and Col II B), two primer pairs 
were used within the same probe resulting in two bands during agarose gel electrophoresis.  
 
  




5.4.4. Quantitative PCR 
Quantitative PCR (qPCR) was performed with a Light Cycler 96 instrument (Roche 
Diagnostics) using either the LightCycler SYBR Green Master Kit (Roche Diagnostics) or Taq-
Man probes. The crossing point (Ct) of each curve was determined by the second derivative 
maximum method. The comparative 2-∆∆Ct method was used to determine the fold change of 
gene expression levels relative to GAPDH between experimental and control conditions. 
Equation 5:  ∆CtExperimental  = CtExperimental (GOI) – CtExperimental (GAPDH)  
  ∆CtControl  = CtControl (GOI) – CtControl (GAPDH) 
  GOI: Gene of interest  
Equation 6:  ∆∆Ct = ∆Ct Experimental - ∆CtControl 
Equation 7: Expression fold change = 2-∆∆Ct 
 
5.4.4.1. LightCycler SYBR Green method 
For qPCR with the LightCycler SYBR Green Master Kit (Roche Diagnostics), 0.5 µl of cDNA 
synthesis mix (Table13) were added to the SYBR Green Master Mix supplemented with 0.5 
pmol gene-specific primers (Table 16). The sequences of the primer pairs used are given in 
Table 17.  
Amplification cycles and melting curve analysis were performed according to the 
manufacturer’s instructions. Quantitative PCR runs with the LightCycler SYBR Green Master 
Kit were performed in triplicates. 
 
Table 16: SYBR Green qPCR reaction set up 
2x SYBR Green Master Mix 10µl 
Primer forward (10 pmol/µl) 1 µl 
Primer reverse (10 pmol/µl) 1 µl 
cDNA 0.5 µl 
dH2O (PCR grade) 7.5 µl 
Total volume 20 µl 
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Table 17: Oligonucleotides used for qPCR (SYBR Green Kit) 
Target gene Primer sequence (5’ to 3’) 




House keeping gene 
GAPDH f: CAACTACATGGTTTACATGTTC r: GCCAGTGGACTCCACGAC 181 [236] 
Pluripotency markers 
Nanog f: GAAATCCCTTCCCTCGCCATC r: CTCAGTAGCAGACCCTTGTAAGC 161 [237] 
Oct3/4 f: TCAGGTTGGACTGGGCCTAGT  r: GGAGGTTCCCTCTGAGTTGCTT 100 [237] 
Endodermal markers 
Sox17 f: GATGCGGGATACGCCAGTG r: CCACCACCTCGCCTTTCAC 136 
Harvard Primer 
Bank 




MyoD1 f: CCACTCCGGGACATAGACTTG r: AAAAGCGCAGGTCTGGTGAG 109 [238] 
Brachyury f: CAGCCCACCTACTGGCTCTA r: GAGCCTGGGGTGATGGTA 72 [53] 
Ectodermal markers 
Pax6 f: GCGCAGACGGCATGTATGATA r: GGGTTGCCCTGGTACTGAAG 104 
Harvard Primer 
Bank 
Ncam1 f: CACTTTGTGTTCAGGACCTCAG r: AAAAGCAATGAGACCAAGGTG 92 [53] 
 
5.4.4.2. Taq-Man probes 
Taq-Man probes containing gene specific primer pairs and quenchers were purchased from IDT 
(Integrated DNA Technologies, Coralville, Iowa, USA). For qPCR, 1 µl of cDNA synthesis 
mix (Table 13) was added to the Prime Time Gene Expression Master Mix (IDT) supplemented 
with 0.5 pmol gene-specific primers (Table 18). The sequences of the primer pairs and 
quenchers are given in Table 19.  
Experimental set up was designed according to the manufacturer’s instructions. Quantitative 
PCR runs with the Taq-Man probes were performed in duplicates. 
Table 18: Taq-Man probes qPCR reaction set up 
2x Prime Time Gene Expression Master Mix 10 µl 
Primer mix (5pmol/µl each) 2 µl 
cDNA (diluted 1:5 in dH2O) 5 µl 
dH2O (PCR grade) 3 µl 
Total volume 20 µl 
 
 




Table 19: Oligonucleotides used for qPCR (Taq Man probes) 
Target gene Primer sequence (5’ to 3’) (P: probe f: forward, r: reverse) 
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5.5. Splinkerette PCR 
Splinkerette PCR is a PCR based method to determine the number of transposon integration 
sites in genomic DNA (gDNA) [53, 239]. It allows to amplify the gDNA sequence that lies 
between the transposon terminal inverted repeats (TIRs) and a nearby restriction site [240].  
A schematic depiction of the Splinkerette PCR protocol is given in Figure 24. Shortly, the 
gDNA is subjected to digestion with a type II restriction enzyme (DpnII) leading to sticky ends 
(1, 2). Then specially designed Splinkerette adapters consisting of a long strand adaptor and a 
short strand adaptor are ligated to these ends. The short strand adaptor contains a hairpin loop 
preventing end-repair priming (3). Next the junction between the genome and the transposon 
TIR is amplified in two nested PCR steps. During the first amplification step one of the primers 
consists of part of the sequence of the long strand adaptor (Splink1), whereas the other primer 
(Tbal Rev3) is compatible to a transposon-specific sequence located on the same strand the long 
strand adaptor is ligated to. Therefore, during the first PCR amplification step only one strand 
starting from the Tbal Rev3 primer is synthesized (4,I). During the next amplification step the 
Splink1 primer can now bind to that newly synthesized strand, and the genomic DNA-
transposon-junction between Tbal Rev3 and Splink1 is amplified during the following PCR 
amplification steps (4,II). Next, a second PCR step using the Splink2 primer, which sequence 
is part of the long strand adaptor, and the Tbal primer, which sequence is compatible to part of 
the transposon sequence, is carried out to enhance the specificity (5). These PCR steps result in 
PCR products of a different length for each integration site as the distance of the integration 
event from the next restriction site is variable (6) [53, 240]. Therefore, the number of PCR 
products seen on the gel after agarose gel electrophoresis represents the number of integration 
sites [53].   
Figure 24: Splinkerette PCR (next page): 
A. Overview of the Splinkerette PCR protocol (self-designed). (1). Genomic DNA isolated from mouse IPSCs containing the 
transposon sequence at an unknown location is subjected to enzymatic digestion with a type II restriction enzyme (DpnII). (2). 
The digestion leads to sticky ends, generating a GATC overhang. (3). Ligation of the Splinkerette adaptor consisting of a long 
strand adaptor (lsA) and a short strand adaptor (ssA) containing a hairpin loop to the sticky ends. (4) First PCR amplification 
step of the genomic DNA-transposon-junction. The primer Splink1 contains part of the sequence of the long strand adaptor. 
Therefore, this primer is compatible to the strand synthesized during the first PCR amplification starting from the second primer 
(Tbal Rev3) which is compatible to a known sequence of the transposon. This ensures that only the genomic DNA-transposon-
junction is amplified. (5). Second PCR amplification step of the genomic DNA-transposon-junction.  






Figure 24: Splinkerette  PCR (continued from previous page) 
A (5, continued from previous page). To increase specificity a second nested PCR step is performed. The primers are identical 
to part of the sequence of the long strand adaptor (Splink) or compatible to the same strand of the transposon-sequence (Tbal). 
(6). The length of final PCR products is different for each integration site. 
B. Primers and adaptors used for Splinkerette PCR, adapted from Uren et al. [240]. The sequences of the primers Splink1 and 
Splink2 are identical to parts of the long strand adaptor (lsA). The long strand adaptor and the short strand adaptor are partially 
compatible leading to formation of a CTAG-sticky end compatible to the GATC-overhang generated by the type II restriction 
enzyme during the first step of splinkerette PCR. The short strand adaptor contains a sequence that forms a hairpin-loop to 
prevent end-repair priming. 
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5.5.1. Isolation of genomic DNA 
Total gDNA was isolated from mouse IPSCs by a phenol-chloroform extraction protocol. Cells 
were harvested and, when necessary, separated from feeder cells using standard procedures 
described in 5.2.1. Standard cell culture conditions and procedures, then lysed overnight in 250 
– 500 µl lysis buffer composed of 100 mM Tris-HCl pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM 
NaCl and 100 µg/ml proteinase K (Merck, Darmstadt, Germany). After total lysis of the cells, 
250 – 500 µl of phenol-chloroform (1:1)-solution (Roth) was added to extract the gDNA. The 
samples were centrifuged for 5 min at 12 000 rpm resulting in two phases. The supernatant 
containing the gDNA was harvested and mixed with 250-500 µl of chloroform (Merck). Then 
the samples were centrifuged again for 5 min at 12 000 rpm resulting in two phases. The 
supernatant containing the gDNA was harvested and mixed with 250 – 500 µl of isopropanol 
(Merck) to precipitate the gDNA. The gDNA was pelleted by centrifugation and washed once 
with 70% ethanol. Finally, gDNA was resuspended in 50 – 100 µl EB Buffer (10 mM Tris-HCl, 
pH 8.5). The gDNA concentration and purity was determined spectrometrically at A260 and 
A260/280, respectively, using a Nanodrop 2000 spectrophotometer (ThermoFisher Scientific). 
gDNA Samples were stored at 4°C.  
 
5.5.2. Digestion of gDNA 
2 µg of gDNA were digested with the restriction enzyme DpnII (New England Biolabs, 
Ipswich, Massachusetts, USA). The digestion mix consisting of 2 µg gDNA, digestion buffer, 
and 10 U DpnII was incubated overnight at 37°C (Table 20). Then the restriction enzyme was 
heat inactivated at 65°C for 20 min. Agarose gel electrophoresis was performed to check for 
complete digestion of gDNA using a 0.8% agarose gel at 120V for 60 min. 
 
Table 20: gDNA digestion set up and program 
total gDNA x µl ≙ 2 µg 
37°C overnight 
Heat inactivation: 65°C for 20 min 
10x NEBuffer 3 µl 
Dpn II (10 U/ml) 1 µl 
dH2O 30 µl – x µl 
Total volume 30 µl 




5.5.3. Ligation of digested gDNA with Splinkerette adapters 
Splinkerette adapters were ligated to the sticky ends of the digested gDNA. Prior to ligation the 
Splinkerette adapter mix consisting of 25 µM long strand adapter and 25 µM short strand 
adapter in 5x NEB Buffer 2 (New England Biolabs) was denaturized at 95°C for 5 min, and 
annealing of the adaptors to each other was allowed by slowly cooling the probe down to room 
temperature at a rate of 0.1°C/s. Then the gDNA ligation mix (Table 21) consisting of 1 µl 
Splinkerette adapter mix, 4.5 µl digested and heat inactivated gDNA digestion mix, 2 µl DNA 
ligase buffer and 40 U T4 DNA Ligase (Promega, Madison, USA) was incubated at 4°C 
overnight. The reaction was stopped by heat inactivation of the ligase at 65°C for 20 min.  
 
Table 21: gDNA ligation set up and program 
Digested gDNA 4.5 µl 
4°C overnight 
Heat inactivation: 65°C for 20 min 
Splinkerette adapter mix 1 µl 
T4 DNA ligase buffer 2 µl 
T4 DNA ligase (20U/µl) 2 µl 
dH2O 35.5 µl 
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5.5.4. PCR amplifications 
Finally, the junction region between the genome and the transposon was amplified in two 
consecutive PCRs. To enhance the specificity, touch-down protocols were used. 
Reaction set ups and PCR protocols are shown in Tables 22 and 23. The reagents are the same 
used in 5.4.3. Semi-quantitative Reverse-Transcription (RT)-PCR. 
 
Table 22: Set up and program of the first PCR amplification 
10x PCR reaction buffer 5.0 µl 94°C 3 min 
15 
cycles 
94°C 30 s 
70°C 30 s 
72°C 30 s 
5 
cycles 
94°C 30 s 
63°C 30 s 
72°C 2 s (+2 s/cycle) 
5 
cycles 
94°C 30 s 
62°C 30 s 
72°C 12 s (+2 s/cycle) 
5 
cycles 
94°C 30 s 
61°C 30 s 
72°C 22 s (+2 s/cycle) 
5 
cycles 
94°C 30 s 
60°C 30 s 
72°C 30 s  
72°C 5 min 
4°C forever 
 
Primer Splink1 1.0 µl 
Primer Tbal Rev3 1.0 µl 
dNTP mix 1.0 µl 
Taq polymerase 0.5 µl 
Ligated digested DNA 5.0 µl 
dH2O (PCR grade) 36.5 µl 
Total volume 50 µl 
 
Table 23: Set up and program of the second PCR amplification 
10x PCR reaction buffer 2.0 µl 94°C 3 min 
10 
cycles 
94°C 30 s 
65°C 30 s 
72°C 30 s 
25 
cycles 
94°C 30 s 
58°C 30 s 
72°C 30 s 
72°C 5 min 
4°C forever 
 
Primer Splink2 0.5 µl 
Primer Tbal 0.5 µl 
dNTP mix 0.4 µl 
TAQ  0.2 µl 
First PCR amplification mix 1.0 µl 
dH2O 15.4 µl 
Total volume 20µl 




5.5.5. Oligonucleotides used for Splinkerette PCR 
The sequences of the Splinkerette adapters and the PCR primers used for Splinkerette PCR are 
listed in Table 24 below.  
 
Table 24: Oligonucleotides used for Splinkerette PCR 
Name Sequence (5’ to 3’) Ref. 
Splinkerette adaptors 
long strand 
adaptor (lsA) CGAAGAGTAACCGTTGCTAGGAGAGACCGTGGCTGAATGAGACTGGTGTCGACACTAGTGC [240] 
short strand 
adaptor (ssA) GATCCCACTAGTGTCGACACCAGTCTCTAATTTTTTTTTTCAAAAAAA [240] 
Primers 
Splink1 CGAAGAGTAACCGTTGCTAGGAGAGACC [240] 
Splink2 GTGGCTGAATGAGACTGGTGTCGAC [240] 
Tbal Rev3 CATGACATCATTTTCTGGAATTT [53] 
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5.6. Histological analysis 
5.6.1. Processing of samples 
5.6.1.1. Fixation 
For histological analysis, chondrogenic nodules and spheroids were washed twice with PBS 
before fixation in pre-cooled 4% paraformaldehyde (PFA, Merck) in PBS for 30 min at room 




After fixation, samples were placed in ascending solutions of sucrose (Sigma) in PBS: 10% and 
20% for 30 min at room temperature and 30% overnight at 4°C. The next day, samples were 
transferred to disposable vinyl specimen molds (Cryomolds, Tissue Tek Sakma Finetek, 
Torrance, California, USA) and embedded in cryomedium (OCT, Tissue Tek). Then samples 
were placed on the surface of a chilled chopper plate on dry ice until frozen completely. Samples 




Cryosectioning was performed with a cryotome Microm HM500O (Fisher, Walldorf, 
Germany). Slices of 10 µm thickness were collected onto SuperFrost glass slides 
(ThermoScientific) and stored at -20°C until use. 
 




5.6.2. Histochemical staining 
5.6.2.1. Safranin Orange staining 
Safranin Orange is a cationic dye showing high affinity to negatively charged GAG chains of 
proteoglycans in the extracellular matrix of cartilage [241]. The intensity of the resulting red-
orange color is proportional to the proteoglycan content in the section [241]. 
For Safranin Orange staining cryosections of chondrogenic nodules and spheroids were washed 
2 x 3 min with PBS to remove any remaining cryomedium. Then the samples were covered 
with 0.1% Safranin Orange (Sigma-Aldrich) solution in dH2O for 5 min. Subsequently, 
excessive staining solution was removed by turning the slides on Wattman paper (Sigma) and 
the slides were mounted with Roti-Histokitt (Sigma). 
 
5.6.2.2. Toluidine blue staining 
Negatively charged GAG chains of proteoglycans in the ECM of cartilage are stained blue-
violett by the cationic dye Toluidine blue [241].  
For Toluidine blue staining cryosections of chondrogenic nodules and spheroids were washed 
2 x 3 min with PBS to remove any remaining cryomedium. Then the samples were covered 
with 0.1% Toluidine Blue (Sigma) solution in toluidine blue buffer (0.05 M K2HPO4 and        
0.04 M HCl pH 2,5) for 5 min. Subsequently excessive staining solution was removed by 




To verify deposition of type II collagen and aggrecan in the ECM of the chondrogenic nodules 
and spheroids, we performed immunohistochemistry (IHC) on cryosections. The antibodies 
used are listed in Table 25. 
The slides were washed twice in PBS to remove any remaining cryomedium. Endogenous 
peroxidase activity was blocked for 20 min at room temperature with 1% H2O2 (Carl Roth) in 
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absolute methanol (Merck). Then 0.2% bovine testicular hyaluronidase in PBS (pH 5, Sigma-
Aldrich) was applied to the sections at 37°C for 30 min before blocking.  
For aggrecan detection, blocking was performed with 1% BSA in PBS for 1h at room 
temperature followed by overnight incubation with the primary antibody at 4°C. The next day 
the slides were washed twice in PBS to remove any antibody that did not bind before incubation 
with biotinylated secondary antibody in 1% BSA for 1h.  
Since the type II collagen primary antibody is a monoclonal, mouse antibody (II-II6B3, 
Developmental Studies Hybridomoa Bank, University of Iowa, Iowa City, Iowa, USA) we used 
the MOM Kit (VectorLabs, Burlingame, California, USA) for reliable detection of the antigen 
on the mouse tissue. After blocking with the MOM Mouse Ig Blocking Reagent (4% in PBS) 
for 1h at room temperature, the sections were preincubated in MOM diluent (5% MOM Protein 
Concentrate in PBS) for 5 min at room temperature followed by overnight incubation with the 
primary antibody. After washing the sections twice in PBS, the next day biotinylated anti-
mouse-IgG-Reagent (4% in PBS) was applied to the sections for 10 min at room temperature. 
Antibody binding was detected by the Vectastain ABC Kit (VectorLabs) followed by 
diaminobenzidine (DAB) staining. Shortly, the Vectastain ABC reagent, prepared according to 
the manufacturer’s instruction, was applied to the slides for 30 min (aggrecan) or 5 min (type 
II collagen) at room temperature. Then the slides were immersed in DAB staining solution 
(0.027% 3,3’-diaminobenzidine (Sigma) in 25 mM Tris-HCl, pH 7.6 + 120 µl 5% H2O2 in 
dH2O) for 7 min at room temperature in the dark. Then slides were washed with dH2O and 
mounted with Roti-Mount Aqua (Carl Roth), and covered with 20 x 40 mm cover slips.   
  




Table 25: Antibodies for immunohistochemistry 
Target Type Company Catalogue number Dilution 
Primary Antibodies 
Anti-Aggrecan polyclonal Rabit IgG 
Merck Millipore  
AB1031 1:400 in 1% BSA 
Anti-Collagen II monoclonal Mouse IgG1 
DSHB  
II-II6B3 1:400 in MOM diluent 
Secondary Antibodies 
Anti-Rabit IgG biotinylated Vectastain ABC HRP Kit (Rabit IgG) PK-4001 1:200 in 1% BSA 




Unless otherwise indicated, chemicals and reagents were obtained from one of the following 
distributors: 
- Invitrogen, Thermo Fisher Scientific, Waltham, Massachusetts, USA 
- Sigma-Aldrich/Merck, Darmstadt, Germany 




To take representative phase contrast, bright field and fluorescent pictures, we either used the 
AxioCam Color 105 or the AxioCam MRm Camera (both Carl Zeiss) mounted on an 
AxioObserver.Z1 microscope (Carl Zeiss). For large specimen we used the AxioCam Color 
105 camera mounted on a Stemi 2000-CS 3D microscope (Carl Zeiss). 
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5.9. Computer programs and statistics 
In this thesis, quantitative data was evaluated and various graphs were created by Microsoft 
Office Excel 2010 (Microsoft, Redmond, USA), SPSS 25.0 (IBM SPSS Statistics, Ehningen, 
Germany) and Graph Pad Prism7 (GraphPad, La Jolla, USA). Data are shown as mean ± 
standard deviation (SD) for normally distributed data or as median (interquartile range, IQR) 
for non-normally distributed data. For comparison of two groups, paired or unpaired t-tests or 
Mann-Whitney-U-tests were performed as applicable. For comparison of more than two groups 
ANOVA was used. A p-value < 0.05 was considered statistically significant and p-values were 
adapted for multiple testing where necessary. 
Photomicrographs were processed with ZEN2012 – ZEISS Efficient Navigation software (Carl 
Zeiss) and arranged in figures with Adobe Photoshop CS26 (Adobe System, San Jose, USA). 
Morphometric analyses were performed with ImageJ 1.41 (http://rsb.info.nih.gov/ij/, USA).  
The following link was used as major source of publications: 
http://www.ncbi.nlm.nih.gov/sites/entrez and references were managed by EndNote X8 







6.1. Isolation and culture of primary fibroblasts 
Murine fibroblasts were the first cells to be successfully reprogrammed and have been widely 
used for the assessment of different reprogramming methods [15, 53].  
Primary fibroblasts were isolated from mouse embryos at 12.5 – 13.5 dpc (MEFs) as well as 
from ear (EAR-FBs) and tail (TAIL-FBs) of adult wild-type mice.  
The cell suspension gained from dissected mouse embryos contained a high number of cells 
from various types. However, after 24h in culture only few spindle shaped cells had adhered to 
the tissue culture plate. These were considered as murine embryonic fibroblasts (MEFs). These 
cells rapidly expanded and nearly covered the complete 10 cm-dish 72h after isolation. The 
cells maintained their typical morphology and high proliferation rate for many passages (up to 
P10) (Figure 25A). After Mitomycin C treatment, however, proliferation ceased. Otherwise, the 
cells appeared healthy and could be used as feeder cells for pluripotent stem cells.  
After mincing and digesting the tissue chunks from ear and tail tip, cells started to spread out 
from the tissue chunks. EAR-FBs and TAIL-FBs both initially showed a spindle-shaped 
morphology but started to spread out during culture. EAR-FBs and TAIL-FBs were 
morphologically indistinguishable (Figure 25 B and C). EAR-FBs however, proliferated faster 
than TAIL-FBs as they could be passaged at a 1 : 2 ratio every 4 – 5 days whereas TAIL-FBs 
could only be passaged at a 1 : 2 ratio every 6 – 7 days.  
 
Figure 25: Morphology of primary murine fibroblasts.  
(A) Murine embryonic fibroblasts (MEFs) at passage 3. (B) Murine fibroblasts isolated from ear (EAR-FBs) at passage 6. (C) 




6.2. Nucleofection of primary fibroblasts 
Nucleofection is an efficient, electroporation-based delivery method for plasmids that transfers 
nucleic acids directly to the nucleus [43]. Transposons are not equipped to cross cell membranes 
themselves, therefore delivery of the transposon plasmids into target-cells is a rate-limiting 
factor in transposition [42]. Nucleofection has been shown suitable for the delivery of Sleeping 
Beauty transposon-based reprogramming plasmids into fibroblasts [53].  
However, efficiency and survival rates vary among cell types and depend upon the solutions 
and programs used. Therefore, the first step was to find the optimal program and solution for 
the primary fibroblasts used in the subsequent reprogramming experiments. Several 
nucleofections with the pmaxGFP vector using different programs and solutions were 
performed as recommended by the manufacturer to optimize efficiency and survival rates. The 
results of the optimization are summarized in Table 26 – 28. Figure 26 shows representative 
photomicrographs of nucleofected fibroblasts expressing GFP.  
For primary mouse embryonic fibroblasts (MEFs) we achieved the best results with the solution 
P3 and the program EH-198. 86% (± 3%) of the cells survived the nucleofection procedure. Of 
these about 87% (± 9%) expressed GFP 24h after nucleofection. For primary fibroblasts derived 
from ear (EAR-FBs) or tail-tips (TAIL-FBs) of adult wild type mice the best results were 
achieved with the solution P2 and the program EH-198. EAR-FBs showed a survival rate of 
73% (± 6%) and an efficiency rate of 41% (± 4%). 62% (± 5%) of the TAIL-FBs survived 
nucleofection and of these about 53% (± 7%) showed GFP expression the next day.  
 
Table 26: Nucleofection of MEFs with the pmaxGFP vector (P3 Solution) 
Program Survival rate (± SD) Efficiency (± SD) 
EN-150 0.93 (± 0.05) 0.62 (± 0.10) 
EH-198 0.86 (± 0.03) 0.87 (± 0.09) 
EH-156 0.74 (± 0.04) 0.90 (± 0.05) 






Table 27: Nucleofection of EAR-FBs with the pmaxGFP vector (P2 Solution) 
Program Survival rate (± SD) Efficiency (± SD) 
EN-150 0.74 (± 0.04) 0.10 (± 0.02) 
EH-198 0.73 (± 0.06) 0.41 (± 0.04) 
EH-156 0.71 (± 0.02) 0.45 (± 0.03) 
ER-150 0.66 (± 0.04) 0.47 (± 0.07) 
 
Table 28: Nucleofection of TAIL-FBs with the pmaxGFP vector (P2 Solution) 
Program Survival rate (± SD) Efficiency (± SD) 
EN-150 0.70 (± 0.03) 0.19 (± 0.04) 
EH-198 0.62 (± 0.05) 0.53 (± 0.07) 
EH-156 0.58 (± 0.08) 0.23 (± 0.10) 
ER-150 0.49 (± 0.16) 0.13 (± 0.08) 
 
 
Figure 26: Nucleofection of primary fibroblasts with the pmaxGFP vector. 
MEFs, EAR-FBs and TAIL-FBs were nucleofected using the pmaxGFP vector and different solutions and programs. Survival 
rate was estimated by counting the dead cells in the supernatant, whereas efficiency rate was estimated by the percentage of 
cells showing GFP expression 24h after nucleofection. Using program EH-198 and solution P3 86% (± 3%) of the MEFs 
expressed GFP 24h after nucleofection. EAR-FB showed an efficiency rate of 41% (± 4%), whereas 53% (± 7%) of the TAIL-




6.3. Reprogramming of primary fibroblasts  
6.3.1. Reprogramming of MEFs, EAR-FBs and TAIL-FBs with the pT2OSKM(L) 
plasmid 
6.3.1.1. Reprogramming of MEFs with the pT2OSKM or pT2OSKML plasmid 
MEFs at passage 3 were nucleofected with the SB100X and the pT2OSKM or the pT2OSKML 
plasmid in a ratio of 1 : 10 (0.5 µg and 5 µg or 0.2 µg and 2 µg), then transferred to Geltrex-
coated 6-well plates, and maintained in ESC-medium. Around day 5, first clusters of small cells 
started to form, which still displayed a fibroblast-like morphology. At day 11, the cells were 
transferred to feeder cells, and by day 13 small IPSC-like colonies became visible in all wells.  
By day 20, the colonies were big enough to be mechanically picked and transferred to feeder-
coated 24-well plates. Picking was performed at days 20, 21 and 22 and altogether 96 colonies 
were picked. The thereby established clonal cell lines were named TAXX (TA01 – TA96). The 
cell lines were maintained in mouse IPSC medium on feeder cells for three to five days before 
they were either frozen for long term storage or discarded.  
From the plate containing the colonies derived from transfection with 2 µg pT2OSKM 20 
colonies could be picked. Seven from the thereby established cell lines consisted of many small 
colonies displaying the typical IPSC morphology (bona fide IPSC), whereas in one well no 
colonies were forming at all. The remnant wells contained either only few colonies that grew 
slowly or colonies that failed to maintain the typical IPSC morphology, and showed signs of 
dedifferentiation. From the colonies derived from MEFs nucleofected with 5 µg pT2OSKM 30 
colonies were picked. Of these 9 bona fide IPS cell lines were emerging, whereas 7 wells 
completely failed to form colonies. From the nucleofection with 2 µg pT2OSKML 30 colonies 
were picked of which 9 gave rise to bona fide IPSC colonies and none failed to form colonies 
at all. 16 colonies were picked from the plate containing the colonies derived from 
nucleofection with 5 µg pT2OSKML and a single IPS cell line could be established, whereas in 
7 wells no colonies formed at all.  
These results are summarized in Table 29. From the 26 cell lines initially showing a typical 





Table 29: Cell lines established from MEFs reprogrammed with pT2OSKM or pT2OSKML  
Plasmid Colonies picked Bona fide IPSC no colonies 
2 µg pT2OSKM 20 7 (35%) 1 (5%) 
5 µg pT2OSKM 30 9 (33%) 7 (23%) 
2 µg pT2OSKML 30 9 (33%) 0 (0%) 
5 µg pT2OSKML 16 1 (6%) 7 (43%) 
TOTAL 96 26 (27%) 15 (16%) 
 
6.3.1.2. Reprogramming of EAR-FBs with the pT2OSKM or pT2OSKML plasmid 
EAR-FBs at passage 6 were nucleofected with the SB100X and the pT2OSKM or the 
pT2OSKML plasmid in a ratio of 1 : 10 (0.5 µg and 5 µg or 0.2 µg and 2 µg). After nucleofection 
the cells were transferred to feeder-coated 6-well plates and maintained in mouse IPSC medium. 
However, by day 9 the cell layer became very dense with the cells forming a thin tissue-like 
sheet that started to lift off the plate at the borders. Therefore, the plates were trypsinized and 
the cell suspension was transferred to 6 cm-cell culture dishes at day 10. Around day 15, the 
first IPSC-like colonies emerged, and at day 17 all dishes contained many small IPSC-like 
colonies.  
Colonies were picked at day 19, 21 and 23 and maintained on feeder-coated 24-well plates for 
5 to 7 days. 12 colonies were picked for each reprogramming factor dosage and the established 
clonal cell lines were named ETAXX (ETA01 – ETA46). As 7 wells contained only a single 
big colony after picking, these cells were trypsinized to dissociate the colony, and reseeded into 
the same well to allow formation of multiple small colonies. 12 cell lines initially or after being 
passaged once formed many small colonies displaying the typical IPSC morphology and were 
considered bona fide IPSCs. From these, 5 clones were chosen for further propagation and 
assessment. In 11 wells however, no colonies were emerging at all. The remaining 25 wells 
contained either only few colonies that grew slower than the bona fide IPSCs or contained 







Table 30: Cell lines established from EAR-FBs reprogrammed with pT2OSKM or  
                  pT2OSKML  
Plasmid Colonies picked Bona fide IPSC no colonies 
2 µg pT2OSKM 12 7 (58%) 1 (8%) 
5 µg pT2OSKM 12 2 (17%) 4 (33%) 
2 µg pT2OSKML 12 1 (8%) 3 (25%) 
5 µg pT2OSKML 12 2 (17%) 3 (25%) 
TOTAL 46 12 (26%) 11 (24%) 
 
6.3.1.3. Reprogramming of TAIL-FBs with the pT2OSKM or pT2OSKML plasmid 
TAIL-FBs at passage 5 were nucleofected with the SB100X and the pT2OSKM or the 
pT2OSKML plasmid in a ratio of 1 : 10 (0.5 µg and 5 µg or 0.2 µg and 2 µg). After nucleofection 
the cells were transferred to feeder-coated 6-well plates and maintained in mouse IPSC medium. 
Around day 12, the first IPSC-like colonies became visible.  
Picking of colonies was performed at days 19, 24 and 27. Altogether 44 colonies were picked 
and the established cell lines were named TTAXX (TTA01 – TTA44). Half of the wells initially 
contained only a single large colony. Therefore, after 4 to 7 days, these wells were trypsinized 
once to dissociate this colony into single cells and allow formation of multiple small IPSC 
colonies. After 4 to 11 days, 16 of the wells contained many small bona fide IPSC colonies, of 
which 4 were chosen for further propagation and assessment. However, one of these chosen 
cell lines (TTA19) failed to maintain IPSC-like morphology during propagation likely due to 
incomplete reprogramming, and was discarded.  The remaining 3 clonal cell lines were assessed 
for pluripotency traits. Three clonal cell lines were discarded after picking as they did not 
contain any IPSC-like colonies. These results are summarized in Table 31.  
 
Table 31: Cell lines established from TAIL-FBs reprogrammed with pT2OSKM or  
                 pT2OSKML  
Plasmid Colonies picked Bona fide IPSC no colonies 
2 µg pT2OSKM 13 4 (31%) 0 (0%) 
5 µg pT2OSKM 12 5 (42%) 1 (8%) 
2 µg pT2OSKML 6 2 (33%) 1 (17%) 
5 µg pT2OSKML 13 5 (38%) 1 (8%) 





Figure 27 gives an overview of the strategies used to reprogram MEFs, EAR-FBs and TAIL-
FBs with the pT2OSKM or pT2OSKML plasmid. In summary, all tested strategies led to 
successful establishment of several IPS cell lines. About ⅓ (26 – 36%) of all initially picked 
IPSC colonies gave rise to bona fide iPS cell lines. Colonies derived from pT2OSKML plasmids 
initially showed a flatter morphology with more roughened borders than colonies derived from 
the pT2OSKM plasmids. These differences, however, vanished after picking and subsequent 
passaging, and the colonies reprogrammed with the pT2OSKM or pT2OSKML plasmid became 
indistinguishable.  
Notably, from TAIL-FBs less colonies that were harder to break down into a single cell 
suspension could be picked than from EAR-FBs and MEFs. This is likely due to the passaging 
step in the reprogramming protocols used for EAR-FBs and MEFs as emerging colonies by day 
10 or 11 were disrupted by passaging and could give rise to several daughter colonies. But, 
although the overall number of colonies available for picking can be increased by the passaging 
step, it bears the risk that several cell lines originate from the same starting cell.   
 
 
Figure 27: Reprogramming of MEFs, EAR-FBs and TAIL-FBs with the pT2OSKM and pT2OSKML plasmids.  
Schematic depiction of the reprogramming strategies used for MEFs, EAR-FBs and TAIL-FBs. After nucleofection with the 
pT2OSKM or pT2OSKML plasmid, MEFs were initially seeded onto Geltrex-coated 6-well plates and transferred to feeder-
coated 6-well plates on day 11. The first colonies were visible at day 13, and picking was performed on days 20, 21 and 22. 
EAR-FBs were seeded onto feeder-coated 6-well plates after nucleofection with the reprogramming factor plasmids and 
passaged onto feeder-coated 6 cm-cell culture dishes on day 10. The first small colonies became visible around day 15 and 
could be picked on days 19, 21 and 23. TAIL-FBs were cultured on a feeder-coated 6-well plate after nucleofection. The first 




6.3.2. Reprogramming of EAR-FBs with the RMCE-OSKM(L)-Cherry plasmid 
The RMCE-OSKM(L)-Cherry plasmids additionally to the reprogramming factor cassette 
contain an (EOS3+)mCherry pluripotency reporter cassette and the transgene is flanked by 
heterospecific loxP sites allowing modification by recombinase mediated cassette exchange 
(RMCE) [53].  
After nucleofection of EAR-FBs at passage 8 with 0.1 µg or 0.2 µg of the SB100X plasmid and 
1 µg or 2 µg of the RMCE-OSKM(L)-Cherry plasmid (ratio 10:1), the cells were either seeded 
onto Geltrex-coated, feeder-coated or uncoated 10 cm-cell culture dishes and maintained under 
ESC conditions. The first colonies became visible around day 13 under all three conditions and 
were picked on days 20 and 24. Figure 28 summarizes the reprogramming strategy used for 
EAR-FBs and RMCE-OSKM(L)-Cherry plasmids.  
 
 
Figure 28: Reprogramming of EAR-FBs with the RMCE-OSKM(L)-Cherry plasmids.  
Schematic depiction of the reprogramming strategies used for EAR-FBs with the RMCE-OSKM(L)-Cherry plasmids. After 
nucleofection, EAR-FBs were seeded either onto uncoated, Geltrex-coated or feeder-coated 10 cm-cell culture dishes and 








Altogether, 96 colonies were picked from the EAR-FBs reprogrammed with the RMCE-
OSKM(L)-Cherry plasmids, and the established clonal cell lines were named ETACXX 
(ETAC01 - ETAC96). Of these, 41 bona fide IPS cell lines emerged whereas in 24 wells no 
colonies could be detected. Notably, from the EAR-FBs reprogrammed with only 1 µg of 
reprogramming factor plasmids less colonies could be picked than from the FBs reprogrammed 
with 2 µg of the reprogramming factor plasmids (21 colonies from 1 µg RMCE-OSKM-Cherry 
and RMCE-OSKML-Cherry each vs. 27 colonies from 2 µg RMCE-OSKM-Cherry and RMCE-
OSKML-Cherry each). There was no difference in the number of colonies that could be picked 
from the different coatings. The exact results are listed in Table 32.  
17 clonal cell lines were chosen for further analysis, however, 4 of these failed to maintain IPSC 
morphology during further propagation and were discarded.  
 
Table 32: Cell lines established from EAR-FBs reprogrammed with  
                 RMCE-OSKM(L)-Cherry  
Plasmid Coating Colonies picked Bona fide IPSC no colonies 
1 µg RMCE-OSKM no coating 8 4 (50%) 2 (25%) 
1 µg RMCE-OSKM Geltrex 7 1 (14%) 4 (57%) 
1 µg RMCE-OSKM Feeder 6 1 (17%) 2 (33%) 
2 µg RMCE-OSKM no coating 9 5 (56%) 1 (11%) 
2 µg RMCE-OSKM Geltrex 9 3 (33%) 2 (22%) 
2 µg RMCE-OSKM Feeder 9 3 (33%) 4 (44%) 
1 µg RMCE-OSKML no coating 7 3 (43%) 2 (29%) 
1 µg RMCE-OSKML Geltrex 7 3 (43%) 1 (14%) 
1 µg RMCE-OSKML Feeder 7 3 (43%) 2 (29%) 
2 µg RMCE-OSKML no coating 9 2 (22%) 4 (44%) 
2 µg RMCE-OSKML Geltrex 9 6 (67%) 0 (0%) 
2 µg RMCE-OSKML Feeder 9 7 (77%) 0 (0%) 
TOTAL  96 41 (43%) 24 (25%) 
 
6.3.3. Morphological changes during the reprogramming process 
Cells of a mesenchymal origin like for example fibroblasts undergo a mesenchymal to epithelial 
transition (MET) during reprogramming [68, 73]. This includes changes of the gene expression 




During the reprogramming process, fibroblasts were observed daily for signs of ongoing 
reprogramming.  Representative photomicrographs taken during the reprogramming process of 
EAR-FBs with RMCE-OSKM(L)-Cherry are depicted in Figure 29.  
By day 9, the fibroblasts cultured on uncoated or Geltrex-coated dishes had become highly 
confluent and the fibroblast and feeder cells had formed a dense cell layer in the feeder-coated 
dishes. Within these cell sheets, diffuse clusters of small round cells started to form, probably 
corresponding to fibroblasts undergoing MET and gaining ESC-like proliferation rate during 
the initiation phase of reprogramming [69, 70].  
By day 13, these clusters had increased in size and spread out diffusely among the surrounding 
fibroblasts in the uncoated and Geltrex-coated dishes, whereas in the feeder-coated plates 
already small IPSC-like colonies became visible. By day, 19 IPSC-like colonies had formed in 
all plates, and the size was considered appropriate for picking which was performed the next 
day.  
Notably, the colonies in the uncoated and Geltrex-coated dishes showed more roughened 
boarders and were harder to dislodge from the surrounding cell sheet than the colonies in the 
feeder-coated dishes. Furthermore, colonies reprogrammed with the RMCE-OSKML-Cherry 
plasmid appeared more flattened than colonies resulting from nucleofection with RMCE-
OSKM-Cherry. These differences, however, vanished after picking and subsequent passaging, 
and the established clonal cell lines became morphologically indistinguishable. 
Conclusively, clonal IPS cell lines could be successfully established from EAR-FBs by 
nucleofection with the RMCE-OSKM-Cherry or the RMCE-OSKML-Cherry plasmid regardless 
of the coating (uncoated, Geltrex-coated or feeder coated 10 cm-cell culture dish) they were 









Figure 29: Morphological changes of EAR-FBs during reprogramming with RMCE-OSKM(L)-Cherry plasmids cultured 
on different coatings. 
Morphological changes of EAR-FBs cultured either on uncoated, Geltrex-coated or feeder-coated 10 cm-cell culture dishes 




6.4. Analysis of induced pluripotent stem cells 
6.4.1. Morphology and proliferation 
Mouse embryonic stem cells (mESCs) grow in characteristic round, dome-shaped colonies 
composed of small cells with large nuclei and scant cytoplasm when maintained on feeder cells 
(Figure 30A) [15, 23]. The morphology of successfully reprogrammed IPSCs is highly similar 
to ESCs [15].  
After picking, the newly established TA, ETA, TTA and ETAC murine IPS cell lines were 
cultured on feeder cells. They showed a mESC-like proliferation rate and could be splitted in a 
ratio of 1 : 5 – 1 : 10 every 2 – 4 days. Successfully reprogrammed IPSCs formed characteristic 
round, dome-shaped colonies with smooth and bright edges when cultured on feeder cells and 
maintained this morphology up to high passages (Figure 30B).  
ETAC-IPSCs contain additionally to the reprogramming factor cassette an (EOS3+)mCherry 
pluripotency reporter cassette. Therefore, successfully reprogrammed colonies initially 
exhibited red fluorescence. At higher passages, however, this fluorescence partially declined 
probably indicating silencing of the transgene (Figure 30C).  
For certain applications, like differentiation assays, feeder-free IPSCs are desirable. Therefore, 
IPSCs can be maintained on synthetic extracellular matrixes like Geltrex. When cultured on 
Geltrex, IPSCs maintain their characteristic growth pattern of round dome-shaped colonies 







Figure 30: Morphology of ESCs and IPSCs.  
(A) mESCs (R1) maintained on feeder cells grow in round, dome-shaped colonies consisting of many small cells. (B) mIPSCs 
(TA51, ETA04, TTA23) show a mESC-like morphology when cultured on feeder cells. (C) ETAC-IPSCs (ETAC41) 
additionally show a red fluorescence due to the presence of the mCherry pluripotency reporter cassette among the inserted 
transgenes. (D) IPSCs (ETA04) cultured on Geltrex form round dome-shaped colonies. Scale bars represent 50 µm. 
 
6.4.2. Alkaline phosphatase staining 
As cells gradually gain traits of pluripotent stem cells during the reprogramming process they 




easily be visualized by alkaline phosphatase staining as it reacts with nitro-blue-tetrazolium-
chloride/ 5-bromo-4-chloro-3-indolyl-phospate (NBT/BCIP) solution leading to an insoluble 
purple precipitation. Alkaline phosphatase staining is therefore a fast and easy screening for 
successful reprogramming. 
We performed alkaline phosphatase staining on the original plates after picking enough colonies 
(Figure 31A). Here the remaining colonies showed a purple color, whereas the surrounding 
feeder cells and fibroblasts did not stain. This shows, that the emerging colonies during the 
reprogramming process passed at least the first steps of the reprogramming process and 
expressed first pluripotency-related genes.  
Furthermore, we stained the established IPS cell lines for alkaline phosphatase using the murine 
ES cell line R1 as a positive control (Figure 31B). All ESC as well as all IPSC colonies gained 
a clear purple color when exposed to NBT/BCIP, whereas the feeder cells did not react with the 
substrate. This indicates successful induction of pluripotency in our established IPS cell lines.  
 
 
Figure 31: Alkaline phosphatase staining of IPSCs 
(A) Alkaline phosphatase staining of EAR-FBs grown on feeder cells in a 6 cm-cell culture dish at day 24 after nucleofection 
with 2µg of the  pT2OSKM plasmid. IPSC colonies stain purple whereas the surrounding feeders and fibroblasts do not stain. 
Arrows mark holes in the cell layer resulting from picking of colonies. (B) Alkaline phosphatase staining of mESCs R1 and 





6.4.3. Number of transposon insertion sites 
For successful subsequent differentiation of IPSCs, or excision or exchange of the 
reprogramming factor cassette, a low number of transposon integration sites or even only a 
single transgene insertion is favorable. Therefore, we performed Splinkerette PCR to analyze 
the number of transposons integrated into the genome of our established IPS cell lines.   
Splinkertte PCR is a PCR-based method to specifically amplify the gDNA sequence that lies 
between the transposon terminal inverted repeats (TIRs) and a nearby restriction site [240]. 
Each integration sites results in a PCR product of a different length. Therefore, the number of 
PCR products seen on the gel after agarose gel electrophoresis represents the number of 
integration sites [53]. 
Splinkerette PCR (Figure 32) showed, that the number of integration sites for the tested clones 
was up to five (ETAC 75). Interestingly, the clones TA55 and TA81 showed an identical pattern 
of PCR products. These clones might therefore de facto represent only a single clonal cell line, 
that has either accidently been picked twice as some remaining cells after the first picking 
formed a new colony, or they result from the same initial colony, that has been disrupted during 
passaging at day 10, which led to formation of at least two colonies on the second plate. To rule 
out the second possibility it seems favorable not to passage the cells during the reprogramming 
process.   
We could identify two clones with only a single integration site: ETA04 and ETAC41. Of these 
ETA04 was chosen for chondrogenic differentiation. 
 
 
Figure 32: Splinkerette PCR  
The number of PCR products seen on the gel corresponds to the number of transgene insertion sites. Stars mark the single 




6.4.4. Expression of pluripotency markers 
During the reprogramming process, the cells gradually reach pluripotency. To prove that 
pluripotency was succeessfully induced, we analyzed the gene expresssion profile of the newly 
established clonal IPS cell lines on mRNA and protein level.  
 
6.4.4.1. mRNA analysis of pluripotent stem cell markers 
We isolated RNA from feeder-free IPSCs as well as from feeder-free mESCs and parental 
MEFs or FBs as a positive or negative control, and performed semiquantitative RT-PCR for 
several stem cell markers. Representative pictures of agarose gel electrophoreses are shown in 
Figure 33 - 36. Quantification of three runs of PCRs is represented as mean + SD relative to 
expression of the housekeeping gene GAPDH. 
The transcription factors Dax1 [55, 242] and Nanog [15, 24] are part of the pluripotency 
network that is established during reprogramming. Ecat1 [15], Eras [55, 243], Rex1 [15, 68] 
and Zfp296 [55, 244] are highly expressed in undifferentiated murine ESCs and well-known 
pluripotency markers. All established clonal IPS cell lines expressed these endogenous 
pluripotency markers at RNA levels comparable to ESCs, whereas the parental MEFs or FBs 






Figure 33: ET-PCR for ESC markers on TA clones.  
 
 






Figure 35: RT-PCR for ESC markers on TTA clones. 
 
 






6.4.4.2. mRNA analysis of reprogramming factors 
Semiquantitative RT-PCR for reprogramming factors was performed on mRNA samples from 
feeder-free mIPSCs as well as on mRNA isolated from feeder-free mESCs, MEFs or adult 
fibroblasts. Representative pictures of agarose gel electrophoreses are shown in Figure 37 – 40. 
Quantification of three runs of PCRs is represented as mean + SD relative to expression of the 
housekeeping gene GAPDH.  
For the reprogramming factors c-Myc and Klf4 we used primers that could specifically detect 
endogenous expression of the reprogramming, whereas mRNA transcribed from the transgenes 
did not result in a PCR product [55].  
All clones tested expressed Klf4 at levels comparable to mESCs indicating successful induction 
of endogenous pluripotency genes during the reprogramming process. Expression of c-Myc 
however, was remarkably lower than in mESCs for all tested clones.  
mRNA levels of Oct3/4 and Sox2 were also comparable between all tested IPSC clones and 
mESCs, although the primers used here could not distinguish between endogenous and 
exogenous transcripts. 
Interestingly, MEFs as well as EAR-FBs and TAIL-FBs showed high endogenous levels of c-
Myc and Klf4 expression. Therefore, exogenous expression of Oct3/4 and Sox2 alone might be 
sufficient to reprogram these cell types reducing size of the introduced transgene and therefore 
potentially facilitating subsequent manipulation of the inserted transgene. Further research is 






Figure 37: RT-PCR for reprogramming factors on TA clones. 
 
 







Figure 39: RT-PCR for reprogramming factors on TTA clones. 
 
 





6.4.4.3. Protein analysis of pluripotency markers by immunocytochemistry 
Immunofluorescence staining was performed for the reprogramming factors Oct3/4 and Sox2 
as well as for the endogenous pluripotency markers Nanog and SSEA1 on all established IPSC 
clones. Murine ESCs were used as a positive control, whereas the feeder cells, on which the 
IPSCs or ESCs were cultured, served as negative control. Representative photomicrographs of 
the immunofluorescence staining of the mES cell line R1 and the mIPS cell lines ETA04 and 
ETAC41 are shown in Figure 41 and Figure 42.   
All tested IPSC clones showed positive immunofluorescence staining for the transcription 
factors Oct3/4, Sox2 and Nanog. Comparison with the nuclear dye 4', 6-diamidino-2-
phenylindole (DAPI) signals confirmed nuclear localization of the transcription factors. The 
fluorescence pattern of the IPSC clones was indistinguishable from the mESCs that served as 
positive control. The nuclei of the MEF-feeder cells, however, showed a clear DAPI signal but 
were negative for Oct3/4, Sox2 and Nanog.  
Furthermore, the tested IPSC colonies showed positive fluorescence for the membrane marker 
SSEA1 that was comparable to the staining pattern of mESCs, whereas the feeder cells did not 
react.  
Positive fluorescence for Oct3/4 and Sox2 could be due to transgene expression. However, 
positive fluorecence for Nanog and SSEA1 clearly confirmed expression of pluripotency 






Figure 41: Immunofluorescence staining for pluripotency markers on mESCs (R1) and ETA04  
Immunofluorescence staining for Oct3/4, Sox2, Nanog and SSEA1 on IPSCs (ETA04, upper rows) and ESCs (R1, lower rows). 





Figure 42: Immunofluorescence staining for pluripotency markers on mESCs (R1) and ETAC41  
Immunofluorescence staining for Oct3/4, Sox2, Nanog and SSEA1 on IPSCs (ETAC41, upper rows) and ESCs (R1, lower 





6.4.5. Trilineage differentiation potential during spontaneous differentiation in 
embryoid bodies 
Pluripotent stem cells have the ability to differentiate into cell types from all three embryonic 
germ layers – ectoderm, mesoderm and endoderm [2]. Therefore, it is a crucial part of the 
assessment of recently established IPS cell lines to prove their three-lineage differentiation 
potential. For murine IPSCs, this is commonly carried out either by chimera formation [15, 17, 
18] or teratoma formation [15, 17, 18] which both require laborious in vivo protocols. 
Spontaneous differentiation in embryoid bodies (EBs) is a feasible and reliable alternative in 
vitro to demonstrate the three-lineage differentiation potential of IPSCs [53]. EBs are small 
clusters of pluripotent stem cells that resemble early stages of embryonic development [4].  
We cultured selected feeder-free clones from all established iPS cell lines as hanging drops 
without LIF leading to formation of small EBs. On day 5, they were transferred to free floating 
culture in non-adherent 96-well plates, and cultured, still without LIF, for additional 16 days 
(Figure 43). Feeder-free culture without LIF allows spontaneous differentiation to occur within 
the EBs. After 21 days in culture, gene expression for pluripotency and lineage-specific markers 
was analyzed by qPCR.  
 
 
Figure 43: Embryoid body on day 21 of spontaneous differentiation in free floating culture.  
Embryoid body derived by spontaneous differentiation of ETA04 in free floating culture on day 21. Scale bar represents 100 
µm. 
 
For the single-integration clone ETA04 both pluripotency markers tested were significantly 
downregulated after 21 days (Oct3/4, p < 0.005; Nanog, p < 0.05). The ectodermal marker Pax6 
was significantly upregulated (p < 0.005) and the ectodermal marker Ncam1 showed a strong 
tendency of higher expression in EBs. Both endodermal markers tested (Sox17 and FoxA2) 




mesodermal markers MyoD1 and Brachyury higher expression levels were detected in EBs at 
day 21, which were, however, not statistically significant. Figure 44 shows the expression of 
these markers as fold change compared to parental IPS cell line ETA04.  
Similar results were obtained for the other clones tested. Notably, there was high variability in 
gene expression between the replicates which correlates well with the results reported e.g. by 
Mansergh et al. for spontaneous differentiation of murine pluripotent stem cells [245]. 
However, our results clearly indicate, that our IPSCs have upregulated ectodermal, endodermal 
and mesodermal markers during spontaneous differentiation in EBs proving their three-lineage 
differentiation potential. 
 
Figure 44: qPCR of pluripotency and lineage-specific markers of IPSCs (ETA04) and embryoid bodies at day 21 (EB 
D21).  
Expression of pluripotency markers Oct3/4 and Nanog was significantly downregulated in EBs at day 21, whereas expression 
of lineage specific markers Ncam1, Pax6, Sox17, FoxA2, MyoD1 and Brachyury was upregulated. Bars represent fold change 






6.5. Chondrogenic differentiation of IPSCs via chondrogenic colonies 
As described in 3.3.2.2. Chondrogenic differentiation of pluripotent stem cells, there are 
different strategies to induce chondrogenic differentiation of pluripotent stem cells.  
In 2015, Yamashita et al. described a scaffoldless method for chondrogenic differentiation of 
human IPSCs via chondrogenic nodules that are formed directly from IPSC colonies through 
exposure to different media supplemented with growth factors [127].  
We attempted to transfer this method to our murine induced pluripotent stem cells generated by 
the Sleeping Beauty transposon system.  
The single integration clone ETA04 was cultured under feeder-free conditions on Geltrex-
coated 6-well plates. As soon as the colonies reached medium size, the culture medium was 
replaced by a mesoendodermal medium supplemented with the growth factors Wnt3a and 
Activin A as described by Yamashita et al. [127]. Colonies were maintained for three days in 
this medium. During that time the colonies did not gain significantly in size but otherwise 
appeared healthy. On day four, chondrogenic differentiation of the colonies was induced by 
changing the media to a chondrogenic medium consisting of DMEM, FBS, Penicillin-
Streptomycin supplemented with non-essential amino acids, sodium pyruvate, insulin 
transferrin and selenite, and L-ascorbic acid [127]. The colonies were either grown in 
chondrogenic medium (noGF) or in chondrogenic medium supplemented with the growth 
factors BMP2, TGFβ1 and GDF5 (BTG), as Yamashita et al. had reported the best results for 
chondrogenic differentiation of human IPSCs using this combination [127]. Around day 6, the 
colonies started to lift off the plate which was about one week earlier than reported by 
Yamashita et al. [127]. The formed chondrogenic nodules were therefore transferred to a free-
floating culture in 6 cm-Petri dishes on day 7. Here, the chondrogenic nodules were maintained 
under the conditions described above for up to 42 days. During that period the spheroids neither 
gained obviously in size nor changed their macroscopic appearance. As reported by Yamashita 
et al. we observed single cells that separated from the developing nodules and sank to the 
bottom of the dishes [127]. On days 14, 31 and 42, the chondrogenic nodules were harvested 




6.5.1. Histological analysis of chondrogenic colonies 
Figure 45 shows representative photomicrographs of chondrogenic nodules derived from 
chondrogenic colonies on day 42. Safranin Orange and Toluidine Blue staining showed no 
substantial deposition of sulfated GAGs in the ECM neither of unstimulated (noGF) nor of 
stimulated (BTG) nodules. Immunohistochemistry for aggrecan and type II collagen was 
negative both in unstimulated (noGF) and stimulated (BTG) nodules. So, no evidence for 
chondrogenic differentiation of IPSCs in chondrogenic nodules was seen in histological 
analysis.   
 
 
Figure 45: Histological analysis of chondrogenic nodules on day 42.  
Chondrogenic nodules were stained with Safranin Orange and Toluidine Blue to detect deposition of GAGs in the ECM. 
Immunohistochemistry was performed for aggrecan and type II collagen. The upper row shows nodules stimulated with the 
chondrogenic growth factors BMP2, TGFβ1 and GDF5, while the lower row shows nodules grown in chondrogenic medium 
without additional growth factors. Scale bars represent 100 µm.  
 
6.5.2. Gene expression analysis of chondrogenic colonies 
We performed qPCR on mRNA isolated from chondrogenic nodules on days 14, 31 and 42 to 
further assess their chondrogenic potential. RNA isolated from parental IPSCs and from rib 






6.5.2.1. Analysis of pluripotency markers in chondrogenic colonies 
Analysis of the expression of the pluripotency markers Oct3/4 and Nanog revealed significant 
downregulation of these markers as soon as day 14 (Oct3/4, p < 0.0001; Nanog, p < 0.0001). 
From thereon expression remained stable at low levels in stimulated and non-stimulated 
nodules.  Figure 46 shows the result of qPCR on pluripotency markers as fold change compared 
to expression in parental IPSC (ETA04). 
 
 
Figure 46: qPCR of pluripotency markers in stimulated (BTG) and non-stimulated (noGF) chondrogenic colonies.  
Expression of pluripotency markers Oct3/4 and Nanog was significantly downregulated in chondrogenic nodules derived from 
chondrogenic colonies as soon as day 14. Bars represent fold change of gene expression compared to ETA04 and are plotted 
as mean ± SD. Asterisks mark significant changes of gene expression levels.  
  
6.5.2.2. Analysis of chondrogenic markers in chondrogenic colonies 
Figure 47 shows the results of qPCR on chondrogenic markers as fold change compared to rib 
cage cartilage. qPCR on the chondrogenic markers aggrecan (Acan), Type II Collagen 
(Col2a1), Sox9 and Integrin α10 (Igta10) confirmed the poor chondrogenic differentiation seen 
in histological analysis. No significant changes were seen for the expression of aggrecan. Sox9 
expression was significantly upregulated in non-stimulated nodules on day 14 (p < 0.01) and 
day 42 (p < 0.001), and type II collagen expression was significantly upregulated in non-
stimulated nodules on day 42 (p < 0.001) compared to expression in parental IPSCs. No 
significant upregulation for these markers, however, was seen in stimulated nodules. 
Expression of Integrin α10 was significantly downregulated in non-stimulated nodules on days 




(p < 0.001). Furthermore, expression of all markers was negligible compared to expression in 
rib cage cartilage tissue. 
 
Figure 47: qPCR of chondrogenic markers in stimulated (BTG) and non-stimulated (noGF) chondrogenic nodules.  
Expression of chondrogenic markers aggrecan (Acan), type II collagen (Col2a1), Sox9 and integrin α10 (Itga10) compared to 
parental IPSCs. Bars represent fold change of gene expression compared to rib cage cartilage and are plotted as mean + SD. 
Asterix mark significant changes of gene expression levels.  
 
So, in conclusion, we were unable to induce chondrogenic differentiation of our murine IPSCs 
with the method described by Yamashita et al. [127]. Despite significant downregulation of 
pluripotency markers, our nodules failed to relevantly upregulate chondrogenic gene expression 





6.6. Chondrogenic differentiation of IPSCs via embryoid bodies 
Therefore, we searched for other methods to efficiently induce chondrogenic differentiation of 
our IPSCs. 
In protocols involving pre-differentiation of IPSCs or ESCs in embryoid bodies (EBs), these 
EBs are either disrupted or plated onto agarose coated plates. Cells directly from disrupted EBs 
or from their outgrowths are then submitted to high-speed centrifugation to generate high-
density pellets similar to the standard protocol used for MSC [229, 230]. However, disruption 
of EBs and subsequent centrifugation are considered stressful for the cells and the outgrowth 
from the EBs usually contains a mixed cell population. It has been shown that chondrogenic 
differentiation of IPSCs can also be achieved by culturing IPSCs in a microcavity hydrogel, in 
which they form EB-like structures that directly undergo chondrogenic differentiation [223].  
Therefore, we suggested, that disrupting the EBs into a single cell suspension is not necessary 
for chondrogenic differentiation. As EBs represent a high-density culture system resembling 
Yamashita’s nodules and conventional centrifugation-derived pellets, we supposed that it might 
be sufficient to maintain EBs under chondrogenic conditions in a free-floating culture system 
to induce chondrogenic differentiation of the IPSCs.   
We cultured feeder-free IPSCs from the single integration cell line ETA04 for five days in 
hanging drops without LIF allowing formation of embryoid bodies. These EBs were then 
directly transferred into a free-floating culture system and maintained in chondrogenic medium 
consisting of DMEM supplemented with dexamethason, natrium pyruvate, L-ascorbic acid and 
insulin transferrin selenite (ITS). The resulting pellet-like aggregates were termed chondrogenic 
spheroids.  
These chondrogenic spheroids were maintained either without additional growth factors (noGF) 
or with the well-known chondrogenic growth factors bone morphogenetic protein 2 (BMP2) 
and transforming growth factor β1 (TGFβ1) added to the medium (BT) for up to 42 days. 
During that period the EBs significantly increased in size (EBs vs. noGF, p < 0.001; EBs vs. 
BT, p < 0.001; Figure 48). EBs at day 5 had a median diameter of 181 µm (IQR 65µm). EBs 
stimulated with BMP2 and TGFß1 reached a mean diameter of 770 ± 60 µm at day 42, and 




±50 µm (p < 0.001). Furthermore, the stimulated spheroids were more compact with smoother 
edges and showed a white color typical for cartilage particles.  
 
 
Figure 48: Size of EBs on day5 and CSs on day 42.  
During chondrogenic differentiation the chondrogenic spheroids gained significantly in size and reached a mean size of 680 ± 
50 µm when maintained without growth factors or 770 ± 60 µm when stimulated with growth factors BMP2 and TGFβ1. 






6.6.1. Histological analysis of chondrogenic spheroids 
Chondrogenic spheroids were harvested after 2, 4 and 6 weeks in free floating culture (Days 
14, 28 and 42). Different histological analyses were performed on cryosections to evaluate 
chondrogenic differentiation of the spheroids. 
 
6.6.1.1. Safranin Orange staining of chondrogenic spheroids 
Safranin Orange staining confirmed deposition of sulfated proteoaminoglycans (PGs) in the 
ECM of chondrogenic spheroids cultured with chondrogenic growth factors (BT) on day 28 
and day 42. Spheroids at day 14 mostly consisted of densely packed cells for both conditions 
(no GF and BT). Spheroids cultured in chondrogenic medium alone (noGF) revealed only small 
areas with PG deposition on day 42 and were less compact than factor-supplemented spheroids.  
Representative photomicrographs of the sections are shown in figure 49 (upper part).  
 
6.6.1.2. Toluidine Blue staining of chondrogenic spheroids 
Toluidine Blue staining confirmed the results of Safranin Orange staining showing deposition 
of negatively charged PGs in the ECM of chondrogenic spheroids maintained with BMP2 and 
TGFβ1 on day 28 and 42 (BT). Only small positive areas could be detected in the control 
spheroids (noGF). Spheroids at day 14 consisted of densely packed cells with no relevant PGs 
deposited in the ECM for both conditions.  





Figure 49. Safranin Orange and Toluidine Blue staining for chondrogenic spheroids.  
The upper rows depict chondrogenic spheroids cultured with BMP2 and TGFβ1 (BT), the lower rows depict the corresponding 
control spheroids maintained in chondrogenic medium without growth factors (noGF) on days 14, 28 and 42. Proteoglycan 








6.6.1.3. Immunohistochemistry for aggrecan and type II collagen  
Immunohistochemistry (IHC) confirmed deposition of aggrecan and type II collagen in the 
ECM of chondrogenic spheroids treated with BMP2 and TGFβ1 on days 28 and 42. Aggrecan 
could be detected diffusely throughout the complete spheroid, whereas deposition of type II 
collagen seemed restricted to certain spots within the spheroid on day 42. No aggrecan or type 
II collagen could be detected in supplemented spheroids on day 14, or in control spheroids at 
any time. Figure 50 shows representative photomicrographs of the immunohistochemistry.  
 
Figure 50: Immunohistochemistry for aggrecan and type II collagen on chondrogenic spheroids 
The upper rows depict chondrogenic spheroids cultured with BMP2 and TGFβ1 (BT), the lower rows depict the corresponding 
control spheroids maintained in chondrogenic medium without growth factors (noGF) on days 14, 28 and 42. Deposition of 





Taken together, histochemical analysis and immunohistochemistry revealed deposition of 
negatively charged proteoglycans as well as aggrecan and type II collagen in the ECM of 
chondrogenic spheroids derived from the IPS cell line ETA04 via EBs stimulated with 
chondrogenic growth factors BMP2 and TGFβ1 (BT). This clearly indicates that chondrogenic 
differentiation can be achieved by culturing EBs under chondrogenic conditions. 
Supplementation of chondrogenic growth factors, however, seems to be required as spheroids 
cultured in chondrogenic medium alone did not deposit PGs, aggrecan or type II collagen in 
their ECM.  
 
6.6.2. Gene expression analysis of chondrogenic spheroids 
To further assess chondrogenic differentiation of IPSCs in EB-derived chondrogenic spheroids, 
qPCR was performed on mRNA isolated from stimulated and non-stimulated chondrogenic 
spheroids (BT and noGF) on days 14, 28 and 42. RNA isolated from the parental IPSCs and 
from rib cage cartilage of mouse embryos served as controls. 
 
6.6.2.1. Expression of pluripotency markers in chondrogenic spheroids 
qPCR for the pluripotency markers Oct3/4 and Nanog showed that both pluripotency markers 
were significantly downregulated compared to parental IPSCs as soon as day 14 (Oct3/4,              
p < 0.05; Nanog, p < 0.001). No significant changes between spheroids cultured with or without 
chondrogenic growth factors (BT vs noGF) could be detected at any timepoint. No significant 
changes of gene expression occurred after day 14 for both markers. Interestingly for Oct3/4 a 
tendency of higher expression could be detected on days 28 and 42 in both stimulated and non-
stimulated spheroids compared to day 14, whereas the expression of Nanog remained stable at 
low levels. This might be due to reactivation of exogenous Oct3/4 from the genomically 
integrated reprogramming factor expression cassette that becomes reactivated during the 






Figure 51 shows the results of the qPCR of pluripotency markers as fold change compared to 
expression in parental IPSC (ETA04).  
 
Figure 51: qPCR of pluripotency markers in stimulated (BT) and non-stimulated (noGF) chondrogenic spheroids.  
Expression of pluripotency markers Oct3/4 and Nanog was significantly downregulated in chondrogenic spheroids as soon as 
day 14. No significant differences could be detected between stimulated and non-stimulated spheroids. Bars represent fold 
change of gene expression compared to ETA04 and are plotted as mean + SD. Asterisks mark significant changes of gene 
expression levels.  
 
6.6.2.2. Expression of chondrogenic markers in chondrogenic spheroids 
We performed qPCR for the chondrogenic markers aggrecan (Acan), type II collagen (Col2a1), 
Sox9 and α10-integrin (Itga10). 
In the stimulated spheroids Acan and Col2a1 expression was significantly upregulated on day 
28 compared to parental IPSCs and high expression levels were maintained until day 42 (Acan, 
day 28, p < 0.05; day 42, p < 0.01; Col2a1, day 28, p < 0.05; day 42, p < 0.005). This matches 
the results of the immunohistochemistry where deposition of aggrecan and type II collagen in 
the ECM could only be detected in stimulated spheroids on day 28 and 42. No relevant 
expression of Acan or Col2a1 was induced by culturing EBs in chondrogenic medium without 
growth factor supplementation.  
Interestingly, the chondrogenic transcription factor Sox9 was significantly upregulated in both, 
stimulated and non-stimulated chondrogenic spheroids as soon as day 28 compared to parental 
IPSCs (noGF, p < 0.05; BT, p < 0.001 at days 28 and 42). There were no significant differences 
in the expression of Sox9 between stimulated and non-stimulated spheroids, although a clear 
tendency for higher expression levels of Sox9 could be seen for the spheroids maintained under 




Similar results were seen for expression of α10-integrin (Itga10). Its expression was 
significantly upregulated in control spheroids on day 42 (p < 0.001) and growth-factor 
stimulated spheroids starting from day 28 (p < 0.01 at day 28; p < 0.001 at day 42) compared 
to parental IPSCs. No significant differences could be detected between supplemented and non-
supplemented spheroids at any time point, although a tendency for higher expression of Itga10 
could be seen in stimulated spheroids.  
Taken together, culture of IPSC-derived EBs in chondrogenic medium alone induced 
significant upregulation of cartilage-specific transcription factor Sox9 as well as of the cartilage-
specific integrin α10. Stimulation of spheroids with the growth factors BMP2 and TGFβ1, 
however, was necessary to induce production of the cartilage-specific ECM proteins aggrecan 
and type II collagen.  
Figure 52 shows the results of the qPCR of chondrogenic markers as fold change compared to 
expression in murine embryonic rib cage cartilage.   
 
 
Figure 52: qPCR of chondrogenic markers in stimulated (BT) and non-stimulated (noGF) chondrogenic spheroids.  
Expression of chondrogenic markers Aggrecan (Acan) and Collagen Type II (Col2a1) was significantly upregulated in 
stimulated chondrogenic spheroids as soon as day 28 compared to parental IPSCs (ETA04). Sox9 and α10-integrin (Itga10) 
expression was significantly upregulated compared to parental IPSCs (ETA04) in stimulated and non-stimulated spheroids on 
day 28 and 42. Bars represent fold change of gene expression compared to rib cage cartilage and are plotted as mean + SD. 





Furthermore, we analyzed expression of both isoforms of type II procollagen, procollagen IIA 
(Col II A) and procollagen IIB (Col II B), in stimulated and non-stimulated chondrogenic 
spheroids on day 42. We used a specially designed quadruple of primers that allow to 
simultaneously detect procollagen IIA and procollagen IIB during one run of PCR leading to 
two PCR products on agarose gel electrophoresis (Figure 53) [129].  
In rib cage cartilage only the mature form Col IIB could be detected. Expression of both isotypes 
was seen in stimulated and non-stimulated spheroids indicating presence of chondroprogenitor 
cells as well as more mature chondrocytes. The stimulated spheroids, however, clearly showed 
higher expression levels of the mature isotype procollagen IIB.  
 
 
Figure 53: RT-PCR for procollagen II isoforms procollagen IIA (Col II A) and B (Col IIB) 
For simultaneous analysis of the expression of the two isoforms of Procollagen II (Col II A and Col II B) in stimulated (BT) 
and non-stimulated (noGF) chondrogenic spheroids on day 42 two primer pairs were used within the same probe resulting in 
two bands after agarose gel electrophoresis. Rib cage Cartilage (RC) was used as a positive control.  
 
These results further support our hypothesis that chondrogenic differentiation of induced 
pluripotent stem cells can be achieved by culturing EBs in chondrogenic medium. To achieve 
a hyaline cartilage phenotype with high expression of mature chondrogenic markers and 
deposition of cartilage specific ECM, however, these spheroids need to be stimulated by 





6.6.2.3. Expression of hypertrophy markers in chondrogenic spheroids 
Finally, we analyzed expression of hypertrophy markers Runx2 and type X Collagen (Col10a1). 
Expression of Runx2 was significantly upregulated in stimulated spheroids as soon as day 28, 
whereas expression of Col X was significantly upregulated in stimulated spheroids only on day 
42 compared to parental IPSCs.  
Figure 54 shows the results of the qPCR of chondrogenic markers as fold change compared to 
expression in murine embryonic rib cage cartilage.  
 
 
Figure 54: qPCR of hypertrophy markers in stimulated (BT) and non-stimulated (noGF) chondrogenic spheroids.  
Expression of hypertrophy marker Runx2 was significantly upregulated in stimulated chondrogenic spheroids as soon as day 
28 compared to parental IPSCs (ETA04). Collagen Type X (Col X) expression was significantly upregulated compared to 
parental IPSCs (ETA04) in stimulated spheroids on day 42. Bars represent fold change of gene expression compared to rib 
cage cartilage and are plotted as mean + SD. Asterisks mark significant changes of gene expression levels.  
 
These results indicate that despite successful chondrogenic differentiation also hypertrophy 
occurred within the stimulated spheroids. This might be due to prolonged exposure to BMP2 
which is known to not only enhance chondrogenesis but also to play an important role in the 
induction of hypertrophy during endochondral ossification [156]. Further research is necessary 
to evaluate the effect of more elaborate growth factor supplementation on the quality of 







7.1. Sleeping Beauty transposon system for reprogramming 
For the generation of the first IPSCs, Takahashi et al. screened 24 candidate genes for their 
ability to direct somatic cells back to a pluripotent state, and identified the four reprogramming 
factors Oct3/4, Sox2, Klf4 and c-Myc. Each gene was transfected by an individual retroviral 
vector. This approach led to high expression of the transfected genes and allowed 
reprogramming at a quite high efficiency [15]. However, multiple genomic insertion sites of 
the individual reprogramming factors were produced [15]. This imposes a high risk of 
insertional mutagenesis, and chances that one of the multiple insertion sites is inefficiently 
silenced or reactivated during differentiation are high [41].  
Since then, multiple gene delivery methods have been used for induction of pluripotency each 
with their own inherit advantages and disadvantages that are summarized in Table 33.  
Viral vectors offer high efficiency for delivery of transgenes into cells as viruses are natural 
gene transfer vehicles that have evolved to cross cellular membranes [43]. However, viruses 
are potentially immunogenic and are therefore generally considered less suitable for generation 
of clinical grade IPSCs. Non-viral methods contrarily suffer from low efficiency rates, but 
provide easier handling and are less immunogenic [51].  
Integrating methods provide stable transgene expression over a prolonged time allowing high 
reprogramming efficiencies, but they bear the risk of insertional mutagenesis [42]. Integration 
of a transgene into a gene or its regulatory elements might not only disrupt transcriptional units, 
but can lead to transcriptional activation or inactivation of nearby genes [42, 246]. Such 
genotoxic effects can have devastating consequences for the cell [42]. Non-integrating methods, 
are considered safer, but suffer from low reprogramming efficiencies due to limited duration of 
transgene-expression rendering repeated transfections necessary [43]. 
In polycistronic vectors, the cDNA sequences of the reprogramming factors are separated by 
self-cleaving 2A peptide sequences [247]. This allows expression of all reprogramming factors 
from a single expression cassette, therefore minimizing the number of integration sites required 
and ensuring expression of the reprogramming factors in a 1:1 stoichiometry [51, 247]. 




interference of the exogenous promoter with nearby endogenous promoters [51]. Therefore, the 
reprogramming factors should be provided as polycistronic vectors for both research and 
clinical purposes.  
Table 33: Methods for the generation of induced pluripotent stem cells 
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• Insertional mutagenesis 
• Transgene reactivation  
• Integration preferentially into 
transcriptional start sites 
Lentiviral 
vectors 
[19, 66, 247, 
248] 
• Highly efficient 
• Insertional mutagenesis 
• Transgene reactivation  
• Integration preferentially into 






  Transposons 
[53-55] 
• Efficient 
• Safe integration profile 
• Possibility of removal 
• Insertional mutagenesis 




















• No genomic integration 
• Inefficient 
• Repeated transfections required 
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• No genomic integration 
• Easy handling 
• Highly inefficient 
• Repeated transfections required 
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• No genomic integration 
• Difficult handling 
• Repeated transfections required 
• High workload 
Protein 
[49] • No genomic integration 
• Inefficient 
• Difficult production 






7.1.1. Integrating viral vectors 
Retroviral vectors have been used by Takahashi et al. for the generation of the first IPSCs [15]. 
They are easy to use and provide stable expression of transgenes facilitating high 
reprogramming efficiency [15, 41]. Lentiviruses do not rely on cell division to integrate their 
cargo into the host’s genome, and thus are able to infect a broader range of cell types [41]. 
Lentiviral vectors have been widely applied for reprogramming of murine and human somatic 
cells [19, 66, 247, 248].  
Retroviral vectors are commonly based on the murine leukemia virus (MLV) and  preferentially 
integrate their genetic cargo into transcriptional start sites of active genes [249]. Lentiviral 
vectors are often derived from the human immune deficiency virus (HIV-1) and show a strong 
tendency to integrate their cargo into actively transcribed genes [250]. Therefore, both gene 
vectors impose a high risk of insertional mutagenesis [59, 65]. Virally induced transgenes 
regularly are silenced during the reprogramming process, however, reactivation of potential 
oncogenes like c-Myc can occur upon differentiation and imposes a high risk of tumor formation 
[17, 41].  
Doxycycline-inducible lentiviral vectors have been used to generate secondary, inducible 
reprogramming systems, that are powerful tools in understanding the molecular mechanism of 
reprogramming [66, 67]. Differentiated cells carrying the inactive transgene (e.g. fibroblasts or 
lymphocytes) are isolated from chimeras generated by injection of “primary” IPSCs into 
blastocysts. Upon exposure to doxycycline, the reprogramming factors are re-expressed and the 
somatic cells are reprogrammed into “secondary” IPSCs in a controllable and synchronous 
manner [67, 71].  
But, despite being valuable tools for basic research on the reprogramming process, retroviral 
and lentiviral vectors are less suitable for clinical applications. 
 
7.1.2. Non-integrating viral vectors 
Replication-defective adenoviral vectors have been used to generate IPSCs [44]. As they do not 




infections are required [41, 44]. Also, production of adenoviral vectors is labor-intensive and 
reprogramming efficiency is low [41]. Therefore, adenoviruses seem less suitable for the 
generation of IPSCs for research or cell therapy purposes. 
Recently the non-integrating RNA Sendai virus has been used successfully to generate IPSCs 
[45]. This method is effective and does not bear the risk of insertional mutagenesis [3]. 
Furthermore, after successful reprogramming, remaining virus containing cells can be easily 
removed by antibody mediated negative selection [41, 45] . However, Sendai viruses are 
difficult to handle, and no good manufacturing practice (GMP)-grade reagents are available so 
far [3, 41]. Although Sendai-virus based vectors are promising, more research is required before 
they can be used to generate clinical-grade IPSCs. 
 
7.1.3. Non-integrating non-viral vectors 
Delivery of the reprogramming factors as plasmids or minicircles is a simple method for 
generation of induced pluripotent stem cells [46, 47]. These DNA-based vectors are easy to 
produce and can be delivered using standard transfection techniques [41, 42]. But, since the 
vectors do not integrate into the genome, they are diluted upon cell division so that multiple 
transfections are required [42]. The overall reprogramming efficiency of these methods remains 
very low [41]. Furthermore, spontaneous genomic integration of these DNA molecules can 
occur requiring labor-intensive screening for integration-free clones [41, 251]. Therefore, these 
plasmid-based vectors are not optimal to generate clinical-grade IPSCs.  
Episomal plasmids are based on the Epstein-Barr Nuclear Antigen-1 (oriP-EBNA1) [41]. 
Although these plasmids do not integrate, they attach to the host chromatin and replicate 
synchronously with the host genome during cell division [41]. Even though the generation of 
induced pluripotent stem cells using episomal vectors has been reported, the reprogramming 
efficiency remains very low hampering widespread application of this method [3, 48].   
The transcription factors can also be provided as mRNA or proteins [49, 50]. Reprogramming 
with mRNA is an effective and safe method, as there is no risk of genomic integration [3]. 
However, mRNA is difficult to handle and suffers from a relatively short half-life, so that 





Delivering the reprogramming factors as synthetic proteins also requires multiple transfections 
and shows only very low reprogramming efficiency [41]. Furthermore, it is difficult to 
synthesize proteins in the required quantities [3]. Therefore, neither mRNA- nor protein-based 
delivery of the reprogramming factors are optimal approaches for reprogramming. 
 
7.1.4. Integrating non-viral vectors 
Transposon-based gene delivery vectors consist of a donor plasmid that contains the gene of 
interest flanked by terminal inverted repeats (TIRs) and a source of the transposase enzyme that 
is mostly provided by a second plasmid. After transfection, the transposase enzyme catalyzes 
excision and genomic integration of the gene of interest in a cut-and-paste mechanism [43, 57].  
 
There are many transposon systems available for gene transfer in murine and human cells. The 
Sleeping Beauty (SB) and PiggyBac (PB) systems belong to the most well-established systems, 
and have been successfully used for the generation of induced pluripotent stem cells from 
murine and human somatic cells [53-55].  
 
Transposons combine the advantages of integrating viral vectors with the advantages of non-
viral delivery systems [42, 51]. Development of hyperactive variants of the transposases (e.g. 
SB100x for Sleeping Beauty) allowed gene delivery at efficiency levels comparable to viral 
vectors overcoming one of the main barriers of non-viral delivery methods [58]. As integrating 
vectors, they provide stable expression of the induced transgenes during the reprogramming 
process facilitating successful reprogramming [51, 53]. On the other hand, transposons are less 
immunogenic than viral vectors [51]. Furthermore, as plasmid-based systems, they can be easily 
and cost-effectively produced at high quality and do not require a biohazard facility [51, 54]. 
They offer high DNA cargo capacity and can accommodate a polycistronic construct containing 
all reprogramming factors and additional genes like for example selection markers [53, 54].  
 
However, as integrating vectors, transposons still impose a risk for insertional mutagenesis. 
Comparison of the integration preferences of several gene transfer vectors including the 
transposons Sleeping Beauty, PiggyBac and Tol2, the retroviral murine leukemia virus (MLV) 




profile for the SB transposon system (Figure 55) [59, 65]. On the primary DNA level, Sleeping 
Beauty is highly specific and integrates strictly only into TA-dinucleotides [56, 64]. On a 
genome-wide basis, however, it shows a nearly random distribution with no bias for integration 
into genes or transcriptional regulatory regions [65, 252]. Therefore, the majority of SB 
integrations occurs in intergenic regions causing no relevant insertional mutagenesis [43]. 
Bioinformatical analysis of the integration sites regarding proximity to genes, cancer-related 
genes and microRNAs further confirmed the favorable integration profile of Sleeping Beauty 
[42].  
The PiggyBac system shows a slight bias for integration into promoters and exonic regions 
which resembles the integration pattern of the retroviral MLV [65, 252].  
 
Although the Sleeping Beauty transposon integrates its cargo into the host genome, its favorable 
integration profile makes it less prone to cause insertional mutagenesis. Therefore, it might 
represent a good compromise between efficient reprogramming, that requires stable transgene 
expression, and safety concerns, that fear insertional mutagenesis. 
 
  
Figure 55: Integration profile of commonly used gene vectors. From Narayanavari et al. [59].  
Whereas the Sleeping Beauty (SB) transposon system shows a nearly random integration profile on a genome wide basis, other 
integrating vectors like the PiggyBac (PB) and Tol2 transposon system as well as the retroviral murine leukemia virus (MLV) 
and the lentiviral human immune deficiency virus (HIV) show a clear bias for integration into genes or transcriptional start 
sites (TSS). 
 
Furthermore, the TIRs of Sleeping Beauty – in contrary to the PiggyBac system – have no 
endogenous enhancer or promoter activity [253, 254]. Also, there are no SB-related elements 
within mammalian genomes that could be cross-mobilized by the introduced transposons as it 





The Sleeping Beauty system is in fact considered safe enough to be applied in clinical trials. It 
has been widely used as a gene delivery vector for gene therapy in several animal models [42]. 
This includes e.g. the delivery of coagulation factor IX to mouse liver cells that led to long term 
stable expression of the factor in a mouse model of hemophilia B [255], or delivery of FAH 
(fumarylacetoacetate hydrolase) to mouse livers that led to correction of murine tyrosinemia 
type I [256]. Recently two clinical trials using SB transposons in humans have been launched. 
One includes the delivery of PDEF (pigment epithelium-derived factor) into retinal pigment 
epithelial or iris pigment epithelial cells, that are harvested and transplanted back into the 
patient after transfection during a single surgical session (TargetAMD) [42, 257]. Furthermore, 
SB is used to deliver chimeric antigen receptors (CAR) into tumor reactive T-cells that are used 
in the treatment of B-cell malignancies [42, 258].  
Taken together, the Sleeping Beauty transposon system has been used successfully for the 
generation of IPSCs in mouse and human. It is an easy to use gene vector, and due to its 
favorable integration profile, considered safe-enough for clinical applications. Therefore, it 
might be applicable to use IPSCs generated with the Sleeping Beauty system not only for 
research purposes but also for IPSC-based therapies in a clinical setting.  
For clinical applications, possible reactivation of the genomically integrated reprogramming 
factors, especially the known oncogenes Klf4 and c-Myc, raises safety concerns [41]. Therefore, 
removal of the reprogramming factor cassette after successful reprogramming would be 
desirable. This could be achieved by re-expressing the transposase enzyme that now catalyzes 
excision of the transposon from its genomic location. This approach has been successfully used 
to produce integration free IPSCs from the PiggyBac transposon [259, 260]. The PiggyBac 
transposon can be removed seamlessly and leaves no footprint in the genome [261]. For the 
Sleeping Beauty system however, excision rates are quite low, and a footprint is left behind that 
imposes a remnant risk for insertional mutagenesis [262, 263]. Excision of the reprogramming 
factor cassette furthermore requires labor-intensive screening for clones with few or only a 
single integration site, mapping of the integration site, excision of the reprogramming factor 
cassette and validation of the factor-free clone [51]. Additionally, there is still a risk of 
reintegration of the excised transposon by the transposase at a new genomic location.  
Exchange of the reprogramming factor cassette by recombinase mediated cassette exchange 




reprogramming factor cassette. By flanking the reprogramming factor expression cassette with 
heterospecific loxP sites, it is possible to exchange the transgene for another gene of interest by 
exposure to the Cre recombinase [53]. The genomically integrated reprogramming factor 
cassette could serve as a “safe harbor site” for other transgenes that would e.g. correct genetic 
diseases. It would be furthermore possible to generate IPSCs “primed” for a certain 
differentiation lineage e.g. by overexpression of lineage-specific key transcription factors. More 
research is required to enlighten the impact of RMCE-introduced genes of interest on IPSC’s 
differentiation potential and safety. 
 
7.1.5. Conclusion 
Since the generation of the first IPSCs more than ten years ago, many advances have been made 
in optimizing the reprogramming process. However, there is still no ideal vector to deliver the 
reprogramming factors, instead the right vector must be carefully chosen for the right 
application.  
For the generation of IPSCs for cell therapy purposes, the vector must be safe, i.e. non-
oncogenic, with no off-target effects even if that involves high work load or rather inefficient 
reprogramming. To generate IPSCs for basic research purposes however, a high reprogramming 
efficiency along with a low work-load is desirable to facilitate e.g. high-throughput screenings 
or enable generation of IPSCs from scare starting cell populations [41].  
There is a broad consent, that avoiding viral insertions is a strict requirement for clinical 
translation of IPSCs. To dissect the reprogramming process itself however, inducible lentiviral 
vectors allow the generation of secondary IPSCs and play a fundamental role in basic IPSC 
research [67, 71]. Non-integrating methods, however, suffer from low reprogramming 
efficiencies. Transposons combine the high reprogramming efficiency of integrating vectors 
with the superior safety profile of non-viral vectors and might therefore be suitable to generate 






7.1.6. Reprogramming of murine fibroblasts with a Sleeping Beauty transposon-
based reprogramming system 
In this thesis, we used a Sleeping Beauty transposon-based reprogramming system consisting 
of two plasmids. One plasmid carried the transposon TIRs flanking the reprogramming factors 
and additional selection markers, whereas the second plasmid served as a source of the 
hyperactive transposase SB100X.  
Four different reprogramming factor plasmids were used. All carried the reprogramming factor 
cassette consisting of a polycistronic vector carrying the cDNAs of Oct3/4, Sox2, Klf4 and          
c-Myc plus/minus Lin28 separated by self-cleaving 2A-peptides [247]. On the pT2OSKM and 
pT2OSKML plasmids the reprogramming factor cassette and a PuroΔTK selection marker was 
inserted between the transposon TIRs. The RMCE-OSKM-Cherry and RMCE-OSKML-Cherry 
plasmids additionally contained a mCherry pluripotency reporting cassette and heterospecific 
loxP sites that would allow for modification of the genomically integrated transposon by RMCE 
[53].  
These plasmids were delivered into primary mouse embryonic and adult fibroblasts by 
nucleofection, which has been shown to be a suitable delivery method for plasmid-based 
transposon systems [53]. Efficiency rates for the delivery of plasmids into our primary cell 
populations by nucleofection were determined by transfection with a GFP-plasmid and ranged 
between 40% for EAR-FBs and 87% for MEFs. Nucleofection efficiencies for the Sleeping 
Beauty transposon system were supposedly lower, due to the larger size of the reprogramming 
factor plasmids and the need for co-transfection of two plasmids. However, since a single 
genomic integration of the transposon is sufficient for successful reprogramming, delivery of 
the transposon system by nucleofection was still considered suitable.    
The optimal transposase : transposon ratio for the Sleeping Beauty transposon system is about 
1:10 [63]. Therefore, we co-transfected 0.1 µg, 0.2 µg or 0.5 µg of the SB100x-transposase 
plasmid with 1 µg, 2 µg or 5 µg of the respective reprogramming factor plasmid.  
With this approach we succeeded at reprogramming primary murine embryonic fibroblasts and 
primary murine adult fibroblasts isolated from ear or tail of adult wild-type mice. More than 
250 IPSC colonies were picked, and assessment of 22 selected IPS cell lines for morphological 




Splinkerette PCR is an established method to determine the number of genomically integrated 
transposon copies [53]. Two of the 22 analyzed cell lines were confirmed to contain only a 
single transposon integration site, and were therefore considered especially suitable for 
subsequent differentiation assays. There was no evident correlation found between the number 
of transposon integration sites and the amount of transposase and transposon used to transfect 
the respective cells, likely due to the limited number of analyzed cell lines.  
In conclusion, we have established a reliable and effective reprogramming protocol for primary 
murine cells using the Sleeping Beauty transposon based reprogramming system. Since the 
reprogramming plasmids used in this thesis have also been successfully used to reprogram 
human cells, transfer of our reprogramming system to primary cells isolated from patients 







7.2. Significance of IPSCs for cartilage regeneration 
7.2.1. State of the art of cartilage repair 
Focal cartilage lesions and osteoarthritis dramatically impair quality of life of affected patients 
and impose a large socioeconomic burden on society [168, 171]. Although modern MRI 
imaging allows detection of early osteoarthritis-associated changes, there is still no causative 
treatment [170, 171]. In early stages treatment of osteoarthritis is limited to reduction of risk 
factors like obesity or surgical correction of joint malalignment [171, 174]. Pharmaceutical 
treatment of symptomatic osteoarthritis by analgesic and anti-inflammatory drugs is hardly 
effective and does not stop progression of cartilage degradation [170, 171]. Definitive treatment 
of osteoarthritis can only be achieved by total joint replacement [174]. Despite good to excellent 
results of total joint replacement for hip and knee osteoarthritis, it remains a maximally invasive 
procedure with non-negligible operative and perioperative risks [174]. The perioperative risks 
include e.g. bleeding with need for transfusion (6-12%), wound infections (1%), deep vein 
thrombosis (0,2 – 0,7%) and pulmonary embolism (0,2 – 0,5%) [264].  The 15-year survival 
rate of the prosthesis is about 86% for total hip replacement and 80% for total knee replacement 
with aseptic loosening being the most common cause for revision [174, 265, 266].  
The poor intrinsic regeneration capacity of articular cartilage as well as the propensity of focal 
cartilage lesions to progress into osteoarthritis are well-known facts [169]. There is broad 
consent that, especially in younger patients, sufficient treatment of focal cartilage lesions to 
prevent progression into osteoarthritis, and delay need for total joint replacement is desirable. 
Current therapeutic options for focal cartilage lesions include microfracture, osteochondral 
autograft transfer and autologous chondrocyte injection.  
The microfracture technique mimics natural repair of osteochondral defects. Small holes are 
made arthroscopically in the subchondral bone through which bone-marrow mesenchymal stem 
cells (BM-MSCs) along with blood and fat emerge [181, 182]. These stem cells differentiate 
over time into chondrocytes and fill the defect with fibrocartilaginous tissue [181, 183]. Initially 
significant clinical improvement is seen with about 67% of patients reporting good to excellent 
knee function two years after microfracture procedure due to symptomatic focal cartilage 




osteophytes and subchondral cysts [183, 186]. Currently, microfracture represents the gold 
standard for the initial treatment of small lesions (< 2cm2) [186]. It is especially suitable as a 
first line treatment in low demanding patients, as it is a minimally invasive, single stage 
procedure with minimal morbidity [181, 185]. However, due to formation of biomechanically 
inferior fibrocartilage many patients report secondary deterioration of symptoms after two to 
four years [181, 184, 267].  Therefore, microfracture does not represent an optimal method for 
cartilage regeneration. 
The AMIC (autologous matrix induced chondrogenesis) procedure represents an advanced 
modification of microfracture. Here a collagen I/III membrane (e.g. Chondro-Gide ®, Geistlich 
Pharma AG, Wolhusen, Switzerland) is applied to stabilize the clot formed by microfracture 
[187]. Patients treated with AMIC reported significant reduction of pain and significant 
improvement of Lysholme score two years after treatment [188, 268]. Even after five years, 
patients treated with AMIC showed stable improvement in the modified Cincinnati score and 
reported very low pain, whereas in patients treated with microfracture alone, both parameters 
had already deteriorated [189].  Histological results, however, showed that the defect areas are 
mostly filled with fibrocartilaginous repair tissue after two years [189]. Therefore, it is likely 
that in a long term follow up with an adequate number of patients the clinical improvement by 
AMIC is not durable, too. 
During osteochondral autograft transfer (OAT) the defect is filled with osteochondral cylinders 
harvested from low weight-bearing areas of the joint [193]. Today, transfer of multiple small 
osteochondral grafts – also known as mosaicplasty – represents the state of art since it results 
in smaller donor site defects and allows better contouring at the recipient site compared to 
transfer of a single large graft [195]. Besides for cartilage lesions in the knee joint, OAT has 
been used successfully for focal cartilage defects of the talar dome, the capitulum humeri, the 
humeral head and the femoral head [196]. Analysis of a prospective database with more than 
1000 patients undergoing mosaicplasty showed good-to excellent results in 74% - 92% of the 
patients after 10 years depending on the location of the recipient site [196]. However, 3% of 
patients reported moderate to severe symptoms at the donor site [196]. Biopsies taken after up 
to 3.5 years after OAT showed fibrocartilage filling at the donor sites and a good survival of 





functional results application of OAT is restricted to small defects due to the limited availability 
of donor sites [186, 193, 196].  
Autologous chondrocyte injection (ACI) is indicated for full-thickness osteochondral defects 
with a size of 2 cm2 to 12 cm2 [177, 186], or in patients where microfracture has failed [115, 
177]. Articular cartilage is harvested from a non-weight bearing area of the joint, then 
chondrocytes are isolated and expanded in vitro before they are injected into the defect area 
during a second surgery [200]. During expansion in monolayer culture, dedifferentiation of 
chondrocytes occurs. The morphology gradually changes from small polygonal cells to a 
flattened, spindle-shaped, fibroblast-like morphology [202, 216]. Furthermore, expression of 
chondrocyte markers like Sox9, aggrecan and type II collagen (Col2a1) decreases whereas 
expression of type I collagen (Col1a1) increases [202]. Injection of these dedifferentiated cells 
leads to biomechanically inferior fibrocartilage as repair tissue [201]. In first generation ACI, 
the cell suspension was injected under a periosteal flap [200]. Although the reported clinical 
outcome was good to excellent after two years, this method not only requires harvesting of a 
periosteal flap, leading to longer operating times and harvesting site morbidity, but over the 
years, often symptomatic hypertrophy of the periosteal flap occurred [176, 177, 200, 269]. 
Therefore, the periosteal flap was replaced by synthetic membranes consisting e.g. of collagen 
I/III (Bio-Gide®, Geistlich Biomaterials, Wolhusen, Switzerland) [203]. Gomoll et al. showed 
that reoperation rate due to patch-related issues was significantly lower in the synthetic 
membrane group (26% vs. 5%) [203]. Furthermore, ACI requires at least two surgeries and a 
long recovering period imposing high costs on the health system as well as pain and discomfort 
on the patient [115, 177, 206]. 
In conclusion, currently available repair strategies for focal chondral lesions suffer from 
formation of biomechanically inferior fibrocartilage, destruction of healthy articular cartilage 
leading to donor-site morbidity, and need for invasive surgical procedures [176, 186].  
During matrix assisted ACI (MACI), the harvested chondrocytes are cultured in hydrogels like 
CaReS® from ArthroKinetics, Esslingen, Germany [204] or BioSeed-C ® from BioTissue, 
Zürich, Switzerland [205]. This not only ensures a more even distribution of the implanted 
chondrocytes within the defect and provides easier surgical handling, but also helps to prevent 
chondrocyte dedifferentiation [186, 205].  Both matrixes resulted in significant clinical 




chondrogenically differentiated MSCs or IPSCs providing ready-to-use off-the-shelf products 
for cartilage repair [176, 206]. 
 
7.2.2. Mesenchymal stem cells for cartilage repair 
Due to their well-described chondrogenic potential, mesenchymal stem cells (MSCs) are an 
intensively studied cell population for cartilage repair. Autologous and allogenic MSCs have 
been used in clinical trials for the treatment of cartilage defects [211, 212]. Compared to 
autologous chondrocytes, MSCs have a superior proliferation capacity and can be harvested in 
higher numbers e.g. from the iliac crest under local anesthesia without need for general 
anesthesia or destruction of healthy cartilage [211]. Comparison of autologous bone marrow 
derived MSCs (BM-MSCs) and autologous chondrocytes for injection into cartilage defects 
showed significant improvement of quality of life as well as knee function two years after 
treatment for both cell types with no significant difference between these approaches [211]. 
However, the most commonly used and best-studied BM-MSCs do not only require invasive 
and painful harvesting but are also known to occur only in very limited numbers in bone marrow 
[213]. MSCs make up only about 0.0001% of all mononuclear cells in a bone marrow aspirate 
[270]. Furthermore, BM-MSCs have an inherit propensity to display a hypertrophic phenotype 
during chondrogenic differentiation, probably due to the role of cartilage as a bone-template 
during endochondral ossification [133, 172]. Deposition of type I and type X collagen in the 
extracellular matrix results in a tissue that is not adapted to the pressure and shear forces 
articular cartilage is subjected to and is therefore an inferior replacement for hyaline cartilage 
[217].  
Adipose tissue derived stem cells (ADSCs) can be harvested from liposuction aspirates and are 
more abundant than BM-MSCs, making up about 0.05% of all mononuclear cells within a 
liposuction sample [270]. However, proliferative capacity and chondrogenic potential of 
ADSCs are lower than of BM-MSCs [133]. ADSCs showed less upregulation of chondrogenic 
markers (ACAN, COL2A1) as well as lower GAG-content in the ECM during chondrogenic 
differentiation [133]. Therefore, ADSCs do not represent an optimal cell source for cartilage 





Furthermore, there is an age-related decline in in vivo frequency and in in vitro proliferation 
rate of MSCs [271, 272]. MSCs isolated from older donors can undergo only a limited number 
of population doublings before senescence, so it might be challenging to retrieve enough cells 
for tissue engineering applications [271]. Additionally, the chondrogenic differentiation 
capacity is reduced in MSCs from older donors [271, 272]. It has also been shown that BM-
MSCs isolated from patients with severe osteoarthritis have a significant lower proliferation 
rate as well as a significant reduced chondrogenic activity compared to healthy age-matched 
controls [273]. Therefore, especially for patients most in need of articular cartilage repair, 
autologous MSCs might not be the optimal cell source for tissue engineering applications [213]. 
Use of allogeneic MSCs would allow for a single-stage cartilage repair procedure [206]. In a 
first-in-human clinical trial Park et al used allogenic human umbilical cord blood derived MSCs 
(hUCB-MSCs) embedded in a hyaluronic acid hydrogel (Cartistem) to treat osteoarthritis or 
focal cartilage defects in seven patients [212]. During the seven year follow up period, all 
patients reported clinical improvement and no serious adverse events (SAEs) occurred [212]. 
Importantly, no rejection of the allogenic stem cell derived product occurred, which is likely 
due to the hypoimmunogenic and immunomodulatory properties of MSCs [212]. Umbilical 
cord blood-derived MSCs can be harvested non-invasively after delivery, but can be only 
isolated from around 30% of the samples. Furthermore, risk of immune reactions and infectious 
disease transmission hampers their clinical applicability [115, 206]. 
Taken together, despite successful clinical application of MSCs for cartilage repair, MSCs 
suffer from invasive harvesting, the propensity to form hypertrophic cartilage as well as an age-
related decline in in vivo frequency and in vitro proliferation potential [172, 213]. Induced 
pluripotent stem cells might overcome the limitations of current cartilage repair strategies and 
become a valuable alternative for treatment of focal cartilage lesions. 
 
7.2.3. Induced pluripotent stem cells for cartilage regeneration 
Due to their somatic origin, their unlimited proliferation potential and their ability to 
differentiate into every desired cell type, induced pluripotent stem cells offer promising 




Patient-derived autologous IPSCs would theoretically facilitate transplantation of patient-
specific tissues or organs without risk of immune-rejection and therefore without need for 
immunosuppressive medication [274, 275]. However, it has been shown, that transplantation 
of undifferentiated IPSCs into syngeneic hosts led to T-cell infiltration and necrosis suggesting 
that these autologous IPSCs are immunogenic [276]. Differentiated derivatives of IPSCs though 
showed less propensity of provoking an immune rejection response [277, 278]. Additionally, it 
has been shown that the immunogenicity of IPSC-derivatives varies among cell types and 
recipient sites [279]. Due to its avascular structure and dense ECM, cartilage is considered a 
immune-privileged tissue, and even transplantation of unrelated donors hardly induces a 
relevant immune response [16]. Immunogenicity of autologous IPSC-derived chondrocytes or 
cartilage matrix might therefore be less clinically relevant. However, more research needs to be 
conducted on determining the underlying mechanisms of IPSC-immunogenicity in general and 
its implications on the utility of IPSCs for cartilage regeneration.  
Autologous IPSCs can be successfully reprogrammed from various cell sources like fibroblast 
[19], keratinocytes [37], blood cells [36] or urinary tract epithelium [280] that can be accessed 
minimally or even non-invasively. Generating autologous IPSCs for each individual patient, 
however, would require time- and labor-intensive isolation and propagation of cells, 
reprogramming, picking and expansion of IPS cell lines, testing for complete reprogramming 
and screening for potentially harmful mutations through the reprogramming process. 
Performing all these procedures under GMP guidelines is extremely laborious and costly [16, 
113].   
As producing autologous IPSCs for every single patient – at least at the moment – seams not 
feasible and still bears a small risk of immune rejection, HLA-matched allogenic IPSCs might 
represent a valuable alternative [16, 274]. Large database-analyses suggested that about 50 
homozygous IPS cell lines would allow a haplotype match of over 90% in Japan, whereas in 
the UK about 150 homozygous IPS cell lines would be needed [274, 281, 282]. It was estimated 
that a bank of 100 homozygous IPS cell lines would offer a haplotype match to 78% of 
Europeans, 63% of Asians, 52% of Hispanics and 45% of African Americans [283].  
For allogenic IPSCs to be used for cartilage repair, probably no ideal HLA match would be 
required due to the immune-privileged nature of articular cartilage. Therefore, such IPSC banks 





However, efficient differentiation of IPSCs into hyaline cartilage tissue remains challenging 
and hampers development of an allogenic IPSC-based off-the shelf product for cartilage repair 
[206]. Reliable and scalable chondrogenic differentiation protocols are needed before IPSC-





7.3. Chondrogenic differentiation of pluripotent stem cells 
In order to apply IPSCs for cartilage repair in patients, safe and reliable differentiation protocols 
that are scalable to produce implantable grafts in sufficient size are needed. Currently four 
different strategies for the differentiation of pluripotent stem cells (PSCs) into cartilage have 
been described: first, co-culture of PSCs with mature chondrocytes [134, 217, 218]; second, 
culture of PSCs under the influence of growth factors mimicking physiological chondrogenic 
development during embryogenesis [127, 135, 219]; third,  two-step differentiation via 
mesenchymal stem cell (MSC)-like cells as an intermediate [220-222]; and finally, formation 
of embryoid bodies (EBs) allowing spontaneous differentiation of PSCs and subsequent 
selection of a chondrogenically primed subpopulation and its direction towards the 
chondrogenic lineage [126, 223, 224]. Upregulation of chondrogenic markers as well as 
formation of implantable grafts can be achieved by all these methods, however, none of these 
methods is already applicable for cartilage repair in patients due to safety concerns or laborious 
and expensive differentiation protocols.  
 
7.3.1. Chondrogenic differentiation of IPSCs via chondrogenic colonies 
Chondrogenic differentiation of PSCs can be achieved by exposure to defined chondrogenic 
growth factors.  
Oldershaw et al. established a protocol for the stepwise differentiation of ESCs towards 
chondrocytes mimicking embryonic development via mesendodermal and mesodermal 
intermediates. ESCs were grown for 14 days in monolayer culture and a sequence of growth 
factors including Wnt3a, Activin A, FGF2, BMP4, follistatin, neurotrophin4 and GDF5 was 
added to the culture medium at defined concentrations for each time point. During the 
differentiation, the cells showed a temporary upregulation of mesoendodermal and mesodermal 
markers. After 14 days, the ESC-derived chondrocyte-like cells expressed chondrogenic 
markers like Sox9, Col2a1 and Acan and showed sGAG and type II collagen deposition in their 
surrounding ECM [219].  
Saito et al adapted this protocol for the differentiation of IPSCs. After 14 days the IPSC-derived 





scaffold was subsequently implanted into cartilage defect in the distal femur of NOD/SCID-
mice. Histological analysis after 8 and 16 weeks revealed that the defects treated with the 
chondrogenic disks were filled with hyaline cartilage-like tissue. However, in one mouse, a 
large tumor containing various tissues was observed indicating the persistence of 
undifferentiated pluripotent stem cells inside the chondrogenic disk. Therefore, it is crucial to 
improve the differentiation method and carefully asses the formed scaffolds for remaining 
undifferentiated cell populations before application in patients might be considered [135]. 
Taken together, exposure of PSCs to growth factors is effective at inducing chondrogenic 
differentiation. But the need for laborious cell culture protocols hampers their application for 
large-scale production of clinical grade cartilage scaffolds. Furthermore, these protocols should 
include a definite separation step to prevent contamination of the final product with an 
undifferentiated cell population to increase the safety profile before their use in patients is 
considered.  
Yamashita et al. induced mesoendodermal differentiation of human IPSCs by culturing IPSC-
colonies on Matrigel-coated dishes in a medium supplemented with the growth factors Wnt3a 
and Activin A. After three days, medium was changed to chondrogenic medium supplemented 
with BMP2, TGFβ1, GDF5 and FGF2. After 14 days, the colonies formed compact spheroid 
nodules that were then maintained in suspension culture for up to 42 days. Successful 
chondrogenic differentiation was confirmed histologically as well as by RT-PCR.  Implantation 
of the nodules into in vivo cartilage defect models in rats and mini-pigs showed good integration 
and maturation of the tissue without any hint for teratoma formation. Compared to the 
Oldershaw-Protocol, this method is simpler since only two different sets of growth factors at 
steady concentrations were used during differentiation. Furthermore, the suspension culture 
reduces risk of teratoma formation since non-chondrogenic cells detached from the particles 
and collected at the bottom of the culture dishes. When the particles were implanted 
subcutaneously into SCID mice, no teratoma formation was observed even after 12 months 
[127]. However, when we applied this protocol to our murine IPSCs no evident chondrogenesis 
was induced. Although small nodules were formed from the IPSC colonies, we observed neither 
an upregulation of chondrogenic gene expression nor significant deposition of GAGs, aggrecan 




Whereas Yamashita et al. differentiated their IPSCs for 14 days in adherent culture, our particles 
started to lift off the plates already on day 6. This might be due to the different coatings the 
IPSCs were cultured on, as Yamashita et al. used Matrigel coating, whereas we cultured our 
IPSCs on Geltrex-coated plates. It could also result from the different structure of the colonies 
formed by human and murine IPSCs. Whereas colonies formed by human IPSCs are flatter and 
proliferate slower, the colonies formed by murine IPSCs are usually dome shaped and contain 
fast proliferating cells [23]. Therefore, differentiation of murine IPSCs in colony-derived 
particles might not be suitable. 
We exposed our cells to a combination of the chondrogenic growth factors BMP2, TGFβ1 and 
GDF5 at a concentration of 10 ng/ml each in a chondrogenic medium consisting of DMEM 
supplemented with FBS, non-essential amino acids, sodium pyruvate, insulin transferrin 
selenite mix and L-ascorbic acid (chondrogenic colonies medium). However, neither through 
the medium alone (noGF) nor through the growth-factor supplemented medium (BTG), 
chondrogenesis could be successfully induced. However, when we exposed EB-derived 
chondrogenic spheroids to a chondrogenic medium consisting of DMEM supplemented with 
sodium pyruvate, insulin transferrin selenite mix, L-ascorbic acid and dexamethasone 
(chondrogenic spheroids medium) and supplemented BMP2 at a concentration of 100 ng/ml 
and TGFβ1 at a concentration of 10 ng/ml chondrogenic differentiation could be observed in 
unstimulated and stimulated spheroids. Therefore, it could be possible that the medium and 
growth factor scheme applied by Yamashita et al. might not be suitable for murine IPSCs. More 
research is required to elucidate whether chondrogenic nodules maintained for example in our 
chondrogenic spheroids medium or under a different growth factor regime show signs of 
chondrogenesis.  
 
7.3.2. Chondrogenic differentiation of IPSCs via embryoid body derived 
chondrogenic spheroids 
One of the simplest and most straight-forward protocols to differentiate PSCs into the 
chondrogenic lineage is to expose outgrowth cultures of embryoid bodies to chondrogenic 
media supplemented with chondrogenic growth factors. Cells that spontaneously differentiated 
towards the mesoendodoermal or mesodermal lineage and therefore are primed for 





Deposition of sGAGs in the ECM of these nodules could be confirmed by Alcian Blue staining. 
Additionally, upregulation of chondrogenic markers like Col2a1 and Sox9 was described [126, 
160]. However, no implantable graft can be derived from this method hampering its 
applicability to clinical cartilage repair.  
In order to form an implantable graft, it is possible to isolate cells from the EB outgrowth or 
directly from dissociated EBs to form chondrogenic pellets by a standard high-speed 
centrifugation method. These pellets are not only comparable to MSC-derived pellets but could 
also successfully fill an osteochondral defect in vivo [230, 231]. Furthermore, it is possible to 
isolate MSC-like cells from embryoid bodies that can be differentiated into the chondrogenic 
lineage by standard micromass and pellet culture protocols [213, 224].  
Pre-differentiation of PSCs in embryoid bodies induces formation of a chondrogenically primed 
subpopulation that has the propensity to differentiate into the chondrogenic lineage. However, 
most of the protocols described in literature require disruption of formed embryoid bodies or 
trypsinization of outgrowth cultures to form a cell suspension that is then transferred to high 
density culture methods like micromass or pellets. These manipulations are laborious and 
potentially damage the cells. He et al. cultured IPSCs for 14 days in an alginate-based 
microcavity hydrogel which allowed formation of EBs inside the mircocavities. Subsequently 
the EBs were exposed to a series of growth factors inducing chondrogenic differentiation via 
mesodermal intermediates similar to the protocol described by Oldershaw et al. [219]. Gene 
expression analysis revealed upregulation of chondrogenic markers Sox9, Col2a1 and Acan, 
while Safranin O staining confirmed deposition of sGAGs and IHC staining demonstrated 
deposition of type II collagen in the ECM. Finally, the alginate matrix could be removed by 
sodium citrate leading to a scaffold free chondrogenic graft [223].  
Since, on the one hand, chondrogenic differentiation of IPSCs could be achieved by exposing 
intact embryoid bodies to chondrogenic differentiation in a hydrogel and, on the other hand, 
Yamashita et al. had shown that suspension culture of chondrogenic nodules is – in principle – 
feasible, we hypothesized that chondrogenic differentiation of IPSC can be easily and 
effectively induced by maintaining EBs in chondrogenic medium [127, 223] . 
EBs are three-dimensional aggregates formed by pluripotent stem cells in the absence of LIF 




EBs mimicking some aspects of early embryogenesis. Therefore, formation of EBs is widely 
used as a trigger for in vitro differentiation of PSCs. There are many methods of producing EBs, 
however suspension culture in liquid media and hanging drop culture are the most commonly 
used protocols [284, 285].  
PSCs can be cultured in suspension culture in bacterial grade Petri dishes. Under these 
conditions, PSCs cannot adhere to the culture vessel and spontaneously aggregate into EBs 
[286]. Although this approach is easy and effective, very heterogenous EBs are formed, because 
the number of cells per aggregate is not determined. The derived EBs show great variation in 
shape and size, and do not differentiate synchronously [284]. Therefore, this method seams not 
suitable to form EBs for chondrogenic differentiation.  
For hanging drop culture, small drops containing a defined number of cells (400 – 1000) are 
placed on the lid of a Petri dish. The lid is inverted, and the cells sediment to the bottom of the 
drop, where they form an aggregate [287]. Here, the size of the formed bodies can be controlled 
by choosing an appropriate concentration of the cell suspension resulting in more homogenous 
EBs. This method seemed suitable to generate EBs for chondrogenic differentiation as it 
effectively forms an appropriate number of relatively homogenous EBs [284]. It remains to be 
elucidated, if embryoid bodies formed by other methods like e.g. stirred suspension culture in 
spinner flaks or rotary cell culture systems are susceptible for chondrogenic differentiation as 
well. These methods are scalable to produce EBs in large quantities, and would therefore 
facilitate production of implantable chondrogenic grafts [285].  
Duration of pre-differentiation of PSCs in EBs varies between 4 [288] to 12 days [230] with 
most authors culturing EBs for 5 [126, 160] to 7 days [162, 165, 231]. A shorter incubation 
period bears the risk for incomplete pre-differentiation resulting in many undifferentiated cells 
that are not susceptible for subsequent differentiation signals, whereas during a longer 
incubation method, especially in non-chondrogenic medium, spontaneous differentiation into 
non-chondrogenic lineages will occur imposing a high risk of contamination of the final product 
with non-cartilaginous tissues. We choose a pre-differentiation period of 5 days in hanging 
drops. After that time, the formed EBs had a medium size of 160 ± 60 µm and were stable 
enough to be transferred from the hanging drops to a 96-well plate for further culture. The EBs 
showed a compact spheroid morphology with no signs of cystic structures indicating formation 





resemble the visceral yolk sac of postimplantation embryos, and are therefore indicative of 
advanced differentiation stages in EBs  [285]. We observed homogenous chondrogenic 
differentiation in our chondrogenic spheroids derived from EBs maintained in HD culture for 
5 days. The impact of a shorter or longer pre-differentiation time in EBs on chondrogenesis 
needs to be further evaluated.  
During hanging drop culture, the EBs were maintained in our standard IPSC medium without 
LIF to allow spontaneous differentiation. There were no specific growth factors added and 
proliferation was stimulated only by the serum present in the medium. However, it has been 
described that a mesoendodermal pre-differentiation of IPSCs can be achieved by growth 
factors Wnt3a and Activin A [127, 219]. This intermediate step mimics the differentiation 
pathway of cartilage during embryonic development [219]. It remains to be elucidated, whether 
supplementation of Wnt3a and Activin A would improve chondrogenesis also in EBs. 
During subsequent free-floating culture, we used a very simple scheme of growth factor 
stimulation with BMP2 and TGFβ1 added over the whole course of the differentiation at 
constant concentrations. Both factors are well known to enhance chondrogenic differentiation 
of PSCs [126, 127, 159-161]. By stimulation of embryoid bodies with these growth factors 
upregulation of chondrogenic markers Sox9, Itga10, Acan and Col2a1 was induced and 
deposition of GAGs, aggrecan and type II collagen could be detected in the ECM. However, 
we found that the hypertrophy markers Runx2 and Col10 were upregulated as well. Hypertrophy 
was significantly stronger induced in growth factor-stimulated spheroids than in control 
spheroids. Since especially BMP2 is known to induce hypertrophy during chondrogenic 
differentiation of stem cells, a more elaborated growth factor supplementation scheme could 
help to prevent or reduce occurrence of hypertrophy [156]. Many other growth factors like for 
example FGF2 [127, 135, 219, 223, 288], GDF5 [127, 135, 219, 223, 288] or BMP4 [135, 219, 
224, 288, 289] have been shown to enhance chondrogenesis.  Their effect on chondrogenic 
differentiation of IPSCs via suspension culture of embryoid bodies needs yet to be determined.  
However, it should be noted that we conducted the experiment using murine IPSCs. Although 
murine IPSCs share many features with human IPSCs, there are certain differences. They are 
known to represent different developmental states regarding embryonic development. Murine 
IPSCs represent naïve IPSCs resembling ESCs from preimplantation blastocysts, whereas 




blastocysts and are therefore termed primed IPSCs [22]. However, the methods to induce 
chondrogenesis in murine and human PSCs are comparable. Chondrogenic differentiation via 
pre-differentiation in embryoid bodies has been described for murine IPSCs [126, 160] as well 
as for human IPSCs [230, 288]. But it still remains to be elucidated, whether by the method 
described here, chondrogenic differentiation can also be induced in human induced pluripotent 
stem cells.  
On the other hand, efficient and reliable methods for chondrogenic differentiation of murine 
IPSCs are needed, nevertheless. To study multifactorial diseases like osteoarthritis, mouse 
models still play an important role in musculoskeletal research [290]. Furthermore, knock-out 
mouse models allow to dissect the role of growth factors, cellular receptors or ECM-
components in articular cartilage development and degradation [141, 291, 292]. Since 
chondrocytes are difficult to isolate in sufficient number and undergo dedifferentiation when 
maintained in culture, IPSCs generated from transgenic mice would be an additional tool to 
reveal molecular consequences of the genetic aberration during chondrogenic differentiation 
and in IPSC-derived chondrocytes [202].  
Taken together, we demonstrated as a proof of principle, that chondrogenic differentiation of 
IPSCs via chondrogenic spheroids derived directly from embryoid bodies is possible and 
effective. Optimization of the differentiation time-table and growth factor supplementation 
scheme is needed to improve chondrogenesis and reduce hypertrophy.  
 
7.3.3. Generation of chondrogenically primed IPSCs by RMCE 
Besides the significant upregulation of chondrogenic markers Sox9, ItgA10, Acan and Col2a1, 
our qPCR results showed, that expression of pluripotency markers Oct3/4 and Nanog was 
significantly downregulated in EB-derived chondrogenic spheroids compared to parental 
IPSCs. However, even at day 42 of chondrogenic differentiation, expression of Oct3/4 and 
Nanog was still detectable. This could be due to the presence of undifferentiated cells within 
the spheroids, or it could result from reactivation of the genomically integrated reprogramming 
factor cassette. To rule out the second possibility, removal of the reprogramming factor cassette 





Although removal of the Sleeping Beauty transposon carrying the reprogramming factor 
cassette by re-expression of the transposase is possible in theory, the efficiency of this method 
is very low [262]. Therefore, exchange of the reprogramming factor cassette for other genes of 
interest e.g. by recombinase mediated cassette exchange (RMCE) is an appealing alternative as 
discussed in 7.1.4. Integrating Non-Viral Vectors.  
In terms of cartilage regeneration, these genes of interest could be chondrogenic transcription 
factors like for example Sox9 or cartilage specific genes like for example integrin α10. The 
transposon could act as a genomic “safe harbor site” for the integration of these transgenes. 
Exchange of the reprogramming factors for these chondrogenic factors would lead to 
chondrogenically-primed IPSCs that might show improved chondrogenesis when exposed to 
chondrogenic conditions, and an enhanced safety profile due to the absence of genomically 
integrated oncogenes after removal of the reprogramming factor cassette (Figure 56). Our 
method would offer an ideal platform to explore the possibilities of these chondrogenically 
primed IPSCs since it offers an efficient and reliable differentiation method to induce 









Figure 56: Generation of chondrogenically primed IPSCs by recombinase mediated cassette exchange (self-designed) 
First, IPSCs are generated with a transposon-based reprogramming system consisting e.g. of a transposase plasmid providing 
the hyperactive transposase SB100X and a reprogramming factor plasmid which contains heterospecific loxP sites flanking the 
reprogramming factors (RF). When these plasmids are delivered into the cell by nucleofection, the transposase mediates 
genomic integration of the reprogramming factor cassette and the heterospecific loxP sites, and the cells are subsequently 
reprogrammed to induced pluripotent stem cells (green box). Then the reprogramming factors are exchanged for chondrogenic 
factors (CF) e.g. provided on a second plasmid by recombinase mediated cassette exchange (RMCE). Thereby 







1. Fortier, L.A., Stem cells: classifications, controversies, and clinical applications. Vet 
Surg, 2005. 34(5): p. 415-23. 
2. Kolios, G. and Y. Moodley, Introduction to stem cells and regenerative medicine. 
Respiration, 2013. 85(1): p. 3-10. 
3. Menon, S., et al., An Overview of Direct Somatic Reprogramming: The Ins and Outs of 
iPSCs. Int J Mol Sci, 2016. 17(1). 
4. Singh, V.K., et al., Describing the Stem Cell Potency: The Various Methods of 
Functional Assessment and In silico Diagnostics. Front Cell Dev Biol, 2016. 4: p. 134. 
5. Stevens, L.C., Studies on transplantable testicular teratomas of strain 129 mice. J Natl 
Cancer Inst, 1958. 20(6): p. 1257-75. 
6. Evans, M.J. and M.H. Kaufman, Establishment in culture of pluripotential cells from 
mouse embryos. Nature, 1981. 292(5819): p. 154-6. 
7. Thomson, J.A., et al., Embryonic stem cell lines derived from human blastocysts. 
Science, 1998. 282(5391): p. 1145-7. 
8. Denker, H.W., Potentiality of embryonic stem cells: an ethical problem even with 
alternative stem cell sources. J Med Ethics, 2006. 32(11): p. 665-71. 
9. Brons, I.G., et al., Derivation of pluripotent epiblast stem cells from mammalian 
embryos. Nature, 2007. 448(7150): p. 191-5. 
10. Campbell, K.H., et al., Somatic cell nuclear transfer: Past, present and future 
perspectives. Theriogenology, 2007. 68 Suppl 1: p. S214-31. 
11. Rodriguez-Osorio, N., et al., Reprogramming mammalian somatic cells. 
Theriogenology, 2012. 78(9): p. 1869-86. 
12. Wilmut, I., et al., Viable offspring derived from fetal and adult mammalian cells. Nature, 
1997. 385(6619): p. 810-3. 
13. Brambrink, T., et al., ES cells derived from cloned and fertilized blastocysts are 
transcriptionally and functionally indistinguishable. Proc Natl Acad Sci U S A, 2006. 
103(4): p. 933-8. 
14. Munsie, M.J., et al., Isolation of pluripotent embryonic stem cells from reprogrammed 
adult mouse somatic cell nuclei. Curr Biol, 2000. 10(16): p. 989-92. 
15. Takahashi, K. and S. Yamanaka, Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell, 2006. 126(4): p. 663-
76. 
16. Tsumaki, N., M. Okada, and A. Yamashita, iPS cell technologies and cartilage 
regeneration. Bone, 2015. 70: p. 48-54. 
17. Okita, K., T. Ichisaka, and S. Yamanaka, Generation of germline-competent induced 
pluripotent stem cells. Nature, 2007. 448(7151): p. 313-7. 
18. Wernig, M., et al., In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like 
state. Nature, 2007. 448(7151): p. 318-24. 
19. Takahashi, K., et al., Induction of pluripotent stem cells from adult human fibroblasts 
by defined factors. Cell, 2007. 131(5): p. 861-72. 
20. Yu, J., et al., Induced pluripotent stem cell lines derived from human somatic cells. 
Science, 2007. 318(5858): p. 1917-20. 
21. NobelMediaAB. Shinya Yamanaka – Facts. . 2019  [cited 2019 March 16, 2019]; 
Available from: https://www.nobelprize.org/prizes/medicine/2012/yamanaka/facts/. 
22. Nichols, J. and A. Smith, Naive and primed pluripotent states. Cell Stem Cell, 2009. 




23. Rawat, N. and M.K. Singh, Induced pluripotent stem cell: A headway in reprogramming 
with promising approach in regenerative biology. Vet World, 2017. 10(6): p. 640-649. 
24. Plath, K. and W.E. Lowry, Progress in understanding reprogramming to the induced 
pluripotent state. Nat Rev Genet, 2011. 12(4): p. 253-65. 
25. Teshigawara, R., et al., Mechanism of human somatic reprogramming to iPS cell. Lab 
Invest, 2017. 97(10): p. 1152-1157. 
26. Hamanaka, S., et al., Generation of germline-competent rat induced pluripotent stem 
cells. PLoS One, 2011. 6(7): p. e22008. 
27. Takenaka-Ninagawa, N., et al., Generation of rat-induced pluripotent stem cells from a 
new model of metabolic syndrome. PLoS One, 2014. 9(8): p. e104462. 
28. Honda, A., et al., Naive-like conversion overcomes the limited differentiation capacity 
of induced pluripotent stem cells. J Biol Chem, 2013. 288(36): p. 26157-66. 
29. Esteban, M.A., et al., Generation of induced pluripotent stem cell lines from Tibetan 
miniature pig. J Biol Chem, 2009. 284(26): p. 17634-40. 
30. Kues, W.A., et al., Derivation and characterization of sleeping beauty transposon-
mediated porcine induced pluripotent stem cells. Stem Cells Dev, 2013. 22(1): p. 124-
35. 
31. Nagy, K., et al., Induced pluripotent stem cell lines derived from equine fibroblasts. 
Stem Cell Rev, 2011. 7(3): p. 693-702. 
32. Talluri, T.R., et al., Derivation and characterization of bovine induced pluripotent stem 
cells by transposon-mediated reprogramming. Cell Reprogram, 2015. 17(2): p. 131-40. 
33. Debowski, K., et al., Non-viral generation of marmoset monkey iPS cells by a six-factor-
in-one-vector approach. PLoS One, 2015. 10(3): p. e0118424. 
34. Fujie, Y., et al., New type of Sendai virus vector provides transgene-free iPS cells 
derived from chimpanzee blood. PLoS One, 2014. 9(12): p. e113052. 
35. Qu, X., et al., Induced pluripotent stem cells generated from human adipose-derived 
stem cells using a non-viral polycistronic plasmid in feeder-free conditions. PLoS One, 
2012. 7(10): p. e48161. 
36. Loh, Y.H., et al., Generation of induced pluripotent stem cells from human blood. 
Blood, 2009. 113(22): p. 5476-9. 
37. Li, W., et al., Generation of human-induced pluripotent stem cells in the absence of 
exogenous Sox2. Stem Cells, 2009. 27(12): p. 2992-3000. 
38. Kim, J.B., et al., Oct4-induced pluripotency in adult neural stem cells. Cell, 2009. 
136(3): p. 411-9. 
39. Liu, H., et al., Generation of endoderm-derived human induced pluripotent stem cells 
from primary hepatocytes. Hepatology, 2010. 51(5): p. 1810-9. 
40. Bar-Nur, O., et al., Epigenetic memory and preferential lineage-specific differentiation 
in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell 
Stem Cell, 2011. 9(1): p. 17-23. 
41. Brouwer, M., H. Zhou, and N. Nadif Kasri, Choices for Induction of Pluripotency: 
Recent Developments in Human Induced Pluripotent Stem Cell Reprogramming 
Strategies. Stem Cell Rev, 2016. 12(1): p. 54-72. 
42. Hudecek, M., et al., Going non-viral: the Sleeping Beauty transposon system breaks on 
through to the clinical side. Crit Rev Biochem Mol Biol, 2017. 52(4): p. 355-380. 
43. Ivics, Z. and Z. Izsvak, Nonviral gene delivery with the sleeping beauty transposon 
system. Hum Gene Ther, 2011. 22(9): p. 1043-51. 
44. Zhou, W. and C.R. Freed, Adenoviral gene delivery can reprogram human fibroblasts 





45. Fusaki, N., et al., Efficient induction of transgene-free human pluripotent stem cells 
using a vector based on Sendai virus, an RNA virus that does not integrate into the host 
genome. Proc Jpn Acad Ser B Phys Biol Sci, 2009. 85(8): p. 348-62. 
46. Narsinh, K.H., et al., Generation of adult human induced pluripotent stem cells using 
nonviral minicircle DNA vectors. Nat Protoc, 2011. 6(1): p. 78-88. 
47. Si-Tayeb, K., et al., Generation of human induced pluripotent stem cells by simple 
transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev 
Biol, 2010. 10: p. 81. 
48. Yu, J., et al., Human induced pluripotent stem cells free of vector and transgene 
sequences. Science, 2009. 324(5928): p. 797-801. 
49. Kim, D., et al., Generation of human induced pluripotent stem cells by direct delivery 
of reprogramming proteins. Cell Stem Cell, 2009. 4(6): p. 472-6. 
50. Warren, L., et al., Feeder-free derivation of human induced pluripotent stem cells with 
messenger RNA. Sci Rep, 2012. 2: p. 657. 
51. Kumar, D., et al., Transposon-based reprogramming to induced pluripotency. Histol 
Histopathol, 2015. 30(12): p. 1397-409. 
52. Skipper, K.A., et al., DNA transposon-based gene vehicles - scenes from an 
evolutionary drive. J Biomed Sci, 2013. 20: p. 92. 
53. Grabundzija, I., et al., Sleeping Beauty transposon-based system for cellular 
reprogramming and targeted gene insertion in induced pluripotent stem cells. Nucleic 
Acids Res, 2013. 41(3): p. 1829-47. 
54. Muenthaisong, S., et al., Generation of mouse induced pluripotent stem cells from 
different genetic backgrounds using Sleeping beauty transposon mediated gene 
transfer. Exp Cell Res, 2012. 318(19): p. 2482-9. 
55. Woltjen, K., et al., piggyBac transposition reprograms fibroblasts to induced 
pluripotent stem cells. Nature, 2009. 458(7239): p. 766-70. 
56. Ivics, Z., et al., Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon 
from fish, and its transposition in human cells. Cell, 1997. 91(4): p. 501-10. 
57. Liu, H. and G.A. Visner, Applications of Sleeping Beauty transposons for nonviral gene 
therapy. IUBMB Life, 2007. 59(6): p. 374-9. 
58. Mates, L., et al., Molecular evolution of a novel hyperactive Sleeping Beauty 
transposase enables robust stable gene transfer in vertebrates. Nat Genet, 2009. 41(6): 
p. 753-61. 
59. Narayanavari, S.A., et al., Sleeping Beauty transposition: from biology to applications. 
Crit Rev Biochem Mol Biol, 2017. 52(1): p. 18-44. 
60. Ivics, Z. and Z. Izsvak, Sleeping Beauty Transposition. Microbiol Spectr, 2015. 3(2): p. 
MDNA3-0042-2014. 
61. Richardson, P.D., et al., Gene repair and transposon-mediated gene therapy. Stem 
Cells, 2002. 20(2): p. 105-18. 
62. Geurts, A.M., et al., Gene transfer into genomes of human cells by the sleeping beauty 
transposon system. Mol Ther, 2003. 8(1): p. 108-17. 
63. Grabundzija, I., et al., Comparative analysis of transposable element vector systems in 
human cells. Mol Ther, 2010. 18(6): p. 1200-9. 
64. Vigdal, T.J., et al., Common physical properties of DNA affecting target site selection 
of sleeping beauty and other Tc1/mariner transposable elements. J Mol Biol, 2002. 
323(3): p. 441-52. 
65. Gogol-Doring, A., et al., Genome-wide Profiling Reveals Remarkable Parallels 
Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac 




66. Buganim, Y., et al., Single-cell expression analyses during cellular reprogramming 
reveal an early stochastic and a late hierarchic phase. Cell, 2012. 150(6): p. 1209-22. 
67. Polo, J.M., et al., A molecular roadmap of reprogramming somatic cells into iPS cells. 
Cell, 2012. 151(7): p. 1617-32. 
68. Samavarchi-Tehrani, P., et al., Functional genomics reveals a BMP-driven 
mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. 
Cell Stem Cell, 2010. 7(1): p. 64-77. 
69. Smith, Z.D., et al., Dynamic single-cell imaging of direct reprogramming reveals an 
early specifying event. Nat Biotechnol, 2010. 28(5): p. 521-6. 
70. David, L. and J.M. Polo, Phases of reprogramming. Stem Cell Res, 2014. 12(3): p. 754-
61. 
71. Hanna, J., et al., Direct cell reprogramming is a stochastic process amenable to 
acceleration. Nature, 2009. 462(7273): p. 595-601. 
72. Krause, M.N., I. Sancho-Martinez, and J.C. Izpisua Belmonte, Understanding the 
molecular mechanisms of reprogramming. Biochem Biophys Res Commun, 2016. 
473(3): p. 693-7. 
73. Li, R., et al., A mesenchymal-to-epithelial transition initiates and is required for the 
nuclear reprogramming of mouse fibroblasts. Cell Stem Cell, 2010. 7(1): p. 51-63. 
74. Aasen, T., et al., Efficient and rapid generation of induced pluripotent stem cells from 
human keratinocytes. Nat Biotechnol, 2008. 26(11): p. 1276-84. 
75. Aoi, T., et al., Generation of pluripotent stem cells from adult mouse liver and stomach 
cells. Science, 2008. 321(5889): p. 699-702. 
76. Koche, R.P., et al., Reprogramming factor expression initiates widespread targeted 
chromatin remodeling. Cell Stem Cell, 2011. 8(1): p. 96-105. 
77. Mikkelsen, T.S., et al., Dissecting direct reprogramming through integrative genomic 
analysis. Nature, 2008. 454(7200): p. 49-55. 
78. Stadtfeld, M., et al., Defining molecular cornerstones during fibroblast to iPS cell 
reprogramming in mouse. Cell Stem Cell, 2008. 2(3): p. 230-40. 
79. Kim, K., et al., Epigenetic memory in induced pluripotent stem cells. Nature, 2010. 
467(7313): p. 285-90. 
80. Polo, J.M., et al., Cell type of origin influences the molecular and functional properties 
of mouse induced pluripotent stem cells. Nat Biotechnol, 2010. 28(8): p. 848-55. 
81. Wang, P. and J. Na, Mechanism and methods to induce pluripotency. Protein Cell, 2011. 
2(10): p. 792-9. 
82. Niwa, H., J. Miyazaki, and A.G. Smith, Quantitative expression of Oct-3/4 defines 
differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet, 2000. 24(4): p. 
372-6. 
83. Adachi, K. and H.R. Scholer, Directing reprogramming to pluripotency by transcription 
factors. Curr Opin Genet Dev, 2012. 22(5): p. 416-22. 
84. Sanges, D. and M.P. Cosma, Reprogramming cell fate to pluripotency: the decision-
making signalling pathways. Int J Dev Biol, 2010. 54(11-12): p. 1575-87. 
85. Sridharan, R., et al., Role of the murine reprogramming factors in the induction of 
pluripotency. Cell, 2009. 136(2): p. 364-77. 
86. Niwa, H., The pluripotency transcription factor network at work in reprogramming. 
Curr Opin Genet Dev, 2014. 28: p. 25-31. 
87. Nandan, M.O. and V.W. Yang, The role of Kruppel-like factors in the reprogramming 






88. Finver, S.N., et al., Sequence analysis of the MYC oncogene involved in the 
t(8;14)(q24;q11) chromosome translocation in a human leukemia T-cell line indicates 
that putative regulatory regions are not altered. Proc Natl Acad Sci U S A, 1988. 85(9): 
p. 3052-6. 
89. Nakagawa, M., et al., Generation of induced pluripotent stem cells without Myc from 
mouse and human fibroblasts. Nat Biotechnol, 2008. 26(1): p. 101-6. 
90. Boyer, L.A., et al., Core transcriptional regulatory circuitry in human embryonic stem 
cells. Cell, 2005. 122(6): p. 947-56. 
91. Kim, J., et al., An extended transcriptional network for pluripotency of embryonic stem 
cells. Cell, 2008. 132(6): p. 1049-61. 
92. Iwafuchi-Doi, M. and K.S. Zaret, Pioneer transcription factors in cell reprogramming. 
Genes Dev, 2014. 28(24): p. 2679-92. 
93. Soufi, A., G. Donahue, and K.S. Zaret, Facilitators and impediments of the pluripotency 
reprogramming factors' initial engagement with the genome. Cell, 2012. 151(5): p. 994-
1004. 
94. Czerwinska, P., S. Mazurek, and M. Wiznerowicz, Application of induced pluripotency 
in cancer studies. Rep Pract Oncol Radiother, 2018. 23(3): p. 207-214. 
95. Sayed, N., C. Liu, and J.C. Wu, Translation of Human-Induced Pluripotent Stem Cells: 
From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol, 2016. 67(18): 
p. 2161-2176. 
96. Elitt, M.S., L. Barbar, and P.J. Tesar, Drug screening for human genetic diseases using 
iPSC models. Hum Mol Genet, 2018. 27(R2): p. R89-R98. 
97. Wu, S.M. and K. Hochedlinger, Harnessing the potential of induced pluripotent stem 
cells for regenerative medicine. Nat Cell Biol, 2011. 13(5): p. 497-505. 
98. Dimos, J.T., et al., Induced pluripotent stem cells generated from patients with ALS can 
be differentiated into motor neurons. Science, 2008. 321(5893): p. 1218-21. 
99. Sanchez-Danes, A., et al., Disease-specific phenotypes in dopamine neurons from 
human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol 
Med, 2012. 4(5): p. 380-95. 
100. Han, L., et al., Study familial hypertrophic cardiomyopathy using patient-specific 
induced pluripotent stem cells. Cardiovasc Res, 2014. 104(2): p. 258-69. 
101. Sun, N., et al., Patient-specific induced pluripotent stem cells as a model for familial 
dilated cardiomyopathy. Sci Transl Med, 2012. 4(130): p. 130ra47. 
102. Cayo, M.A., et al., JD induced pluripotent stem cell-derived hepatocytes faithfully 
recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology, 2012. 
56(6): p. 2163-71. 
103. Jang, J., et al., Disease-specific induced pluripotent stem cells: a platform for human 
disease modeling and drug discovery. Exp Mol Med, 2012. 44(3): p. 202-13. 
104. Chamberlain, S.J., Disease modelling using human iPSCs. Hum Mol Genet, 2016. 
25(R2): p. R173-R181. 
105. Lee, G., et al., Large-scale screening using familial dysautonomia induced pluripotent 
stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol, 2012. 
30(12): p. 1244-8. 
106. McNeish, J., et al., From Dish to Bedside: Lessons Learned While Translating Findings 
from a Stem Cell Model of Disease to a Clinical Trial. Cell Stem Cell, 2015. 17(1): p. 
8-10. 
107. Liu, H., et al., In vivo liver regeneration potential of human induced pluripotent stem 




108. Takebe, T., et al., Vascularized and functional human liver from an iPSC-derived organ 
bud transplant. Nature, 2013. 499(7459): p. 481-4. 
109. Nori, S., et al., Grafted human-induced pluripotent stem-cell-derived neurospheres 
promote motor functional recovery after spinal cord injury in mice. Proc Natl Acad Sci 
U S A, 2011. 108(40): p. 16825-30. 
110. Suzuki, N., et al., Generation of engraftable hematopoietic stem cells from induced 
pluripotent stem cells by way of teratoma formation. Mol Ther, 2013. 21(7): p. 1424-
31. 
111. Xie, F., et al., Seamless gene correction of beta-thalassemia mutations in patient-
specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res, 2014. 24(9): p. 1526-
33. 
112. Kimbrel, E.A. and R. Lanza, Current status of pluripotent stem cells: moving the first 
therapies to the clinic. Nat Rev Drug Discov, 2015. 14(10): p. 681-92. 
113. Solomon, S., F. Pitossi, and M.S. Rao, Banking on iPSC--is it doable and is it 
worthwhile. Stem Cell Rev, 2015. 11(1): p. 1-10. 
114. Turner, M., et al., Toward the development of a global induced pluripotent stem cell 
library. Cell Stem Cell, 2013. 13(4): p. 382-4. 
115. Zhang, L., J. Hu, and K.A. Athanasiou, The role of tissue engineering in articular 
cartilage repair and regeneration. Crit Rev Biomed Eng, 2009. 37(1-2): p. 1-57. 
116. Temenoff, J.S. and A.G. Mikos, Review: tissue engineering for regeneration of 
articular cartilage. Biomaterials, 2000. 21(5): p. 431-40. 
117. Brody, L.T., Knee osteoarthritis: Clinical connections to articular cartilage structure 
and function. Phys Ther Sport, 2015. 16(4): p. 301-16. 
118. Poole, A.R., et al., Composition and structure of articular cartilage: a template for 
tissue repair. Clin Orthop Relat Res, 2001(391 Suppl): p. S26-33. 
119. Lach, M., et al., Directed differentiation of induced pluripotent stem cells into 
chondrogenic lineages for articular cartilage treatment. J Tissue Eng, 2014. 5: p. 
2041731414552701. 
120. Hunziker, E.B., T.M. Quinn, and H.J. Hauselmann, Quantitative structural organization 
of normal adult human articular cartilage. Osteoarthritis Cartilage, 2002. 10(7): p. 564-
72. 
121. Foster, N.C., et al., Dynamic 3D culture: models of chondrogenesis and endochondral 
ossification. Birth Defects Res C Embryo Today, 2015. 105(1): p. 19-33. 
122. Hulmes, D.J., Building collagen molecules, fibrils, and suprafibrillar structures. J 
Struct Biol, 2002. 137(1-2): p. 2-10. 
123. Ricard-Blum, S., The collagen family. Cold Spring Harb Perspect Biol, 2011. 3(1): p. 
a004978. 
124. Mackay, A.M., et al., Chondrogenic differentiation of cultured human mesenchymal 
stem cells from marrow. Tissue Eng, 1998. 4(4): p. 415-28. 
125. Pittenger, M.F., et al., Multilineage potential of adult human mesenchymal stem cells. 
Science, 1999. 284(5411): p. 143-7. 
126. Saito, T., et al., Generation of Col2a1-EGFP iPS cells for monitoring chondrogenic 
differentiation. PLoS One, 2013. 8(9): p. e74137. 
127. Yamashita, A., et al., Generation of scaffoldless hyaline cartilaginous tissue from 
human iPSCs. Stem Cell Reports, 2015. 4(3): p. 404-18. 
128. McAlinden, A., Alternative splicing of type II procollagen: IIB or not IIB? Connect 





129. Gouttenoire, J., et al., BMP-2 and TGF-beta1 differentially control expression of type 
II procollagen and alpha 10 and alpha 11 integrins in mouse chondrocytes. Eur J Cell 
Biol, 2010. 89(4): p. 307-14. 
130. Zhang, L., et al., Chondrogenic differentiation of human mesenchymal stem cells: a 
comparison between micromass and pellet culture systems. Biotechnol Lett, 2010. 
32(9): p. 1339-46. 
131. Heinegard, D., Fell-Muir Lecture: Proteoglycans and more--from molecules to biology. 
Int J Exp Pathol, 2009. 90(6): p. 575-86. 
132. Roughley, P.J., The structure and function of cartilage proteoglycans. Eur Cell Mater, 
2006. 12: p. 92-101. 
133. Diekman, B.O., et al., Chondrogenesis of adult stem cells from adipose tissue and bone 
marrow: induction by growth factors and cartilage-derived matrix. Tissue Eng Part A, 
2010. 16(2): p. 523-33. 
134. Qu, C., et al., Chondrogenic differentiation of human pluripotent stem cells in 
chondrocyte co-culture. Int J Biochem Cell Biol, 2013. 45(8): p. 1802-12. 
135. Saito, T., et al., Hyaline cartilage formation and tumorigenesis of implanted tissues 
derived from human induced pluripotent stem cells. Biomed Res, 2015. 36(3): p. 179-
86. 
136. Lüllmann-Rauch, R., Taschenlehrbuch Histologie. 3., vollst. überarb. Aufl. ed. 2009, 
Stuttgart, Germany: Georg-Thieme Verlag KG. 137-143. 
137. Loeser, R.F., Integrins and chondrocyte-matrix interactions in articular cartilage. 
Matrix Biol, 2014. 39: p. 11-6. 
138. Zeltz, C. and D. Gullberg, The integrin-collagen connection - a glue for tissue repair? 
J Cell Sci, 2016. 129(6): p. 1284. 
139. Lundgren-Akerlund, E. and A. Aszodi, Integrin alpha10beta1: a collagen receptor 
critical in skeletal development. Adv Exp Med Biol, 2014. 819: p. 61-71. 
140. Camper, L., U. Hellman, and E. Lundgren-Akerlund, Isolation, cloning, and sequence 
analysis of the integrin subunit alpha10, a beta1-associated collagen binding integrin 
expressed on chondrocytes. J Biol Chem, 1998. 273(32): p. 20383-9. 
141. Bengtsson, T., et al., Loss of alpha10beta1 integrin expression leads to moderate 
dysfunction of growth plate chondrocytes. J Cell Sci, 2005. 118(Pt 5): p. 929-36. 
142. Varas, L., et al., Alpha10 integrin expression is up-regulated on fibroblast growth 
factor-2-treated mesenchymal stem cells with improved chondrogenic differentiation 
potential. Stem Cells Dev, 2007. 16(6): p. 965-78. 
143. Long, F. and D.M. Ornitz, Development of the endochondral skeleton. Cold Spring Harb 
Perspect Biol, 2013. 5(1): p. a008334. 
144. Wuelling, M. and A. Vortkamp, Chondrocyte proliferation and differentiation. Endocr 
Dev, 2011. 21: p. 1-11. 
145. Wang, L. and Y.G. Chen, Signaling Control of Differentiation of Embryonic Stem Cells 
toward Mesendoderm. J Mol Biol, 2016. 428(7): p. 1409-22. 
146. Tickle, C., How the embryo makes a limb: determination, polarity and identity. J Anat, 
2015. 227(4): p. 418-30. 
147. Fang, J., et al., Roles of TGF-beta 1 signaling in the development of osteoarthritis. Histol 
Histopathol, 2016. 31(11): p. 1161-7. 
148. Derynck, R. and Y.E. Zhang, Smad-dependent and Smad-independent pathways in 
TGF-beta family signalling. Nature, 2003. 425(6958): p. 577-84. 
149. Song, B., K.D. Estrada, and K.M. Lyons, Smad signaling in skeletal development and 




150. Massague, J., TGFbeta signaling: receptors, transducers, and Mad proteins. Cell, 1996. 
85(7): p. 947-50. 
151. Augustyniak, E., et al., The role of growth factors in stem cell-directed chondrogenesis: 
a real hope for damaged cartilage regeneration. Int Orthop, 2015. 39(5): p. 995-1003. 
152. Kim, Y.I., et al., Overexpression of TGF-beta1 enhances chondrogenic differentiation 
and proliferation of human synovium-derived stem cells. Biochem Biophys Res 
Commun, 2014. 450(4): p. 1593-9. 
153. Noth, U., et al., Chondrogenic differentiation of human mesenchymal stem cells in 
collagen type I hydrogels. J Biomed Mater Res A, 2007. 83(3): p. 626-35. 
154. Yoo, J.U., et al., The chondrogenic potential of human bone-marrow-derived 
mesenchymal progenitor cells. J Bone Joint Surg Am, 1998. 80(12): p. 1745-57. 
155. Chen, D., M. Zhao, and G.R. Mundy, Bone morphogenetic proteins. Growth Factors, 
2004. 22(4): p. 233-41. 
156. Zhou, N., et al., BMP2 induces chondrogenic differentiation, osteogenic differentiation 
and endochondral ossification in stem cells. Cell Tissue Res, 2016. 366(1): p. 101-11. 
157. Liao, J., et al., Sox9 potentiates BMP2-induced chondrogenic differentiation and 
inhibits BMP2-induced osteogenic differentiation. PLoS One, 2014. 9(2): p. e89025. 
158. Sakaguchi, Y., et al., Comparison of human stem cells derived from various 
mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum, 2005. 
52(8): p. 2521-9. 
159. Koay, E.J., G.M. Hoben, and K.A. Athanasiou, Tissue engineering with 
chondrogenically differentiated human embryonic stem cells. Stem Cells, 2007. 25(9): 
p. 2183-90. 
160. Kuboth, S., J. Kramer, and J. Rohwedel, Chondrogenic differentiation in vitro of murine 
two-factor induced pluripotent stem cells is comparable to murine embryonic stem cells. 
Cells Tissues Organs, 2012. 196(6): p. 481-9. 
161. Toh, W.S., et al., Cartilage repair using hyaluronan hydrogel-encapsulated human 
embryonic stem cell-derived chondrogenic cells. Biomaterials, 2010. 31(27): p. 6968-
80. 
162. Suchorska, W.M., et al., Gene expression profile in human induced pluripotent stem 
cells: Chondrogenic differentiation in vitro, part A. Mol Med Rep, 2017. 15(5): p. 2387-
2401. 
163. Akiyama, H., et al., The transcription factor Sox9 has essential roles in successive steps 
of the chondrocyte differentiation pathway and is required for expression of Sox5 and 
Sox6. Genes Dev, 2002. 16(21): p. 2813-28. 
164. Nishimura, R., et al., Regulation of bone and cartilage development by network between 
BMP signalling and transcription factors. J Biochem, 2012. 151(3): p. 247-54. 
165. Augustyniak, E., et al., Gene expression profile in human induced pluripotent stem 
cells: Chondrogenic differentiation in vitro, part B. Mol Med Rep, 2017. 15(5): p. 2402-
2414. 
166. Aroen, A., et al., Articular cartilage lesions in 993 consecutive knee arthroscopies. Am 
J Sports Med, 2004. 32(1): p. 211-5. 
167. Solheim, E., et al., Symptoms and function in patients with articular cartilage lesions in 
1,000 knee arthroscopies. Knee Surg Sports Traumatol Arthrosc, 2016. 24(5): p. 1610-
6. 
168. Heir, S., et al., Focal cartilage defects in the knee impair quality of life as much as 
severe osteoarthritis: a comparison of knee injury and osteoarthritis outcome score in 






169. Lohmander, L.S., et al., The long-term consequence of anterior cruciate ligament and 
meniscus injuries: osteoarthritis. Am J Sports Med, 2007. 35(10): p. 1756-69. 
170. Felson, D.T. and R. Hodgson, Identifying and treating preclinical and early 
osteoarthritis. Rheum Dis Clin North Am, 2014. 40(4): p. 699-710. 
171. Glyn-Jones, S., et al., Osteoarthritis. Lancet, 2015. 386(9991): p. 376-87. 
172. Oldershaw, R.A., Cell sources for the regeneration of articular cartilage: the past, the 
horizon and the future. Int J Exp Pathol, 2012. 93(6): p. 389-400. 
173. Braun, H.J. and G.E. Gold, Diagnosis of osteoarthritis: imaging. Bone, 2012. 51(2): p. 
278-88. 
174. de l'Escalopier, N., P. Anract, and D. Biau, Surgical treatments for osteoarthritis. Ann 
Phys Rehabil Med, 2016. 59(3): p. 227-33. 
175. Braun, S., et al., The 5.5-year results of MegaOATS--autologous transfer of the 
posterior femoral condyle: a case-series study. Arthritis Res Ther, 2008. 10(3): p. R68. 
176. Dewan, A.K., et al., Evolution of autologous chondrocyte repair and comparison to 
other cartilage repair techniques. Biomed Res Int, 2014. 2014: p. 272481. 
177. Batty, L., et al., Autologous chondrocyte implantation: an overview of technique and 
outcomes. ANZ J Surg, 2011. 81(1-2): p. 18-25. 
178. Oehler, N., T. Schmidt, and A. Niemeier, [Total Joint Replacement and Return to 
Sports]. Sportverletz Sportschaden, 2016. 30(4): p. 195-203. 
179. Wengler, A., U. Nimptsch, and T. Mansky, Hip and knee replacement in Germany and 
the USA: analysis of individual inpatient data from German and US hospitals for the 
years 2005 to 2011. Dtsch Arztebl Int, 2014. 111(23-24): p. 407-16. 
180. Steadman, J.R., W.G. Rodkey, and J.J. Rodrigo, Microfracture: surgical technique and 
rehabilitation to treat chondral defects. Clin Orthop Relat Res, 2001(391 Suppl): p. 
S362-9. 
181. Mithoefer, K., et al., The microfracture technique for the treatment of articular cartilage 
lesions in the knee. A prospective cohort study. J Bone Joint Surg Am, 2005. 87(9): p. 
1911-20. 
182. Shapiro, F., S. Koide, and M.J. Glimcher, Cell origin and differentiation in the repair 
of full-thickness defects of articular cartilage. J Bone Joint Surg Am, 1993. 75(4): p. 
532-53. 
183. Gudas, R., et al., A prospective randomized clinical study of mosaic osteochondral 
autologous transplantation versus microfracture for the treatment of osteochondral 
defects in the knee joint in young athletes. Arthroscopy, 2005. 21(9): p. 1066-75. 
184. Erggelet, C. and P. Vavken, Microfracture for the treatment of cartilage defects in the 
knee joint - A golden standard? J Clin Orthop Trauma, 2016. 7(3): p. 145-52. 
185. Devitt, B.M., et al., Surgical treatments of cartilage defects of the knee: Systematic 
review of randomised controlled trials. Knee, 2017. 24(3): p. 508-517. 
186. Schenker, H., et al., [Current overview of cartilage regeneration procedures]. 
Orthopade, 2017. 46(11): p. 907-913. 
187. Benthien, J.P. and P. Behrens, Autologous Matrix-Induced Chondrogenesis (AMIC): 
Combining Microfracturing and a Collagen I/III Matrix for Articular Cartilage 
Resurfacing. Cartilage, 2010. 1(1): p. 65-8. 
188. Schagemann, J., et al., Mid-term outcome of arthroscopic AMIC for the treatment of 
articular cartilage defects in the knee joint is equivalent to mini-open procedures. Arch 
Orthop Trauma Surg, 2018. 138(6): p. 819-825. 
189. Volz, M., et al., A randomized controlled trial demonstrating sustained benefit of 
Autologous Matrix-Induced Chondrogenesis over microfracture at five years. Int 




190. Mithoefer, K., et al., Chondral resurfacing of articular cartilage defects in the knee with 
the microfracture technique. Surgical technique. J Bone Joint Surg Am, 2006. 88 Suppl 
1 Pt 2: p. 294-304. 
191. Outerbridge, H.K., R.E. Outerbridge, and D.E. Smith, Osteochondral defects in the 
knee. A treatment using lateral patella autografts. Clin Orthop Relat Res, 2000(377): p. 
145-51. 
192. Richter, D.L., et al., Knee Articular Cartilage Repair and Restoration Techniques: A 
Review of the Literature. Sports Health, 2016. 8(2): p. 153-60. 
193. Hangody, L. and P. Fules, Autologous osteochondral mosaicplasty for the treatment of 
full-thickness defects of weight-bearing joints: ten years of experimental and clinical 
experience. J Bone Joint Surg Am, 2003. 85-A Suppl 2: p. 25-32. 
194. Hangody, L., et al., Arthroscopic autogenous osteochondral mosaicplasty for the 
treatment of femoral condylar articular defects. A preliminary report. Knee Surg Sports 
Traumatol Arthrosc, 1997. 5(4): p. 262-7. 
195. Matsusue, Y., T. Yamamuro, and H. Hama, Arthroscopic multiple osteochondral 
transplantation to the chondral defect in the knee associated with anterior cruciate 
ligament disruption. Arthroscopy, 1993. 9(3): p. 318-21. 
196. Hangody, L., et al., Autologous osteochondral grafting--technique and long-term 
results. Injury, 2008. 39 Suppl 1: p. S32-9. 
197. Brucker, P.U., S. Braun, and A.B. Imhoff, [Mega-OATS technique--autologous 
osteochondral transplantation as a salvage procedure for large osteochondral defects 
of the femoral condyle]. Oper Orthop Traumatol, 2008. 20(3): p. 188-98. 
198. Sherman, S.L., et al., Fresh osteochondral allograft transplantation for the knee: 
current concepts. J Am Acad Orthop Surg, 2014. 22(2): p. 121-33. 
199. Winthrop, Z., G. Pinkowsky, and W. Hennrikus, Surgical treatment for osteochondritis 
dessicans of the knee. Curr Rev Musculoskelet Med, 2015. 8(4): p. 467-75. 
200. Brittberg, M., et al., Treatment of deep cartilage defects in the knee with autologous 
chondrocyte transplantation. N Engl J Med, 1994. 331(14): p. 889-95. 
201. Roberts, S., et al., Immunohistochemical study of collagen types I and II and 
procollagen IIA in human cartilage repair tissue following autologous chondrocyte 
implantation. Knee, 2009. 16(5): p. 398-404. 
202. Minegishi, Y., K. Hosokawa, and N. Tsumaki, Time-lapse observation of the 
dedifferentiation process in mouse chondrocytes using chondrocyte-specific reporters. 
Osteoarthritis Cartilage, 2013. 21(12): p. 1968-75. 
203. Gomoll, A.H., et al., Use of a type I/III bilayer collagen membrane decreases 
reoperation rates for symptomatic hypertrophy after autologous chondrocyte 
implantation. Am J Sports Med, 2009. 37 Suppl 1: p. 20S-23S. 
204. Maus, U., et al., [Clinical results after three years use of matrix-associated ACT for the 
treatment of osteochondral defects of the knee]. Z Orthop Unfall, 2008. 146(1): p. 31-
7. 
205. Ossendorf, C., et al., Treatment of posttraumatic and focal osteoarthritic cartilage 
defects of the knee with autologous polymer-based three-dimensional chondrocyte 
grafts: 2-year clinical results. Arthritis Res Ther, 2007. 9(2): p. R41. 
206. Vonk, L.A., et al., Autologous, allogeneic, induced pluripotent stem cell or a 
combination stem cell therapy? Where are we headed in cartilage repair and why: a 
concise review. Stem Cell Res Ther, 2015. 6: p. 94. 
207. Docheva, D., et al., Human mesenchymal stem cells in contact with their environment: 





208. Friedenstein, A.J., et al., Heterotopic of bone marrow. Analysis of precursor cells for 
osteogenic and hematopoietic tissues. Transplantation, 1968. 6(2): p. 230-47. 
209. Dominici, M., et al., Minimal criteria for defining multipotent mesenchymal stromal 
cells. The International Society for Cellular Therapy position statement. Cytotherapy, 
2006. 8(4): p. 315-7. 
210. Ando, W., et al., In vitro generation of a scaffold-free tissue-engineered construct (TEC) 
derived from human synovial mesenchymal stem cells: biological and mechanical 
properties and further chondrogenic potential. Tissue Eng Part A, 2008. 14(12): p. 
2041-9. 
211. Nejadnik, H., et al., Autologous bone marrow-derived mesenchymal stem cells versus 
autologous chondrocyte implantation: an observational cohort study. Am J Sports Med, 
2010. 38(6): p. 1110-6. 
212. Park, Y.B., et al., Cartilage Regeneration in Osteoarthritic Patients by a Composite of 
Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells and Hyaluronate 
Hydrogel: Results from a Clinical Trial for Safety and Proof-of-Concept with 7 Years 
of Extended Follow-Up. Stem Cells Transl Med, 2017. 6(2): p. 613-621. 
213. Chen, Y.S., et al., Small molecule mesengenic induction of human induced pluripotent 
stem cells to generate mesenchymal stem/stromal cells. Stem Cells Transl Med, 2012. 
1(2): p. 83-95. 
214. Lee, J., et al., Generation of disease-specific induced pluripotent stem cells from 
patients with rheumatoid arthritis and osteoarthritis. Arthritis Res Ther, 2014. 16(1): p. 
R41. 
215. Xu, M., et al., Chondrocytes Derived From Mesenchymal Stromal Cells and Induced 
Pluripotent Cells of Patients With Familial Osteochondritis Dissecans Exhibit an 
Endoplasmic Reticulum Stress Response and Defective Matrix Assembly. Stem Cells 
Transl Med, 2016. 5(9): p. 1171-81. 
216. Ma, B., et al., Gene expression profiling of dedifferentiated human articular 
chondrocytes in monolayer culture. Osteoarthritis Cartilage, 2013. 21(4): p. 599-603. 
217. Bigdeli, N., et al., Coculture of human embryonic stem cells and human articular 
chondrocytes results in significantly altered phenotype and improved chondrogenic 
differentiation. Stem Cells, 2009. 27(8): p. 1812-21. 
218. Hwang, N.S., S. Varghese, and J. Elisseeff, Derivation of chondrogenically-committed 
cells from human embryonic cells for cartilage tissue regeneration. PLoS One, 2008. 
3(6): p. e2498. 
219. Oldershaw, R.A., et al., Directed differentiation of human embryonic stem cells toward 
chondrocytes. Nat Biotechnol, 2010. 28(11): p. 1187-94. 
220. Chijimatsu, R., et al., Characterization of Mesenchymal Stem Cell-Like Cells Derived 
From Human iPSCs via Neural Crest Development and Their Application for 
Osteochondral Repair. Stem Cells Int, 2017. 2017: p. 1960965. 
221. Guzzo, R.M., et al., Efficient differentiation of human iPSC-derived mesenchymal stem 
cells to chondroprogenitor cells. J Cell Biochem, 2013. 114(2): p. 480-90. 
222. Hynes, K., et al., Generation of functional mesenchymal stem cells from different 
induced pluripotent stem cell lines. Stem Cells Dev, 2014. 23(10): p. 1084-96. 
223. He, P., J. Fu, and D.A. Wang, Murine pluripotent stem cells derived scaffold-free 
cartilage grafts from a micro-cavitary hydrogel platform. Acta Biomater, 2016. 35: p. 
87-97. 
224. Umeda, K., et al., Human chondrogenic paraxial mesoderm, directed specification and 




225. Driessen, B.J.H., C. Logie, and L.A. Vonk, Cellular reprogramming for clinical 
cartilage repair. Cell Biol Toxicol, 2017. 33(4): p. 329-349. 
226. Kang, R., et al., Mesenchymal stem cells derived from human induced pluripotent stem 
cells retain adequate osteogenicity and chondrogenicity but less adipogenicity. Stem 
Cell Res Ther, 2015. 6: p. 144. 
227. Nejadnik, H., et al., Improved approach for chondrogenic differentiation of human 
induced pluripotent stem cells. Stem Cell Rev, 2015. 11(2): p. 242-53. 
228. Fukuta, M., et al., Derivation of mesenchymal stromal cells from pluripotent stem cells 
through a neural crest lineage using small molecule compounds with defined media. 
PLoS One, 2014. 9(12): p. e112291. 
229. Pettinato, G., X. Wen, and N. Zhang, Engineering Strategies for the Formation of 
Embryoid Bodies from Human Pluripotent Stem Cells. Stem Cells Dev, 2015. 24(14): 
p. 1595-609. 
230. Ko, J.Y., et al., In vitro chondrogenesis and in vivo repair of osteochondral defect with 
human induced pluripotent stem cells. Biomaterials, 2014. 35(11): p. 3571-81. 
231. Nam, Y., et al., Cord blood cell-derived iPSCs as a new candidate for chondrogenic 
differentiation and cartilage regeneration. Stem Cell Res Ther, 2017. 8(1): p. 16. 
232. Chen, Y.T. and A. Bradley, A new positive/negative selectable marker, puDeltatk, for 
use in embryonic stem cells. Genesis, 2000. 28(1): p. 31-5. 
233. Szymczak, A.L., et al., Correction of multi-gene deficiency in vivo using a single 'self-
cleaving' 2A peptide-based retroviral vector. Nat Biotechnol, 2004. 22(5): p. 589-94. 
234. Hirai, H., P. Karian, and N. Kikyo, Regulation of embryonic stem cell self-renewal and 
pluripotency by leukaemia inhibitory factor. Biochem J, 2011. 438(1): p. 11-23. 
235. Rohwedel, J., et al., Muscle cell differentiation of embryonic stem cells reflects 
myogenesis in vivo: developmentally regulated expression of myogenic determination 
genes and functional expression of ionic currents. Dev Biol, 1994. 164(1): p. 87-101. 
236. Bocker, W., et al., IKK-2 is required for TNF-alpha-induced invasion and proliferation 
of human mesenchymal stem cells. J Mol Med (Berl), 2008. 86(10): p. 1183-92. 
237. Darini, C.Y., et al., Self-renewal gene tracking to identify tumour-initiating cells 
associated with metastatic potential. Oncogene, 2012. 31(19): p. 2438-49. 
238. Gupta, R.K., et al., Transcriptional control of preadipocyte determination by Zfp423. 
Nature, 2010. 464(7288): p. 619-23. 
239. Potter, C.J. and L. Luo, Splinkerette PCR for mapping transposable elements in 
Drosophila. PLoS One, 2010. 5(4): p. e10168. 
240. Uren, A.G., et al., A high-throughput splinkerette-PCR method for the isolation and 
sequencing of retroviral insertion sites. Nat Protoc, 2009. 4(5): p. 789-98. 
241. Kiraly, K., et al., Application of selected cationic dyes for the semiquantitative 
estimation of glycosaminoglycans in histological sections of articular cartilage by 
microspectrophotometry. Histochem J, 1996. 28(8): p. 577-90. 
242. Niakan, K.K. and E.R. McCabe, DAX1 origin, function, and novel role. Mol Genet 
Metab, 2005. 86(1-2): p. 70-83. 
243. Takahashi, K., K. Mitsui, and S. Yamanaka, Role of ERas in promoting tumour-like 
properties in mouse embryonic stem cells. Nature, 2003. 423(6939): p. 541-5. 
244. Fujii, Y., et al., Zfp296 is a novel Klf4-interacting protein and functions as a negative 
regulator. Biochem Biophys Res Commun, 2013. 441(2): p. 411-7. 
245. Mansergh, F.C., et al., Gene expression profiles during early differentiation of mouse 
embryonic stem cells. BMC Dev Biol, 2009. 9: p. 5. 
246. Baum, C., et al., Chance or necessity? Insertional mutagenesis in gene therapy and its 





247. Carey, B.W., et al., Reprogramming of murine and human somatic cells using a single 
polycistronic vector. Proc Natl Acad Sci U S A, 2009. 106(1): p. 157-62. 
248. Sommer, C.A., et al., Excision of reprogramming transgenes improves the 
differentiation potential of iPS cells generated with a single excisable vector. Stem 
Cells, 2010. 28(1): p. 64-74. 
249. Wu, X., et al., Transcription start regions in the human genome are favored targets for 
MLV integration. Science, 2003. 300(5626): p. 1749-51. 
250. Schroder, A.R., et al., HIV-1 integration in the human genome favors active genes and 
local hotspots. Cell, 2002. 110(4): p. 521-9. 
251. Zhang, Y., et al., A poor imitation of a natural process: a call to reconsider the iPSC 
engineering technique. Cell Cycle, 2012. 11(24): p. 4536-44. 
252. Yant, S.R., et al., High-resolution genome-wide mapping of transposon integration in 
mammals. Mol Cell Biol, 2005. 25(6): p. 2085-94. 
253. Moldt, B., et al., Cis-acting gene regulatory activities in the terminal regions of sleeping 
beauty DNA transposon-based vectors. Hum Gene Ther, 2007. 18(12): p. 1193-204. 
254. Walisko, O., et al., Transcriptional activities of the Sleeping Beauty transposon and 
shielding its genetic cargo with insulators. Mol Ther, 2008. 16(2): p. 359-69. 
255. Yant, S.R., et al., Somatic integration and long-term transgene expression in normal 
and haemophilic mice using a DNA transposon system. Nat Genet, 2000. 25(1): p. 35-
41. 
256. Montini, E., et al., In vivo correction of murine tyrosinemia type I by DNA-mediated 
transposition. Mol Ther, 2002. 6(6): p. 759-69. 
257. Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-Related Macular 
Degeneration (TargetAMD). Hum Gene Ther Clin Dev, 2015. 26(2): p. 97-100. 
258. Kebriaei, P., et al., Phase I trials using Sleeping Beauty to generate CD19-specific CAR 
T cells. J Clin Invest, 2016. 126(9): p. 3363-76. 
259. Woltjen, K., et al., Transgene-free production of pluripotent stem cells using piggyBac 
transposons. Methods Mol Biol, 2011. 767: p. 87-103. 
260. Igawa, K., et al., Removal of reprogramming transgenes improves the tissue 
reconstitution potential of keratinocytes generated from human induced pluripotent 
stem cells. Stem Cells Transl Med, 2014. 3(9): p. 992-1001. 
261. Fraser, M.J., et al., Precise excision of TTAA-specific lepidopteran transposons 
piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from 
two species of Lepidoptera. Insect Mol Biol, 1996. 5(2): p. 141-51. 
262. Davis, R.P., et al., Generation of induced pluripotent stem cells from human foetal 
fibroblasts using the Sleeping Beauty transposon gene delivery system. Differentiation, 
2013. 86(1-2): p. 30-7. 
263. Luo, G., et al., Chromosomal transposition of a Tc1/mariner-like element in mouse 
embryonic stem cells. Proc Natl Acad Sci U S A, 1998. 95(18): p. 10769-73. 
264. Courtney, P.M., A.J. Boniello, and R.A. Berger, Complications Following Outpatient 
Total Joint Arthroplasty: An Analysis of a National Database. J Arthroplasty, 2017. 
32(5): p. 1426-1430. 
265. Hopley, C.D., L.S. Crossett, and A.F. Chen, Long-term clinical outcomes and 
survivorship after total knee arthroplasty using a rotating platform knee prosthesis: a 
meta-analysis. J Arthroplasty, 2013. 28(1): p. 68-77 e1-3. 
266. Makela, K.T., et al., Countrywise results of total hip replacement. An analysis of 
438,733 hips based on the Nordic Arthroplasty Register Association database. Acta 




267. Kreuz, P.C., et al., Is microfracture of chondral defects in the knee associated with 
different results in patients aged 40 years or younger? Arthroscopy, 2006. 22(11): p. 
1180-6. 
268. Gille, J., et al., Outcome of Autologous Matrix Induced Chondrogenesis (AMIC) in 
cartilage knee surgery: data of the AMIC Registry. Arch Orthop Trauma Surg, 2013. 
133(1): p. 87-93. 
269. Harris, J.D., et al., Failures, re-operations, and complications after autologous 
chondrocyte implantation--a systematic review. Osteoarthritis Cartilage, 2011. 19(7): p. 
779-91. 
270. Kern, S., et al., Comparative analysis of mesenchymal stem cells from bone marrow, 
umbilical cord blood, or adipose tissue. Stem Cells, 2006. 24(5): p. 1294-301. 
271. Baxter, M.A., et al., Study of telomere length reveals rapid aging of human marrow 
stromal cells following in vitro expansion. Stem Cells, 2004. 22(5): p. 675-82. 
272. Stolzing, A., et al., Age-related changes in human bone marrow-derived mesenchymal 
stem cells: consequences for cell therapies. Mech Ageing Dev, 2008. 129(3): p. 163-
73. 
273. Murphy, J.M., et al., Reduced chondrogenic and adipogenic activity of mesenchymal 
stem cells from patients with advanced osteoarthritis. Arthritis Rheum, 2002. 46(3): p. 
704-13. 
274. Garreta, E., et al., Roadblocks in the Path of iPSC to the Clinic. Curr Transplant Rep, 
2018. 5(1): p. 14-18. 
275. Tapia, N. and H.R. Scholer, Molecular Obstacles to Clinical Translation of iPSCs. Cell 
Stem Cell, 2016. 19(3): p. 298-309. 
276. Zhao, T., et al., Immunogenicity of induced pluripotent stem cells. Nature, 2011. 
474(7350): p. 212-5. 
277. Guha, P., et al., Lack of immune response to differentiated cells derived from syngeneic 
induced pluripotent stem cells. Cell Stem Cell, 2013. 12(4): p. 407-12. 
278. de Almeida, P.E., et al., Transplanted terminally differentiated induced pluripotent stem 
cells are accepted by immune mechanisms similar to self-tolerance. Nat Commun, 
2014. 5: p. 3903. 
279. Zhao, T., et al., Humanized Mice Reveal Differential Immunogenicity of Cells Derived 
from Autologous Induced Pluripotent Stem Cells. Cell Stem Cell, 2015. 17(3): p. 353-
9. 
280. Sun, H., et al., Generation of induced pluripotent stem cell line (ZZUi011-A) from urine 
sample of a normal human. Stem Cell Res, 2018. 29: p. 28-31. 
281. Nakatsuji, N., F. Nakajima, and K. Tokunaga, HLA-haplotype banking and iPS cells. 
Nat Biotechnol, 2008. 26(7): p. 739-40. 
282. Taylor, C.J., et al., Generating an iPSC bank for HLA-matched tissue transplantation 
based on known donor and recipient HLA types. Cell Stem Cell, 2012. 11(2): p. 147-
52. 
283. Gourraud, P.A., et al., The role of human leukocyte antigen matching in the development 
of multiethnic "haplobank" of induced pluripotent stem cell lines. Stem Cells, 2012. 
30(2): p. 180-6. 
284. Brickman, J.M. and P. Serup, Properties of embryoid bodies. Wiley Interdiscip Rev Dev 
Biol, 2017. 6(2). 
285. Kurosawa, H., Methods for inducing embryoid body formation: in vitro differentiation 





286. Doetschman, T.C., et al., The in vitro development of blastocyst-derived embryonic stem 
cell lines: formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp 
Morphol, 1985. 87: p. 27-45. 
287. Hopfl, G., M. Gassmann, and I. Desbaillets, Differentiating embryonic stem cells into 
embryoid bodies. Methods Mol Biol, 2004. 254: p. 79-98. 
288. Lee, J., et al., Early induction of a prechondrogenic population allows efficient 
generation of stable chondrocytes from human induced pluripotent stem cells. FASEB 
J, 2015. 29(8): p. 3399-410. 
289. Diekman, B.O., et al., Cartilage tissue engineering using differentiated and purified 
induced pluripotent stem cells. Proc Natl Acad Sci U S A, 2012. 109(47): p. 19172-7. 
290. Bapat, S., et al., Pros and cons of mouse models for studying osteoarthritis. Clin Transl 
Med, 2018. 7(1): p. 36. 
291. Lauing, K.L., et al., Aggrecan is required for growth plate cytoarchitecture and 
differentiation. Dev Biol, 2014. 396(2): p. 224-36. 
292. Usami, Y., et al., Wnt signaling in cartilage development and diseases: lessons from 
animal studies. Lab Invest, 2016. 96(2): p. 186-96. 
 
  
List of Figures 
186 
 
9. List of Figures 
Figure 1: Potency of stem cells (self-designed)........................................................................ 18 
Figure 2: Types of pluripotent stem cells (self-designed). ....................................................... 21 
Figure 3: Transposons. Modified from Ivics et al. [43]............................................................ 24 
Figure 4: Sleeping Beauty transposition. Modified from Liu et al [57]. .................................. 25 
Figure 5: Phases of the reprogramming process. Adapted from David et al. [70] and Plath et al. 
[24]. .......................................................................................................................................... 29 
Figure 6: Applications of induced pluripotent stem cells (self-designed). ............................... 35 
Figure 7: Structure of aggrecan. Adapted from Brody et al. [117]. ......................................... 39 
Figure 8: Extracellular matrix of articular cartilage. Adapted from Brody et al [117] and Poole 
et al. [118]. ............................................................................................................................... 41 
Figure 9: Endochondral ossification. Adapted from Long et al. [143]..................................... 45 
Figure 10: TGFß signaling pathway. ........................................................................................ 47 
Figure 11: BMP signaling pathway. ......................................................................................... 49 
Figure 12: X-Ray Image of an osteoarthritic knee joint. Modified from Braun et al. [173].... 52 
Figure 13: Total joint replacement of the knee with an endoprosthesis. From de l’Escalopier et 
al. [174] .................................................................................................................................... 53 
Figure 14: Microfracture. Modified from Mithoefer et al. [190]. ............................................ 54 
Figure 15: Osteochondral autograft transfer (OAT). From Winthrop et al. [199]. .................. 56 
Figure 16: Autologous chondrocyte injection (ACI). From Brittberg et al. [200]. .................. 57 
Figure 17: Methods for the chondrogenic differentiation of pluripotent stem cells. Adapted from 
Driessen et al. [225]. ................................................................................................................ 61 
Figure 18: Plasmids of the Sleeping Beauty reprogramming system. Modified from 
Grabundjiza et al. [53]. ............................................................................................................ 67 
Figure 19: Schematic depiction of the picking of bona fide IPSC colonies (self-designed). ... 78 
Figure 20: Hanging drop culture of mIPSCs. ........................................................................... 79 
Figure 21: Spontaneous differentiation of mIPSCs in embryoid bodies (self-designed). ........ 80 
Figure 22: Chondrogenic differentiation of mIPSCs via chondrogenic colonies (self-designed)
 .................................................................................................................................................. 82 
Figure 23: Chondrogenic differentiation of mIPSCs via embryoid bodies (self-designed). .... 84 
Figure 24: Splinkerette PCR (next page): ................................................................................ 94 
Figure 25: Morphology of primary murine fibroblasts. ......................................................... 105 




Figure 26: Nucleofection of primary fibroblasts with the pmaxGFP vector. ......................... 107 
Figure 27: Reprogramming of MEFs, EAR-FBs and TAIL-FBs with the pT2OSKM and 
pT2OSKML plasmids. ............................................................................................................. 111 
Figure 28: Reprogramming of EAR-FBs with the RMCE-OSKM(L)-Cherry plasmids. ....... 112 
Figure 29: Morphological changes of EAR-FBs during reprogramming with RMCE-OSKM(L)-
Cherry plasmids cultured on different coatings. .................................................................... 115 
Figure 30: Morphology of ESCs and IPSCs. .......................................................................... 117 
Figure 31: Alkaline phosphatase staining of IPSCs ............................................................... 118 
Figure 32: Splinkerette PCR ................................................................................................... 119 
Figure 33: ET-PCR for ESC markers on TA clones. ............................................................. 121 
Figure 34: RT-PCR for ESC markers on ETA clones. ........................................................... 121 
Figure 35: RT-PCR for ESC markers on TTA clones. ........................................................... 122 
Figure 36: RT-PCR for ESC markers on ETAC clones. ........................................................ 122 
Figure 37: RT-PCR for reprogramming factors on TA clones. .............................................. 124 
Figure 38: RT-PCR for reprogramming factors on ETA clones. ........................................... 124 
Figure 39: RT-PCR for reprogramming factors on TTA clones. ........................................... 125 
Figure 40: RT-PCR for reprogramming factors on ETAC clones. ........................................ 125 
Figure 41: Immunofluorescence staining for pluripotency markers on mESCs (R1) and ETA04
 ................................................................................................................................................ 127 
Figure 42: Immunofluorescence staining for pluripotency markers on mESCs (R1) and 
ETAC41 .................................................................................................................................. 128 
Figure 43: Embryoid body on day 21 of spontaneous differentiation in free floating culture.
 ................................................................................................................................................ 129 
Figure 44: qPCR of pluripotency and lineage-specific markers of IPSCs (ETA04) and embryoid 
bodies at day 21 (EB D21). .................................................................................................... 130 
Figure 45: Histological analysis of chondrogenic nodules on day 42. ................................... 132 
Figure 46: qPCR of pluripotency markers in stimulated (BTG) and non-stimulated (noGF) 
chondrogenic colonies. ........................................................................................................... 133 
Figure 47: qPCR of chondrogenic markers in stimulated (BTG) and non-stimulated (noGF) 
chondrogenic nodules. ............................................................................................................ 134 
Figure 48: Size of EBs on day5 and CSs on day 42. .............................................................. 136 
Figure 49. Safranin Orange and Toluidine Blue staining for chondrogenic spheroids. ......... 138 
List of Figures 
188 
 
Figure 50: Immunohistochemistry for aggrecan and type II collagen on chondrogenic spheroids
 ................................................................................................................................................ 139 
Figure 51: qPCR of pluripotency markers in stimulated (BT) and non-stimulated (noGF) 
chondrogenic spheroids. ......................................................................................................... 141 
Figure 52: qPCR of chondrogenic markers in stimulated (BT) and non-stimulated (noGF) 
chondrogenic spheroids. ......................................................................................................... 142 
Figure 53: RT-PCR for procollagen II isoforms procollagen IIA (Col II A) and B (Col IIB) 143 
Figure 54: qPCR of hypertrophy markers in stimulated (BT) and non-stimulated (noGF) 
chondrogenic spheroids. ......................................................................................................... 144 
Figure 55: Integration profile of commonly used gene vectors. From Narayanavari et al. [59].
 ................................................................................................................................................ 150 
Figure 56: Generation of chondrogenically primed IPSCs by recombinase mediated cassette 
exchange (self-designed) ........................................................................................................ 170 
 
  




10. List of Tables 
Table 1: Mouse EF medium ..................................................................................................... 69 
Table 2: Mouse IPSC medium ................................................................................................. 71 
Table 3: Freezing medium ........................................................................................................ 73 
Table 4: Collagenase-Dispase medium .................................................................................... 74 
Table 5: Nucleofection reaction set up ..................................................................................... 77 
Table 6: Hanging drop medium ................................................................................................ 80 
Table 7: Free floating medium ................................................................................................. 81 
Table 8: Mesoendodermal medium .......................................................................................... 82 
Table 9: Chondrogenic colonies medium ................................................................................. 83 
Table 10: Chondrogenic spheroid medium .............................................................................. 84 
Table 11: Antibodies for immunocytochemistry ...................................................................... 86 
Table 12: RNA denaturation mix and program ........................................................................ 88 
Table 13: cDNA synthesis mix and program ........................................................................... 88 
Table 14: RT-PCR reaction set up and program ...................................................................... 89 
Table 15: Oligonucleotides used for RT-PCR .......................................................................... 90 
Table 16: SYBR Green qPCR reaction set up .......................................................................... 91 
Table 17: Oligonucleotides used for qPCR (SYBR Green Kit) ............................................... 92 
Table 18: Taq-Man probes qPCR reaction set up..................................................................... 92 
Table 19: Oligonucleotides used for qPCR (Taq Man probes) ................................................ 93 
Table 20: gDNA digestion set up and program ........................................................................ 96 
Table 21: gDNA ligation set up and program .......................................................................... 97 
Table 22: Set up and program of the first PCR amplification .................................................. 98 
Table 23: Set up and program of the second PCR amplification ............................................. 98 
Table 24: Oligonucleotides used for Splinkerette PCR ............................................................ 99 
Table 25: Antibodies for immunohistochemistry ................................................................... 103 
Table 26: Nucleofection of MEFs with the pmaxGFP vector (P3 Solution) ......................... 106 
Table 27: Nucleofection of EAR-FBs with the pmaxGFP vector (P2 Solution) ................... 107 
Table 28: Nucleofection of TAIL-FBs with the pmaxGFP vector (P2 Solution) .................. 107 
Table 29: Cell lines established from MEFs reprogrammed with pT2OSKM or pT2OSKML
 ................................................................................................................................................ 109 
Table 30: Cell lines established from EAR-FBs reprogrammed with pT2OSKM or ............. 110 
List of Tables 
190 
 
Table 31: Cell lines established from TAIL-FBs reprogrammed with pT2OSKM or ............ 110 
Table 32: Cell lines established from EAR-FBs reprogrammed with .................................... 113 
Table 34: Methods for the generation of induced pluripotent stem cells ............................... 146 
 
  




11. List of Equations 
Equation 1: number of cells/ml (CC) = [(A+B+C+D)/4] x 104 .............................................. 72 
Equation 2: total cell count (n) = number of cells/ml (CC) x total cell suspension volume (V)
 .................................................................................................................................................. 72 
Equation 3: Survival rate (%) = (1 – mean dead cell count/100 000) x 100. .......................... 76 
Equation 4: Efficiency rate (%) = (fluorescent cells pvf/ total cell number pvf) x 100. ......... 76 
Equation 5: ∆CtExperimental  = CtExperimental (GOI) – CtExperimental (GAPDH)                          
∆CtControl  = CtControl (GOI) – CtControl (GAPDH) .................................................. 91 
Equation 6:  ∆∆Ct = ∆Ct Experimental - ∆CtControl ......................................................................... 91 
Equation 7: Expression fold change = 2-∆∆Ct .......................................................................... 91 
 
  
List of abbreviations 
192 
 
12. List of abbreviations 
Acan Aggrecan 
ACI Autologous chondrocyte injection 
ADAMTS A disintegrin and metalloproteinase with thrombospondin-like motifs 
ADSC Adipose tissue derived stem cell 
AMIC Autologous matrix-induced chondrogenesis 
AP Alkaline phosphatase 
BCIP 5-bromo-4-chloro-3-indolyl-phosphate 
BM-MSC Bone marrow mesenchymal stem cell 
BMP Bone morphogenetic protein 
BMPR BMP receptor 
BSA Bovine serum albumin 
CAR Chimeric antigen receptor 
cDNA Complementary DNA 
CF Chondrogenic factor 
CMV Cytomegalovirus 
c-Myc Avian myelocytomatosis viral oncogene homolog 
Col2a1 Collagen type II alpha 1  chain 
COMP Cartilage oligomeric matrix protein 
Co-SMAD Common-mediator Smad 
CP chondrocytes Columnar proliferating chondrocytes 
CS Chondroitin sulfate 
DAB Diaminobenzidine 
DAPI 4',6-diamino-2-phyenylindole 
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EpiSC Epiblast stem cells 
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ICC Immunocytochemistry 
ICM Inner cell mass 
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IL-6 Interleukin 6 
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IQR Interquartile range 
ISCT International Society for Cellular Therapy 
Itga10 Alpha 10 ingetrin 
ITS Insulin-Transferrin-Selenite 
JNK C-Jun-N-terminal kinase 
Klf4 Kruppel-like factor 4 
KS Keratan sulfate 
LP Link protein 
lsA Long strand adaptor 
LTR Long terminal repeat 
MACI Matrix assisted autologous chondrocyte injection 
MAPK Mitogen activated protein kinase 
MEF Mouse embryonic fibroblast 
mESC Mouse embryonic stem cell 
MET Mesenchymal to epithelial transition 
MIF Mullerian inhibitory factor 
mIPSC Mouse induced pluripotent stem cell 
MLV Murine leukemia virus 
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NCC Neural crest cell 
NTC Nitro blue tetrazolium chloride 
NT-SC Nuclear transfer-derived stem cell 
OAT Osteochondral autograft transfer 
OCAT Osteochondral allograft transplantation 
Oct3/4 Octamer-binding transcription factor 3/4 
OSKM Oct3/4, Sox2, Klf4 and c-Myc 
OSKML Oct3/4, Sox2, Klf4, c-Myc and Lin28 
PB PiggyBac 
PBS Phosphate Buffered Saline 
PCR Polymerase chain reaction 
PDEF Pigment epithelium-derived factor 
PFA Paraformaldehyde 
PG Proteoglycan 
PGC Primary germ cell 
PI3K Phosphatidylinositol-3-kinase 
PP2A Proteinphosphatase2A 
PSCs Pluripotent stem cell 
Puro Puromycin N-actetyltransferase 
pvf Per viewing field 
qPCR Quantitative PCR 
RC Rib cage cartilage 
RF Reprogramming factor 
RMCE Recombinase mediated cassette exchange 
RP chondrocytes Round proliferating chondrocytes 
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RT-PCR Reverse transcription PCR 
Runx2 Runt-related transcription factor 2 
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SCNT Somatic cell nuclear transfer 
SD Standard deviation 
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Sox2 Sex determining region of Y box 2 
Sox9 Sex determining region of Y box 9 
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